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ABSTRACT
BRCA1,  a  key  factor  in  homologous  recombination  (HR)  repair  may also  regulate  base 
excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-
PKcs could be a promising strategy in breast cancer. We investigated BRCA1, XRCC1 and 
pol  β  protein  expression  in  two  cohorts  (n=1602  sporadic  and  n=50  germ-line  BRCA1 
mutated)  and  mRNA expression  in  two  cohorts  (n=1952  and  n=249).  Artificial  neural 
network analysis for BRCA1-DNA repair interacting genes was conducted in 249 tumours. 
Pre-clinically, BRCA1 proficient and deficient cells were DNA repair expression profiled and 
evaluated  for  synthetic  lethality  using ATM and DNA-PKcs inhibitors  either  alone  or  in 
combination with cisplatin. In human tumours, BRCA1 negativity was strongly associated 
with low XRCC1, and low pol β at mRNA and protein levels (p<0.0001). In patients with 
BRCA1 negative tumours, low XRCC1 or low pol β expression was significantly associated 
with poor survival in univariate and multivariate analysis compared to high XRCC1 or high 
pol  β  expressing  BRCA1 negative  tumours  (ps<0.05).    Pre-clinically,  BRCA1 negative 
cancer cells exhibit low mRNA and low protein expression of XRCC1 and pol β.  BRCA1-
BER deficient cells were sensitive to ATM and DNA-PKcs inhibitor treatment either alone or 
in combination with cisplatin and synthetic lethality was evidenced by DNA double strand 
breaks accumulation, cell cycle arrest and apoptosis. We conclude that XRCC1 and pol β 
expression status in BRCA1 negative tumours may have prognostic significance. BRCA1-
BER deficient  cells  could be targeted by ATM or  DNA-PKcs inhibitors  for  personalized 
therapy.
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INTRODUCTION
Breast  Cancer Susceptibility Gene 1 (BRCA1) facilitates  the efficient  resolution of  DNA 
double-strand breaks (DSBs) through HR (Caestecker and Van de Walle, 2013; Huen et al., 
2010). Cells lacking functional BRCA1 protein have impaired HR, and thus depend on the 
more  error-prone  non-homologous  end  joining  (NHEJ)  pathway leading  to  chromosomal 
instability that drive breast cancer development (Huen et al., 2010). In women, BRCA1 germ 
line  mutation  is  associated  with  a  60%-70%  lifetime  risk  of  developing  breast  cancer 
(O'Donovan and Livingston, 2010). In the more common sporadic breast cancers, epigenetic 
silencing of the BRCA1 promoter has been reported in up to 11%-14% of tumours (Turner et 
al., 2004) and a dysfunctional BRCA pathway may also contribute to a BRCAness phenotype 
in about 25% of cancers (Turner et al., 2004), where breast cancers do not harbour germ-line 
BRCA mutations but display similar phenotypes including HR deficiency. BER is critical for 
processing DNA damage caused by alkylation, oxidation, ring saturation, single strand breaks 
and base deamination. DNA polymerase β (pol β) and XRCC1 are key BER factors.  PARP1 
(poly [ADP-ribose] polymerase 1) may play an essential role in single strand break repair 
(SSBR), a BER-related pathway (Langelier and Pascal, 2013).  The DNA repair intermediates 
generated during BER/SSBR, if unrepaired, may get converted to toxic double strand breaks 
(DSBs) (Dianov and Hubscher, 2013).
Emerging studies suggest a cross talk between BRCA1 and BER factors. BRCA1 mutated 
and  basal-like  breast  cancer  cells  were  found  to  be  sensitive  to  oxidative  DNA damage 
induced by H2O2 treatment. The increased sensitivity was associated with defective BER as 
assessed by cell based BER assay in BRCA1 deficient cells (Alli et al., 2009).  In a more 
recent study, BRCA1 deficient cells were sensitive to methyl methane sulfonate (alkylating 
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agent) and functional interaction between polβ and BRCA1 was demonstrated in that study 
(Masaoka et al., 2013) implying a potential role for polβ in BRCA1 mediated DSB repair. In 
addition, BRCA1 has also been shown to be involved in the transcriptional regulation of BER 
factor such as OGG1, NTH1 and APE1 (Saha et al., 2010). 
Synthetic  lethality  is  a  promising  strategy  for  personalized  cancer  therapy.  PARP [poly-
(ADP-ribose) polymerase] inhibitors induce synthetic lethality in germ line BRCA1-deficient 
breast  cancers  and  demonstrate  clinical  benefit  in  patients  (Lord  and  Ashworth,  2008). 
Similarly, we have recently shown that APE1 inhibition is synthetically lethal in BRCA1 
deficient breast cancer cells and in PTEN (and DSB repair) deficient melanoma cells.  The 
data provides compelling reasons to investigate other potential synthetic lethal interactions 
targeting DNA repair for clinical application.  Cells that are BRCA1 deficient as well as BER 
impaired may be reliant upon other back-up repair pathways to maintain genomic integrity 
and survival. ATM  and DNA-PKcs play essential roles in the DNA damage response (DDR) 
and link DNA damage sensing to DDR effectors that  regulate cell  cycle progression and 
DNA repair (Shiloh and Ziv, 2013). ATM, a member of the phosphatidylinositol-3-kinase-like 
protein kinase (PIKK) family,  is  a  key sensor and transducer of  DNA damage signalling 
during HR (Lee and Paull, 2007; Shiloh and Ziv, 2013). ATM recruitment at sites of DNA 
damage may be dependent upon functional BRCA1 in cells (Lee et al., 2010). DNA-PKcs is 
another key member of the PIKK family and a critical component of NHEJ pathway required 
for repair of DSBs generated throughout the cell cycle (Hill and Lee, 2010). BRCA1 through 
a role in DNA end-processing may also be involved in the regulation of NHEJ (Durant and 
Nickoloff, 2005).  
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Our hypothesis is that impaired BER in BRCA1 deficient tumours may influence prognosis. 
BRCA1-BER deficient  cells  may be  reliant  upon  ATM or  DNA-PKcs  mediated  back-up 
pathways for cellular survival and could be targeted by synthetic lethality using inhibitors of 
ATM or DNA-PKcs. 
MATERIALS AND METHODS
Clinical study
BRCA1 and BER protein expression analysis in Nottingham Tenovus Primary Breast 
Carcinoma cohort: The study was performed in a consecutive series of 1650 patients with 
primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered 
into the Nottingham Tenovus Primary Breast Carcinoma series described previously (Sultana 
et  al.,  2013).    Supplemental  Table  S1  summarizes  patient  demographics.  Supplemental 
treatment data 1 summarizes various adjuvant treatments received by patients in this cohort. 
BRCA1 and  BER protein  expression  analysis  in  germ line  BRCA1 deficient  breast 
cancer:  The  demographics  of  a  cohort  of  50  germ-line  BRCA1 mutated  breast  cancers 
confirmed  by  genetic  testing  is  shown  in  supplementary  table  S6.  All  patients  received 
surgery,  adjuvant  chemotherapy  and  radiotherapy  according  to  our  institutional  policy 
(supplementary treatment data 1). 
 
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) and immunohistochemically profiled for BRCA1, APE1, XRCC1, 
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Pol  β,  and  other  biological  markers  (Supplementary  Table  S2)  as  previously  described 
(Sultana et al., 2013). Supplementary Table S2 summarizes immunohistochemistry protocols 
for  the markers tested using the Bond Max automated staining machine and Leica Bond 
Refine Detection kit (DS9800) according to manufacturer instructions (Leica Microsystems). 
We have recently published optimisation and specificity of XRCC1 and pol β antibody used 
in the current study (Abdel-Fatah et al., 2014b; Sultana et al., 2013).  To validate the use of 
TMAs  for  immunophenotyping,  full-face  sections  of  40  cases  were  stained  and  protein 
expression  levels  of  the  different  antibodies  were  compared.   The  concordance  between 
TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of 
the primary antibody and IgG-matched serum) controls were included in each run. 
Evaluation of immune staining: The tumour cores were evaluated by specialist pathologists 
blinded to the clinicopathological characteristics of patients, in two different settings. There 
was excellent intra and inter-observer agreements (k > 0.8; Cohen’s κ and multi-rater κ tests, 
respectively).    Whole  field  inspection of  the  core  was  scored and intensities  of  nuclear 
staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 
= strong staining. The percentage of each category was estimated (0-100%).  H-scores (range 
0-300)  were  calculated  by  multiplying  intensity  of  staining  and  percentage  staining  as 
previously described (Sultana et al., 2013). Supplementary Table S2 summarizes cut-offs for 
individual markers.
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
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hazard model. A p value < 0.05 considered significant.  For multiple comparisons, p values 
were adjusted according to Holm-Bonferroni correction method. 
Transcript  levels  in  the  METABRIC  (Molecular  Taxonomy  of  Breast  Cancer 
International Consortium) cohort: Investigation of the mRNA expression was performed 
in METABRIC cohort which refers to a set of 1980 breast cancer samples with a minimum of 
5 years of  clinical  follow up where mRNA expression data was available (Curtis  et  al.). 
Patient demographics are summarized in supplementary Table S9. ER positive and/or lymph-
node negative patients did not receive adjuvant chemotherapy. ER negative and/or lymph-
node positive patients received adjuvant chemotherapy.  All   the samples were analysed as 
triplicates. A sliding window analysis was used to identify a cut-off in gene expression values 
such that the resulting subgroups have significantly different survival courses. 
Artificial neural network (ANN) analysis in Uppsala cohort: The demographics of the 
Uppsala cohort is summarized in supplementary Table S10 and mRNA analysis has been 
described previously (Bergh et al.,  1995).   All  microarray data are accessible at  National 
Center  for  Biotechnology  Information  (NCBI)  Gene  Expression  Omnibus  (http://
www.ncbi.nlm.nih.gov/geo/,  accession number: GSE4922) (Pawitan et al.,  2005).  All data 
were normalized using the global mean method (MAS5), and probe set signal intensities were 
natural log transformed and scaled by adjusting the mean signal to a target value of log 500. 
The expression levels of the BRCA1, for the probe 204531_s_at located on the HG-U133A 
chip was utilized to generate the ANN based model as described previously (30) (Lancashire 
et al., 2010) (Lemetre, 2009). A non-linear, ANN modelling based, data mining approach was 
utilised to identify the best gene probes for sample classification as described previously (30). 
47,293  probes  were  screened  for  each  sample  in  the  test  set  (n=249).  The  data  mining 
algorithm comprised a three layer multilayer perception architecture modified with a feed 
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forward  back-propagation  algorithm  and  a  sigmoidal  transfer  function,  as  previously 
described  (Lancashire  et  al.,  2010).  The  network  momentum  and  learning  rate  were 
respectively set as 0.1 and 0.5. Two hidden nodes were utilised. The output node was coded 
as 0 if a case was low BRCA1 expression (<the median) and 1 if high BRCA1 expression 
(>median). Inputs were ranked in ascending order based on their classification error. The top 
50 predictive genes identified were merged with 150 gene probes  involved in the DNA repair 
process (Supplementary Table S11) and  then applied to an ANN based network inference 
algorithm as described in earlier studies (Lemetre, 2009).  This model predicted a weighted 
link (direction and magnitude) between each of the gene probe markers.  This weighting was 
based  on  the  non-linear  correlation  between  a  source  gene  and  a  target  gene  in  a 
multifactorial ANN model.  This approach defines a linkage or interaction with a magnitude 
between every possible pair of genes in the set presented to the algorithm.  The approach is 
data driven and unweighted by biological function.  The 100 strongest interactions were then 
visualised as a map with Cytoscape  (Smoot et al., 2011). In a second bioinformatics analysis 
step, we sought to obtain a robust ranking of genes that are differentially expressed between 
the mRNA BRCA1+  cases and the mRNA BRCA1-  and have high predictive power,  by 
applying an ensemble sample classification method within a leave-one-out cross-validation 
scheme.  For  this  purpose,  the  249  patient  samples  were  first  grouped  into  249  different 
training/test set partitions, using 248 samples for the training sets and the remaining sample 
as the test set. For each of the 248 training sets differentially expressed genes were selected 
independently with the "Empirical Bayes moderated t-statistic"  (Smyth, 2004) and used to 
train  a  machine  learning  model,  which  was  evaluated  based  on  the  left-out  sample  (a 
procedure  known  as  "external  cross-validation").  To  classify  the  left-out  sample,  the 
prediction results  of four algorithms (Support  Vector Machine,  Random Forest,  kNN and 
Prediction Analysis for Microarrays,  with all  parameters being optimised by using a grid 
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search  within  a  nested  cross-validation)  (Tibshirani  et  al.,  2002)  were  combined  to  a 
majority-vote  ensemble classifier  as  to  compensate  for  the  inevitable  inherent  biases  and 
variances that exists amongst each of these machine learning algorithms. In order to rank the 
genes  based  on  the  cross-validation  results,  their  frequency  of  occurrence  in  the  list  of 
significantly differentially expressed genes (p-value < 0.05) across different cross-validation 
cycles was recorded, and genes received higher scores the more often they had been selected. 
All steps of the analysis were conducted using an in-house web-application for microarray 
analysis, available at www.arraymining.net.
Pre-clinical study
Compounds  and  reagents:  ATM  inhibitors  (KU55933  and  KU60019)  and  DNA-PKcs 
inhibitors  (NU7441  and  NU7026)  were  purchased  from  Tocris  Bioscience,  UK.  The 
compounds were dissolved in 100% DMSO and stored at - 20ºC. Cisplatin was obtained from 
Nottingham University Hospitals. 
Cell lines and culture media: BRCA1 deficient HeLa SilenciX® cells and control BRCA 
proficient  HeLa  SilenciX®  cells  were  purchased  from  Tebu-Bio  (www.tebu-bio.com). 
SilenciX cells were grown in DMEM medium (with L-Glutamine 580mg/L, 4500 mg/L D19 
Glucose,  with  110mg/L Sodium  Pyruvate)  supplemented  with  10%  FBS,  1%  penicillin/
streptomycin and 125 μg/ml Hygromycin B. MDA-MB-436 (BRCA1 deficient human breast 
cancer cells) was grown in DMEM (Sigma, UK) and MCF7 (BRCA1 proficient human breast 
cancer cells) was grown in RPMI1640 (Sigma, UK). All media used to culture human cancer 
cell lines were supplemented with 10% FBS (PAA, UK) and 1% penicillin/streptomycin. 
Clonogenic survival assay: 200-500 hundred cells per well were seeded in six-well plates. 
Cells  were  allowed  to  adhere  for  4  hours.  Compounds  (ATM  inhibitors  or  DNA-PKcs 
inhibitors) were added at the indicated concentrations. For cisplatin combination studies, cells 
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were initially  treated with  cisplatin  for  16 hours  and then gently  washed twice  with  1X 
phosphate buffered saline and incubated in fresh media with or without ATM or DNA-PK 
inhibitors at indicated concentration. The plates were left in the incubator for 12-14 days. 
After incubation, the media was discarded, fixed (with methanol and acetic acid mixture) and 
stained with crystal violet and counted. Surviving Fraction = [No. of colonies formed/ (No. of 
cells seeded x Plating efficiency)] x100.  All clonogenic assays were done in triplicate.
Evaluation  of  drug  interaction  (Combination  index):  To  investigate  synergistic  and 
additive  activity,  combination  index  was  calculated  as  described  previously  (Berenbaum, 
1981). If D (combination index) is <1 the effect of the combination is synergistic, whereas if 
D=1 or D is >1 the effect is additive or antagonistic respectively.  
γH2AX  immunofluorescence  microscopy:  This  assay  was  performed  as  described 
previously(Sultana et al.,  2013). Briefly, cells were incubated in medium containing ATM 
inhibitor or DNA-PKCS inhibitor  for 48 hours. For cisplatin combination studies, cells were 
initially treated with cisplatin for 16 hours and then gently washed twice with 1X phosphate 
buffered saline and incubated in fresh media with or without ATM or DNA-PK inhibitors at 
indicated concentration for 48 hours.
Neutral COMET assay: COMET assay reagents were purchased from Trevigen and used 
according to the manufacturer’s neutral COMET protocol (Gaithersburg, MD, USA). Briefly, 
1 x 105 cells per well were seeded into a 6 well plate and treated with KU55933 (7.5µM) or 
NU7441 (0.75µM). After 48 hours treatment cells were resuspended in 250 µl PBS.  For 
COMET analysis 25 µl of cell suspension was mixed with 250 µl molten LMAgarose and 
then 75 µl of the mixture pipetted immediately onto COMET slides. Slides were allowed to 
set at 4oC for 20 minutes and then immersed in lysis buffer for 60 minutes at 4oC. Slides were 
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then subjected to electrophoresis at 20 V for 60 minutes in chilled electrophoresis buffer (0.5 
M  Tris,  1.5  M  sodium acetate).  Following  electrophoresis  slides  were  incubated  for  30 
minutes in DNA precipitation solution (5 M ammonium acetate in 95% ethanol) at room 
temperature  and subsequently  fixed in  70% ethanol  for  20 minutes  at  room temperature. 
Slides were left to dry overnight at 4oC and then each sample stained with 50 µl Sybr green 
and  scored  using  COMET  ASSAY  IV  software  (Perceptive  Instruments  Ltd,  Bury  St 
Edmonds, UK).  Treatments were performed in triplicate and 50 cells counted for each. 
Flow cytometric analyses (FACS): Cells grown to sub-confluence were exposed to ATM or 
DNA-PKcs inhibitors either alone or in combination with cisplatin for 48 hours and collected 
by  trypsinization  and  centrifugation  (1000  rpm for  5  minutes).  FACS was  performed as 
described previously (Sultana et al., 2013). 
Annexin V flow cytometric analyses: Cells grown to sub-confluence were exposed to ATM 
or  DNA-PKcs  inhibitors  either  alone  or  in  combination  with  cisplatin  for  48  hours  and 
collected  by  trypsinization  and  centrifugation  (1000  rpm for  5  minutes).  The  assay  was 
performed as described previously (Sultana et al., 2013).  
Quantitative real time PCR: RNA was extracted from cell lines using the RNeasy Mini Kit 
(Qiagen)  and  quantified  using  a  microvolume  spectrophotometer.  cDNA synthesis  was 
performed using the RT2 First Strand Kit (Qiagen). Primers used for RT-PCR for BER genes 
are shown in supplementary table S9. Quantitative PCR was performed on an ABI prism 
7700 (Applied Biosystems) using SYBR green detection (Applied Biosystems®, UK). The 
housekeeping gene GAPDH was used to standardise the samples.
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RT² Profiler™ PCR Array for global DNA Repair expression analysis: To evaluate the 
expression of 84 DNA repair genes simultaneously, real-time PCR was performed using the 
RT² Profiler™ PCR Array for global DNA Repair expression analysis in technical triplicates 
(ABI 7500 Fast Block Detection System; Applied Biosystems, Foster City, USA) and the data 
analysed as per manufacturer’s recommendation. GAPDH was used for normalization of the 
data. A 2 fold change or greater change in expression was considered significant. 
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RESULTS
Clinical studies
XRCC1, pol β, APE1 and SMUG1 are key BER proteins. Moreover, we have recently shown 
that XRCC1 (Sultana et al., 2013), pol β (Abdel-Fatah et al., 2014b), APE1 (Abdel-Fatah et 
al.,  2014a)  and  SMUG1 (Abdel-Fatah  et  al.,  2013b)  are  promising  biomarkers  in  breast 
cancer. To evaluate whether they also have prognostic and predictive significance based on 
BRCA1 status, we proceeded to immunohistochemical evaluation of XRCC1, pol β, APE1 
and SMUG1 in BRCA1 positive and BRCA1 negative breast tumours.
BRCA1 negativity is associated with impaired XRCC1 and pol β protein expression in 
human sporadic breast cancers: A total of 1602 breast tumours were suitable for BRCA1 
expression analysis.   1085/1602 (67.7%) of tumours were BRCA1 positive and 517/1602 
(32.3%) were negative for  BRCA1 expression (Figure 1A).   As shown in supplementary 
Table S3, BRCA1 negative tumours were highly significantly associated with low XRCC1 
(p<0.00001) and low polβ (p<0.000001). In the BRCA1 negative cohort we then evaluated 
clinicopathological associations of XRCC1 and pol β protein expression (Figure 1A). The 
data for XRCC1 and polβ are summarized in supplementary tables S4 and S5 respectively. 
Although no significant associations were seen with stage, tumour grade, tumour types or 
pleomorphism,  BRCA1 negative/ polβ low tumours were more likely to be Bcl2 negative 
(p=0.001) and BRCA1 negative/ XRCC1 low tumours were more likely to be p53 negative 
(p= 0.015). 
BRCA1 negative/low XRCC1 or BRCA1 negative/low polβ tumours are associated with 
poor  breast  cancer  specific  survival  (BCSS):   BRCA1  negativity  was  significantly 
associated with poor BCSS compared to BRCA1 positive tumours (p<0.000001) (Figure 1B) 
and  is  consistent  with  previous  studies  showing  poor  prognostic  significance  of  BRCA1 
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silencing in sporadic breast tumours (Hsu et al.,  2013; Wu et al.,  2013).   In the BRCA1 
negative group we investigated the prognostic influence of XRCC1 and pol β. As shown in 
Figure 1C1, BRCA1 negative/ low XRCC1 tumours had worse BCSS compared to BRCA1 
negative/ high XRCC1 tumours (p=0.001). Similarly, BRCA1 negative/ low polβ  tumours 
had worse BCSS compared to BRCA1 negative/ high polβ tumours (p=0.008) (Figure 1D1). 
As BRCA1 negativity is likely to be associated with ER negative tumours we conducted 
further analysis. In the BRCA1 negative/ER negative subgroup, low XRCC1 or low polβ 
remains associated with poor survival (p=0.033 and p=0.034 respectively, Figure 1C2 and 
1D2). In the BRCA1 negative/ER positive subgroup, similarly, low XRCC1 was associated 
with poor survival (p=0.003, Figure 1C3) and although not significant there was trend with 
low  polβ  (p=0.121,  Figure1D3).  In  multivariate  cox  regression  analysis  (Table  1),  low 
XRCC1  (p=0.005)  and  low  pol  β  (p=0.036)  were  independently  associated  with  poor 
survival. 
In the current study, APE1 and SMUG1 did not influence survival and was not associated 
with any clinicopathological parameters in BRCA1 negative breast tumours (data not shown).
XRCC1  and  pol  β  expression  in  germ-line  BRCA1  mutated  breast  cancers:  To 
investigate whether XRCC1 and polβ would also influence outcomes in germ-line BRCA1 
deficient  breast  cancer  we investigated  a  cohort  of  50  germ-line  BRCA1 mutated  breast 
cancers.   Demographics  are  summarised  in  supplementary  table  S6.  No  significant 
clinicopathological  correlations  were  observed  (supplementary  tables  S7  and S8).  In  this 
small  exploratory cohort,  low polβ  (5/34 tumours) was significantly associated with poor 
survival (p=0.007) in germ line BRCA1 mutated breast cancers (Figure 2A) compared to 
high polβ (29/34 tumours). Low XRCC1 expression did not influence survival in this cohort 
(Supplementary Figure S1A) 
   16
Low XRCC1 and low  pol  β  transcript  levels  have prognostic  significance in  BRCA1 
mRNA low sporadic breast cancers: To confirm whether the association between BRCA1 
and BER also operated at the mRNA level we investigated the Metabric cohort (n=1920, 
demographics  summarized  in  supplementary  table  S9)  and  the  Uppsala  cohort  (n=249, 
demographics summarized in supplementary table S10) - cohorts where mRNA expression 
data was available. In ER+ tumours (n=1485, Metabric), low BRCA1 (n=81) was associated 
with  poor  survival  compared  to  high  BRCA1  mRNA expressing  tumours  (n=  1404)  (p= 
0.0226, Figure 2B1). In the low BRCA1/ER+ group, low polβ (n=66) or low XRCC1 (n=42) 
remains associated with poor survival (ps= 0.038 and 0.0321 respectively) compared to high 
polβ (n=14) or high XRCC1 (n=38) mRNA expressing tumours (Figures 2B2 and 2B3). In 
the ER- tumours (n=435, metabric), high BRCA1 (n= 385) was associated with poor survival 
compared  to  low BRCA1 mRNA expressing  tumours  (n=50)  (p=  0.0365,  Supplementary 
Figure S2B).  In the low BRCA1/ER- group, low polβ (n=5) or low XRCC1 (n=17) remains 
associated with poor survival compared to high polβ (n=43) or high XRCC1 (n=31) mRNA 
expressing tumours [ps= 0.0224 and 0.0206 respectively) (Figures 2C1 and 2C2).  In the 
Uppsala cohort,  low polβ  mRNA (36/175 tumours)  was associated with poor survival  in 
BRCA1 low mRNA breast cancers (p=0.03, Supplementary Figure S1C) compared to high 
polβ mRNA tumours (139/175 tumours). XRCC1 mRNA expression levels did not influence 
survival in the Uppsala cohort (Supplementary Figure S1D). 
Artificial neural network (ANN), ensemble classification and cross-validation analysis 
for BRCA1 interacting DNA repair genes: The top 100 strongest are shown in Figure 2D. 
The biological functions of BRCA1 interaction genes are summarized in supplementary Table 
S12. The predominant interactions with genes involved in  BER, NER, HR, NHEJ, inter-
strand crosslink repair, MMR and transcription  is not only consistent with the previously 
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described functions of BRCA1 (Caestecker and Van de Walle, 2013; Huen et al., 2010; Silver 
and Livingston, 2012) but also reveals new BRCA1 interacting genes.  
Pre-clinical studies
The clinical and bioinformatics data presented above provides evidence that BRCA1 may 
influence the expression of multiple DNA repair genes. To provide additional pre-clinical 
evidence we investigated the expression of DNA repair in BRCA1 deficient and proficient 
cancer cell lines. 
BRCA1 deficient cancer cells exhibit impaired BER expression: BRCA1 deficient HeLa 
SilenciX  cells,  control  BRCA1 proficient  HeLa  SilenciX  cells,  BRCA1 deficient  MDA-
MB-436 breast cancer cells and BRCA1 proficient MCF7 breast cancer cells were initially 
examined for the expression of BRCA1, XRCC1 and pol β proteins.  BRCA1 deficiency was 
first confirmed at the protein level in BRCA1 deficient HeLa SilenciX and MDA-MB-436 
cells compared to control HeLa SilenciX cells and MCF7 cells (Figures 3A1, 3A2, 3B1, 
3B2). The relative expression of XRCC1 and pol β  was also found to be low in BRCA1 
deficient cells compared to BRCA1 proficient cells at the protein level (Figures 3A1, 3A2, 
3B1, 3B2).  Low mRNA expression of BRCA1, XRCC1 and pol β was confirmed by qRT-
PCR in MDA-MB-436 cells compared to MCF-7 cells and BRCA1 deficient HeLa SilenciX 
compared to control HeLa SilenciX cells (Figure 3A3, 3B3 respectively). The data is also 
summarized in supplementary Tables S14 and S15.  To provide additional evidence that low 
polβ  and low XRCC1 expression confers phenotypic consequence, we investigated MMS 
sensitivity in MDA-MB-436 and MCF-7 cells. As shown in supplementary Figure S3B, we 
found that MDA-MB-436 cells are sensitive to MMS. The data concurs with a recent study 
that showed a similar MMS sensitivity in BRCA1 deficient cells that was associated with 
impaired functional interaction between polβ and BRCA1(Masaoka et al., 2013).
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BRCA1  deficient  cells  have  deregulated  gene  expression  of  multiple  DNA  repair 
pathways: To investigate whether down regulation of DNA repair is restricted to polβ and 
XRCC1 or also includes additional DNA repair pathways, we profiled a panel of 84 DNA 
repair genes in BRCA1 deficient and BRCA1 proficient cells using the RT2 Profiler DNA 
Repair PCR array. All experiments were done in triplicates and DNA repair expression was 
compared between BRCA1 deficient and BRCA1 proficient cells [BRCA1 deficient HeLa 
SilenciX versus control BRCA1 proficient HeLa SilenciX cells and MDA-MB-436 versus 
MCF7 cells]. The data is summarized in Figure 3C (BRCA1 deficient and proficient HeLa 
SilenciX cells),  supplementary table S16 (BRCA1 deficient and proficient HeLa SilenciX 
cells),  Figure 3D (MDA-MB-436 and MCF7 cells),  and supplementary table S17 (MDA-
MB-436 and MCF7 cells).   In MDA-MB-436 cells as well  as in BRCA1 deficient HeLa 
SilenciX cells, we observed a consistent down regulation of several BER genes as well as 
genes involved in other pathways including base excision repair, nucleotide excision repair, 
homologous recombination, non-homologous end joining, inter-strand crosslink repair and 
mismatch repair.  
BRCA1  deficient  cancer  cells  are  sensitive  to  ATM  inhibitors  either  alone  or  in 
combination with cisplatin:  KU55933 (2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one) is 
an ATP-competitive potent ATM inhibitor with an IC50 of 13 nmol/L (Hickson et al., 2004). 
For  additional  validation  we  also  tested  KU60019  [(2R,6S-rel)-2,6-Dimethyl-N-[5-[6-(4-
morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl-4-morpholineacetamide]  another 
ATP-competitive  potent  ATM inhibitor  (Golding  et  al.,  2009).  Treatment  with  KU55933 
resulted in reduced survival of BRCA1 deficient HeLa SilenciX cells compared to BRCA1 
proficient HeLa SilenciX cells (Figure 4A1). Similarly, MDA-MB-436 cells were sensitive to 
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KU55933 compared to MCF7 cells respectively (Figures 4B1). As an additional validation 
we  investigated  KU60019.  As  shown  in  supplementary  Figures  S3A and  S3E,  BRCA1 
deficient  HeLa  SilenciX  cells  and  MDA-MB-436  cells  were  also  sensitive  to  KU60019 
compared to BRCA1 proficient cells.  3-aminobenzamide,  a PARP inhibitor (Shekh et  al., 
2014) was used as  a  positive control.  As shown in supplementary Figure S2A and S2B, 
BRCA1 deficient cells, as expected, are sensitive to PARP inhibitor. 
To provide mechanistic evidence that ATM inhibition leads to a synthetic lethality effect in 
BRCA1 deficient  cells,  we investigated the functional  consequence of  ATM inhibition in 
BRCA1  proficient  and  BRCA1  deficient  cells.   Double  strand  breaks  (DSBs)  induce 
phosphorylation of H2AX at serine 139 (γH2AX), and accumulation of γH2AX foci in the 
nucleus is a marker of DSBs. Therefore, γH2AX immunocytochemistry was performed in 
BRCA1 deficient HeLa SilenciX cells and MDA-MB-436 cells and compared to BRCA1 
proficient control SilenciX or MCF7 cells (Supplementary Figure S3A). Nuclei containing 
more  than  six  γH2AX foci  were  considered  positive.  Cells  were  treated  with  KU55933 
(10µM)  for  48  hours.  The  percentage  of  cells  with  more  than  six  γH2AX  foci  was 
significantly  higher  in  BRCA1  deficient  cells  in  comparison  to  BRCA1  proficient  cells 
(Figures 4A2, 4B2). Similar results were observed with KU60019 (Supplementary Figures 
S4B and S4F). The data provides evidence that BRCA1 deficient cells accumulate DSBs at 
an increased rate after treatment with an ATM inhibitor relative to BRCA1proficient cells. As 
an  additional  validation  we performed neutral  COMET assays  after  ATM or  DNA-PKcs 
inhibitor treatment in cells. As shown in supplementary Figure S3C, BRCA1 deficient cells 
accumulated significantly more DSBs compared to BRCA1 proficient cells. Accumulation of 
DSBs may delay cell cycle progression. In BRCA1 deficient and BRCA1 proficient cells, cell 
cycle  progression  was  monitored  after  48  hours  of  treatment  with  KU55933  (10µM) 
(Supplementary Figure S4B). BRCA1 deficient cells were shown to be significantly arrested 
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in G2/M phase of the cell cycle compared to BRCA1 proficient cells (Figures 4A3, 4B3). 
Similar  results  were  observed  with  KU60019  (Supplementary  Figures  S5C  and  S5G). 
Accumulation of DSBs may result in eventual induction of apoptosis.  Apoptosis detection by 
FITC-annexin  V flow  cytometric  analysis  was  therefore  performed  in  cells  treated  with 
KU55933  (10µM)  for  48  hours  (Supplementary  Figure  S4C).   The  percentage  of  cells 
undergoing apoptosis following ATM inhibitor treatment was significantly higher in BRCA1 
deficient cells in comparison to BRCA1 proficient cells (Figures 4A4, 4B4). Similar results 
were  observed  with  KU60019  (Supplementary  Figures  S5D  and  S5H).   The  functional 
studies  together  provide  evidence  that  ATM  inhibition  can  induce  synthetic  lethality  in 
BRCA1  deficient  cells  by  causing  accumulation  of  DSBs,  G2M  cell  cycle  arrest  and 
induction  of  apoptosis.  However  the  level  of  synthetic  lethality  effect  seen  with  ATM 
inhibitor  was  modest  compared  that  demonstrated  previously  using  PARP inhibitors  in 
BRCA1 deficient cells (Lord and Ashworth, 2008). 
Cisplatin hypersensitivity has been well established in BRCA1 deficient cells (Tassone et al., 
2009).  We  investigated  whether  low  dose  cisplatin  could  potentiate  synthetic  lethality 
induced  by  KU55933.  Cells  were  treated  with  a  combination  of  low  dose  cisplatin 
(0.00001µM – 0.1 µM) and KU55933 (5µM).  As shown in Figure 4C1 and 4D1, KU55933 
treatment increased cytotoxicity of cisplatin in BRCA1 deficient HeLa SilenciX as well in 
MDA-MB-436  compared  to  BRCA1  proficient  control  SilenciX  and  MCF7  cells.  The 
interaction was synergistic [combination index= 0.6 (BRCA1 deficient HeLa SilneciX) and 
0.7 (MDA-MB-436), supplementary Figure S7A]. In BRCA1 deficient cells treated with a 
combination of cisplatin and KU55933, the observed increased cytotoxicity was associated 
with accumulation of DSBs (Figure 4C2 and 4D2), G2/M cell cycle arrest (Figure 4C3 and 
4D3) and increased apoptosis (Figure 4C4 and 4D4). 
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BRCA1 deficient cancer cells are sensitive to DNA-PKcs inhibitors either alone or in 
combination  with  cisplatin:  NU7441  (2-N-morpholino-8-dibenzothiophenyl-chromen-4-
one) is a potent and a specific inhibitor of DNA-PKcs with an IC50 of 14 nmol/L for DNA-PK 
inhibition (Tavecchio et al., 2012). NU7026 (2-(morpholin-4-yl)-benzo[h]chromen-4-one) is 
another DNA-PKcs inhibitor (Nutley et al., 2005).  
Treatment with NU7441 resulted in reduced survival of BRCA1 deficient HeLa SilenciX 
cells compared to BRCA1 deficient HeLa SilenciX cells (Figure 5A1). MDA-MB-436 cells 
were modestly sensitive to NU7441 compared to MCF7 cells respectively (Figures 5B1). As 
an additional validation we investigated NU7026. As shown in supplementary Figures S6A 
and S6E, BRCA1 deficient HeLa SilenciX cells and MDA-MB-436 cells were also sensitive 
to NU7026 compared to BRCA1 proficient cells. To provide mechanistic evidence that DNA-
PKcs inhibition leads to a synthetic lethality effect in BRCA1 deficient cells, we investigated 
the  functional  consequence  of  DNA-PKcs  inhibition  in  BRCA1  proficient  and  BRCA1 
deficient cells.  Cells were treated with NU7441 (1.5µM) for 48 hours. The percentage of 
cells with more than six γH2AX foci was significantly higher in BRCA1 deficient cells in 
comparison to BRCA1 proficient cells (Figures 5A2, 5B2). Similar results were observed 
with  NU7026  (supplementary  Figures  S6B  and  S6F).  In  BRCA1  deficient  and  BRCA1 
proficient  cells,  cell  cycle  progression  was  monitored  after  48  hours  of  treatment  with 
NU7441 (1.5µM). BRCA1 deficient cells were shown to be significantly arrested in G1 phase 
of the cell cycle compared to BRCA1 proficient cells (Figures 5A3, 5B3). Similar results 
were observed with NU7026 (supplementary Figures S6C and S6G).  Apoptosis detection by 
FITC-annexin  V flow  cytometric  analysis  was  therefore  performed  in  cells  treated  with 
NU7441 (1.5µM) for  48 hours.   The percentage of  cells  undergoing apoptosis  following 
DNA-PKcs  inhibitor  treatment  was  significantly  higher  in  BRCA1  deficient  cells  in 
comparison to BRCA1 proficient cells (Figures 5A4, 5B4). Similar results were observed 
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with  NU7026  (Supplementary  Figures  S6D  and  S6H).  The  functional  studies  together 
provide  evidence  that  DNA-PKcs  inhibition  can  induce  synthetic  lethality  in  BRCA1 
deficient  cells  by  causing  accumulation  of  DSBs,  G1  cell  cycle  arrest  and  induction  of 
apoptosis.  We  then  investigated  whether  low  dose  cisplatin  could  potentiate  synthetic 
lethality induced by NU7441. Cells were treated with a combination of cisplatin (0.00001µM 
– 0.1 µM) and NU7441 (0.75µM).  As shown in Figure 5C1 and 5D1, NU7441 treatment 
substantially increased cytotoxicity of low dose cisplatin in BRCA1 deficient HeLa SilenciX 
as well  as in MDA-MB-436 compared to BRCA1 proficient control  SilenciX and MCF7 
cells.  The  interaction  was  synergistic  [combination  index=  0.5  (BRCA1  deficient  HeLa 
SilneciX) and 0.6 (MDA-MB-436), supplementary figure S7B]. Increased cytotoxicity was 
associated with accumulation of DSBs (Figure 5C2 and 5D2), G2/M cell cycle arrest (Figure 
5C3 and 5D3) and increased apoptosis (Figure 5C4 and 5D4). 
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DISCUSSION 
We have shown, for the first time, that BRCA1 negative tumours have significantly lower 
expression of XRCC1 and Polβ, a feature that was also seen in BRCA1 deficient cancer cell 
lines.  Patients  with BRCA1 negative/  low XRCC1 or  BRCA1 negative /low Polβ  breast 
tumours  also  have worse  breast  cancer  specific survival  including in  ER+ and ER- sub-
groups. These new observations suggest that polβ/XRCC1 based sub-stratification may refine 
prognostication in BRCA1 deficient phenotypes. In addition, poor prognostic significance of 
pol β in a small cohort of germ-line BRCA1 mutated tumours is also consistent with a recent 
preclinical study linking BRCA1 and pol β in cancer cell line models (Masaoka et al., 2013). 
Additionally, at the mRNA level we conducted neural network analysis and demonstrated that 
the predominant BRCA1  interactions were with genes involved in BER, NHEJ, NER and 
MMR inter-strand crosslink repair and transcription.  To compliment clinical observations we 
DNA repair  profiled  BRCA1  proficient  and  deficient  cell  lines  and  also  demonstrated 
impairment in BER, NHEJ, NER and MMR. A surprising finding in the current study was 
that several genes involved in DDR were down regulated in BRCA1 deficient HeLa as well 
as  in  breast  cancer  cells  as  one  would  anticipate  that  this  would  reduce  survival  in  the 
absence of exogenous DNA damage. Moreover, as inhibition of BER (via PARP inhibition) is 
synthetically lethal in association with BRCA defects, we expected BRCA deficient cells to 
have compensatory up-regulation of BER pathway. In contrast we observed consistent down 
regulation of  BER implying a  complex regulation,  including transcriptional  regulation of 
BER by  BRCA1.   Although  in  BRCA deficient  cells  PARP1 may  be  up-regulated  as  a 
compensatory mechanism, in our cell line models we actually observed low expression of 
PARP1 mRNA, PARP2 mRNA and PARP3 mRNA in BRCA1 deficient HeLa cells and low 
expression of PARP1 mRNA and PARP2 mRNA in MDA-MB-436 cells.  Although these new 
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observations are intriguing, mechanism for down-regulation is currently unknown. However, 
we speculate that genomic instability in BRCA1 null cells may over a period of time, in the 
cell lines used in the current study, eventually lead to acquisition of new defects in other 
DNA repair pathways along with compensatory up-regulation of pro-survival pathways. In 
addition, recent studies implicating a role for BRCA1 in transcriptional regulation of BER 
(Saha et al., 2010) and NER(Hartman and Ford, 2002) suggests additional mechanisms may 
also  operate  for  the  observed  genomic  instability  in  BRCA1 deficient  cells.  The  altered 
expression of XRCC1 and polβ shown here also concurs to a large extent with a recent study 
by De Summa et  al.  who investigated the expression of APE1, NTHL1, OGG1, PARP1, 
XRCC1 and miR17 in BRCA1/2 mutated and sporadic breast cancers (De Summa et al., 
2014).  Down-regulation  of  XRCC1,  APE1  and  NTHL1  was  evident  in  that  study. 
Interestingly  overexpression  of  PARP1  and  miR17  were  observed  in  BRCA1  mutated 
tumours implying that they could be investigated as biomarker of BRCAness phenotype. In 
contrast, we observed PARP1 down regulation in BRCA1 deficient HeLa as well as in MDA-
MB-436 breast cancer cell line in our study.  Larger studies in human breast tumours are 
required to confirm these findings.
Although from preclinical studies we would expect DNA repair deficiency to be associated 
with chemosensitivity and improved survival in patient who received adjuvant chemotherapy, 
in the current clinical study we found that low BRCA1 or low BRCA1/low XRCC1 or low 
BRCA1/low Pol β was associated with poor survival. Our recent studies of DNA repair in 
breast cancer suggest that the relationship may be complex.  In previous studies we found 
that low XRCC1 (Sultana et al., 2013) and low DNA pol β (Abdel-Fatah et al., 2014b) to be 
associated with poor survival. As BER deficiency could lead to accelerated accumulation of 
mutations resulting in a mutator phenotype (Bielas et al., 2006) that is associated with an 
aggressive biology, we speculate that the observed effect for XRCC1 and pol β may reflect 
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this phenomenon.   On the other hand, high SMUG1 (Abdel-Fatah et al., 2013b) and high 
FEN1 (Abdel-Fatah et al., 2014c) was associated with poor survival in patients who have 
received adjuvant chemotherapy implying a DNA repair influenced  predictive significance 
for SMUG1 and FEN1 in breast cancer.  
We have demonstrated that a potential  synthetic lethality relationship also exists between 
BRCA1 deficiency and blockade of ATM or DNA-PKcs in cells.   A model for  synthetic 
lethality is shown in supplementary figure S8. We have concluded synthetic lethality for the 
following reasons: a) BRCA1 deficient cells have increased sensitivity to ATM or DNA-PKcs 
inhibitors;  b)  upon  ATM  inhibitor  treatment,  BRCA1  deficient  cells  accumulate  DSBs, 
exhibit G2/M cell cycle arrest and induction of apoptosis; and c) upon DNA-PKcs inhibitor 
treatment,  BRCA1  deficient  cells  accumulate  DSBs,  exhibit  G1  cell  cycle  arrest  and 
induction of apoptosis. Interestingly, BRCA1 deficient cells also exhibit low mRNA levels of 
ATM and DNA-PKcs but are sensitive to ATM and DNA-PKcs inhibitors. The data suggest a 
dose dependent effect where although ATM and DNA levels are low the cells are able to 
tolerate  genomic  instability  and  survive.  However,  with  additional  functional  inhibition 
through  small  molecule  inhibition,  pronounced  accumulation  of  DSBs  could  lead  to  a 
synthetic  lethality  effect.  Although  phosphorylation  of  H2AX  is  ATM  and  DNA-Pkcs 
dependent, we observed accumulation of γH2AX foci in BRCA1 deficient cells incubated in 
medium containing ATM inhibitor or DNA-PKcs inhibitor for 48 hours. Whether reflects a 
timing issue are whether H2AX phosphorylation may be contributed by other factors such as 
activated ATR is unclear. To confirm DSB accumulation we also performed neutral COMET 
assay and have demonstrated DSB accumulation in BRCA1 deficient cells treated with ATM 
or DNA-PKcs inhibitor. Moreover the effects on cell cycle progression, although significant, 
appear  to  be  modest.   In  the  current  study,  the  magnitude  of  synthetic  lethality  seen  in 
BRCA1  deficient  cells  treated  with  ATM  or  DNA-PKcs  inhibitor  alone  was  not  as 
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pronounced as that demonstrated for PARP inhibitors (Lord and Ashworth, 2008), we found 
that low dose cisplatin combination significantly enhanced synthetic lethality.   Of note, the 
dose of cisplatin used in our study was 1/10th the dose used in previous preclinical studies 
investigating cisplatin sensitivity in vitro in BRCA1 deficient cells (Husain et al., 1998). At 
higher doses of cisplatin similar to the doses used by Husain et al, BRCA1 deficient cells 
remain highly sensitive to platinum therapy (data not shown). We speculate that low dose 
cisplatin treatment generates low levels of DSBs.  In cells with proficient BRCA1 and BER, 
despite ATM or DNA-PKcs blockade, DSBs may be rapidly repaired in back-up DNA repair 
pathways and cells continue to survive. The back-up repair could operate at multiple levels 
including the complex interactions/overlap between HR, NHEJ, alternative NHEJ (B-NHEJ) 
(Chapman et  al.,  2012;  Schipler  and  Iliakis,  2013),  components  of  NER and ICL repair 
pathways.  On the other hand, in cells with deficient BRCA1 and low BER, the associated 
pharmacological  blockade  with  ATM  or  DNA-PKcs  inhibitors  may  lead  to  DSB 
accumulation  which  beyond a  threshold,  may severely  compromise  back-up  DNA repair 
machinery leading to DSB accumulation, cell cycle arrest and apoptosis. We have recently 
shown that XRCC1 deficient cells are cisplatin sensitive (Abdel-Fatah et al., 2013a) and ATM 
or DNA-PKcs inhibitors are also synthetically lethal in XRCC1 deficient cells (Sultana et al., 
2013).  Given the  potential  role  of  XRCC1 in  B-NHEJ (Mladenov and Iliakis,  2011)  we 
speculate that BRCA1 deficient cells that have low XRCC1 could also  have compromised B-
NHEJ in addition to BER resulting in increased genomic instability and  enhanced synthetic 
lethality with cisplatin treatment seen in the current study. Moreover, ATM or DNA-PKcs 
modulation has previously been shown to enhance cisplatin cytotoxicity (Dejmek et al., 2009; 
Yoshida et al., 2008).  Taken together, the data suggests that cisplatin combination may be 
more successful than ATM or DNA-PK monotherapy in BRCA1 negative tumours and would 
be consistent with a recent study showing enhancement of synthetic lethality with ABT-888 
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(PARP inhibitor) in combination with platinum chemotherapy in BRCA deficient cells (Clark 
et al., 2012).  
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Table 1. Multivariate analysis in BRCA1 negative sporadic breast cancers (Nottingham 
cohort).
  
Variables
Multivariate Model
Exp (B) CI 95% P Value
Pol beta expression 0.810 0.666-0.986 0.036
XRCC1 expression 0.831 0.731-0.945 0.005
Tumour stage 3.088 2.414-3.950 <0.0001
ER receptor status 0.522 0.328-0.833 0.006
Chemotherapy status 0.522 0.356-0.764 0.001
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FIGURE LEGENDS
Figure  1.  BRCA1  and  BER  protein  expression  in  human  breast  cancer.  A. 
Microphotographs of BRCA1 negative, BRCA1 positive, polβ positive and XRCC1 positive 
breast cancers. B. Kaplan Meier curves showing breast cancer specific survival (BCSS) in 
patients based on BRCA1 expression status.  C1. Kaplan Meier curves showing breast cancer 
specific  survival  (BCSS)  in  patients  with  BRCA1  negative  tumours  based  on  XRCC1 
expression status. C2. Kaplan Meier curves showing breast cancer specific survival (BCSS) 
in patients with BRCA1 negative/ER negative tumours based on XRCC1 expression status. 
C3. Kaplan Meier curves showing breast cancer specific survival (BCSS) in patients with 
BRCA1 negative/ER positive tumours based on XRCC1 expression status. D1. Kaplan Meier 
curves showing breast  cancer  specific survival  (BCSS) in  patients  with BRCA1 negative 
tumours based on polβ expression status. D2. Kaplan Meier curves showing breast cancer 
specific survival (BCSS) in patients with BRCA1 negative/ER negative tumours based on 
polβ  expression status.  D3.  Kaplan Meier  curves showing breast  cancer  specific survival 
(BCSS) in patients  with BRCA1 negative/ER positive tumours based on polβ  expression 
status.
Figure  2.  A.  Kaplan  Meier  curves  showing  overall  survival  in  patients  with  germ-line 
BRCA1mutated tumours based on polβ protein expression status. B1. Kaplan Meier curves 
showing  breast  cancer  specific  survival  (BCSS)  in  patients  based  on  BRCA1  mRNA 
expression  status  in  ER+  breast  cancer  (METABRIC  cohort).  B2.  Kaplan  Meier  curves 
showing breast cancer specific survival (BCSS) in patients with BRCA1 mRNA low/ER+ 
who received adjuvant endocrine therapy based on polβ mRNA status (METABRIC cohort). 
B3.  Kaplan Meier curves showing breast cancer specific survival (BCSS) in patients with 
BRCA1 mRNA low/ER+ who received adjuvant endocrine therapy based on XRCC1 mRNA 
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status  (METABRIC  cohort).  C1.  Kaplan  Meier  curves  showing  breast  cancer  specific 
survival  (BCSS)  in  patients  with  BRCA1  mRNA  low/ER-  who  received  adjuvant 
chemotherapy based on polβ mRNA status (METABRIC cohort). C2. Kaplan Meier curves 
showing breast cancer specific survival (BCSS) in patients with BRCA1 mRNA low/ER- 
who received adjuvant chemotherapy based on XRCC1 mRNA status (METABRIC cohort). 
D. The neural network illustrates the top genes that interact with BRCA1 and other DNA 
repair  genes.   In  addition,  the artificial  neural  network also reveals  how these top genes 
interact with each other. Top pair-wise interactions for gene probe markers associated with 
BRCA1 expression and the DNA repair process in 249 breast cancers is shown here. Each 
gene probe is represented by a node and the interaction weight between them as an edge, the 
width being defined by the magnitude of the weight. Interactions are directed from a source 
gene  to  a  target  gene  as  indicated  by  arrows.   Red  interactions  indicate  an  excitatory 
interaction and blue indicates an inhibitory interaction. Highly linked genes represent hubs 
that  are indicated to be highly influential  or  highly regulated in the BRCA1-DNA repair 
system. See supplementary data x for the biological functions of individual genes. 
Figure 3. DNA repair expression in BRCA1 deficient and BRCA1 proficient cells A1. 
Representative Western blots of BRCA1, XRCC1 and polβ in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells. A2. Protein quantification 
in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells 
are shown here. The Figure shows fold change in BRCA1 deficient cells in comparison to 
BRCA1 proficient cells. A3. mRNA expression in BRCA1 deficient HeLa SilenciX cells and 
control BRCA1 proficient HeLa SilenciX cells are shown here. The Figure shows fold 
change in BRCA1 deficient cells in comparison to BRCA1 proficient cells.  B1. 
Representative Western blots of BRCA1, XRCC1 and polβ in BRCA1 deficient MDA-
MB-436 cells and BRCA1 proficient MCF7 cells. B2. Protein quantification in MDA-
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MB-436 cells and MCF7 cells are shown here. The Figure shows fold change in BRCA1 
deficient cells in comparison to BRCA1 proficient cells.  B3. mRNA expression in MDA-
MB-436 cells and MCF7 cells are shown here. The Figure shows fold change in BRCA1 
deficient cells in comparison to BRCA proficient cells.   C. Scatter plots indicate up- and 
down-regulation of DNA repair mRNA expression in BRCA1 deficient HeLa SilenciX cells 
compared to BRCA1 proficient HeLa SilenciX cells. D. Scatter plots indicate up- and down-
regulation of DNA repair mRNA expression in MDA-MB-436 cells compared to MCF7 cells 
are shown here. Green circles show genes that are two-fold or more down-regulated. See also 
results section and supplementary table S16 and S17.
Figure 4. ATM inhibitors in BRCA1 deficient and BRCA1 proficient cells. A1. Clonogenic 
survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa 
SilenciX  cells  treated  with  KU55933.  A2.   уH2AX  immunohistochemistry  in  BRCA1 
deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with 
KU55933. A3. FACS analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient  HeLa  SilenciX  cells  treated  with  KU55933.  A4.  Annexin  V  flow  cytometric 
analysis  in  BRCA1  deficient  HeLa  SilenciX  cells  and  control  BRCA1  proficient  HeLa 
SilenciX cells treated with KU55933.B1. Clonogenic survival assays in MDA-MB-436 and 
MCF7 cells treated with KU55933. B2.  уH2AX immunohistochemistry in MDA-MB-436 
and MCF7 cells treated with KU55933.  B3. FACS analysis in MDA-MB-436 and MCF7 
cells treated with KU55933. B4. Annexin V flow cytometric analysis in MDA-MB-436 and 
MCF7 cells treated with KU55933. Inhibitors were added at the indicated concentrations (see 
methods for details).  C1.  Clonogenic survival  assays in BRCA1 deficient  HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
combination with KU55933. C2. уH2AX immunohistochemistry in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone 
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or in combination with KU55933. C3. FACS analysis in BRCA1 deficient HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
combination with KU55933. C4. Annexin V flow cytometric analysis in BRCA1 deficient 
HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin 
alone or in combination with KU55933. D1. Clonogenic survival assays in MDA-MB-436 
and MCF7 cells treated with cisplatin alone or in combination with KU55933. D2. уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in 
combination with KU55933. D3. FACS analysis in MDA-MB-436 and MCF7 cells treated 
with  cisplatin  alone  or  in  combination  with  KU55933.  D4.  Annexin  V flow  cytometric 
analysis in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in combination 
with KU55933. * p<0.05, ** p<0.01.
Figure  5.  DNA-PKcs  inhibitors  in  BRCA1  deficient  and  BRCA1  proficient  cells.  A1. 
Clonogenic survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient HeLa SilenciX cells treated with NU7441. A2.  уH2AX immunohistochemistry in 
BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells 
treated  with  NU7441.  A3.  FACS analysis  in  BRCA1 deficient  HeLa  SilenciX cells  and 
control BRCA1 proficient HeLa SilenciX cells treated with NU7441. A4. Annexin V flow 
cytometric analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient 
HeLa SilenciX cells treated with NU7441.B1. Clonogenic survival assays in MDA-MB-436 
and MCF7 cells treated with NU7441. B2. уH2AX immunohistochemistry in MDA-MB-436 
and MCF7 cells treated with NU7441.  B3. FACS analysis in MDA-MB-436 and MCF7 cells 
treated with NU7441. B4. Annexin V flow cytometric analysis in MDA-MB-436 and MCF7 
cells  treated  with  NU7441.  Inhibitors  were  added  at  the  indicated  concentrations  (see 
methods for details).  C1.  Clonogenic survival  assays in BRCA1 deficient  HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
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combination with NU7441. C2. уH2AX immunohistochemistry in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone 
or in combination with NU7441. C3. FACS analysis in BRCA1 deficient HeLa SilenciX cells 
and  control  BRCA1  proficient  HeLa  SilenciX  cells  treated  with  cisplatin  alone  or  in 
combination with NU7441.  C4.  Annexin V flow cytometric analysis  in BRCA1 deficient 
HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin 
alone or in combination with NU7441. D1. Clonogenic survival assays in MDA-MB-436 and 
MCF7  cells  treated  with  cisplatin  alone  or  in  combination  with  NU7441.  D2.  уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in 
combination with NU7441. D3.  FACS analysis in MDA-MB-436 and MCF7 cells treated 
with cisplatin alone or in combination with NU7441. D4. Annexin V flow cytometric analysis 
in  MDA-MB-436  and  MCF7  cells  treated  with  cisplatin  alone  or  in  combination  with 
NU7441. * p<0.05, ** p<0.01.
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ABSTRACT
BRCA1,  a  key  factor  in  homologous  recombination  (HR)  repair  may also  regulate  base 
excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-
PKcs could be a promising strategy in breast cancer. We investigated BRCA1, XRCC1 and 
pol  β  protein  expression  in  two  cohorts  (n=1602  sporadic  and  n=50  germ-line  BRCA1 
mutated)  and  mRNA expression  in  two  cohorts  (n=1952  and  n=249).  Artificial  neural 
network analysis for BRCA1-DNA repair interacting genes was conducted in 249 tumours. 
Pre-clinically, BRCA1 proficient and deficient cells were DNA repair expression profiled and 
evaluated  for  synthetic  lethality  using ATM and DNA-PKcs inhibitors  either  alone  or  in 
combination with cisplatin. In human tumours, BRCA1 negativity was strongly associated 
with low XRCC1, and low pol β at mRNA and protein levels (p<0.0001). In patients with 
BRCA1 negative tumours, low XRCC1 or low pol β expression was significantly associated 
with poor survival in univariate and multivariate analysis compared to high XRCC1 or high 
pol  β  expressing  BRCA1 negative  tumours  (ps<0.05).    Pre-clinically,  BRCA1 negative 
cancer cells exhibit low mRNA and low protein expression of XRCC1 and pol β.  BRCA1-
BER deficient cells were sensitive to ATM and DNA-PKcs inhibitor treatment either alone or 
in combination with cisplatin and synthetic lethality was evidenced by DNA double strand 
breaks accumulation, cell cycle arrest and apoptosis. We conclude that XRCC1 and pol β 
expression status in BRCA1 negative tumours may have prognostic significance. BRCA1-
BER deficient  cells  could be targeted by ATM or  DNA-PKcs inhibitors  for  personalized 
therapy.
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INTRODUCTION
Breast  Cancer Susceptibility Gene 1 (BRCA1) facilitates  the efficient  resolution of  DNA 
double-strand breaks (DSBs) through HR (Caestecker and Van de Walle, 2013; Huen et al., 
2010). Cells lacking functional BRCA1 protein have impaired HR, and thus depend on the 
more  error-prone  non-homologous  end  joining  (NHEJ)  pathway leading  to  chromosomal 
instability that drive breast cancer development (Huen et al., 2010). In women, BRCA1 germ 
line  mutation  is  associated  with  a  60%-70%  lifetime  risk  of  developing  breast  cancer 
(O'Donovan and Livingston, 2010). In the more common sporadic breast cancers, epigenetic 
silencing of the BRCA1 promoter has been reported in up to 11%-14% of tumours (Turner et 
al., 2004) and a dysfunctional BRCA pathway may also contribute to a BRCAness phenotype 
in about 25% of cancers (Turner et al., 2004), where breast cancers do not harbour germ-line 
BRCA mutations but display similar phenotypes including HR deficiency. BER is critical for 
processing DNA damage caused by alkylation, oxidation, ring saturation, single strand breaks 
and base deamination. DNA polymerase β (pol β) and XRCC1 are key BER factors.  PARP1 
(poly [ADP-ribose] polymerase 1) may play an essential role in single strand break repair 
(SSBR), a BER-related pathway (Langelier and Pascal, 2013).  The DNA repair intermediates 
generated during BER/SSBR, if unrepaired, may get converted to toxic double strand breaks 
(DSBs) (Dianov and Hubscher, 2013).
Emerging studies suggest a cross talk between BRCA1 and BER factors. BRCA1 mutated 
and  basal-like  breast  cancer  cells  were  found  to  be  sensitive  to  oxidative  DNA damage 
induced by H2O2 treatment. The increased sensitivity was associated with defective BER as 
assessed by cell based BER assay in BRCA1 deficient cells (Alli et al., 2009).  In a more 
recent study, BRCA1 deficient cells were sensitive to methyl methane sulfonate (alkylating 
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agent) and functional interaction between polβ and BRCA1 was demonstrated in that study 
(Masaoka et al., 2013) implying a potential role for polβ in BRCA1 mediated DSB repair. In 
addition, BRCA1 has also been shown to be involved in the transcriptional regulation of BER 
factor such as OGG1, NTH1 and APE1 (Saha et al., 2010). 
Synthetic  lethality  is  a  promising  strategy  for  personalized  cancer  therapy.  PARP [poly-
(ADP-ribose) polymerase] inhibitors induce synthetic lethality in germ line BRCA1-deficient 
breast  cancers  and  demonstrate  clinical  benefit  in  patients  (Lord  and  Ashworth,  2008). 
Similarly, we have recently shown that APE1 inhibition is synthetically lethal in BRCA1 
deficient breast cancer cells and in PTEN (and DSB repair) deficient melanoma cells.  The 
data provides compelling reasons to investigate other potential synthetic lethal interactions 
targeting DNA repair for clinical application.  Cells that are BRCA1 deficient as well as BER 
impaired may be reliant upon other back-up repair pathways to maintain genomic integrity 
and survival. ATM  and DNA-PKcs play essential roles in the DNA damage response (DDR) 
and link DNA damage sensing to DDR effectors that  regulate cell  cycle progression and 
DNA repair (Shiloh and Ziv, 2013). ATM, a member of the phosphatidylinositol-3-kinase-like 
protein kinase (PIKK) family,  is  a  key sensor and transducer of  DNA damage signalling 
during HR (Lee and Paull, 2007; Shiloh and Ziv, 2013). ATM recruitment at sites of DNA 
damage may be dependent upon functional BRCA1 in cells (Lee et al., 2010). DNA-PKcs is 
another key member of the PIKK family and a critical component of NHEJ pathway required 
for repair of DSBs generated throughout the cell cycle (Hill and Lee, 2010). BRCA1 through 
a role in DNA end-processing may also be involved in the regulation of NHEJ (Durant and 
Nickoloff, 2005).  
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Our hypothesis is that impaired BER in BRCA1 deficient tumours may influence prognosis. 
BRCA1-BER deficient  cells  may be  reliant  upon  ATM or  DNA-PKcs  mediated  back-up 
pathways for cellular survival and could be targeted by synthetic lethality using inhibitors of 
ATM or DNA-PKcs. 
MATERIALS AND METHODS
Clinical study
BRCA1 and BER protein expression analysis in Nottingham Tenovus Primary Breast 
Carcinoma cohort: The study was performed in a consecutive series of 1650 patients with 
primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered 
into the Nottingham Tenovus Primary Breast Carcinoma series described previously (Sultana 
et  al.,  2013).    Supplemental  Table  S1  summarizes  patient  demographics.  Supplemental 
treatment data 1 summarizes various adjuvant treatments received by patients in this cohort. 
BRCA1 and  BER protein  expression  analysis  in  germ line  BRCA1 deficient  breast 
cancer:  The  demographics  of  a  cohort  of  50  germ-line  BRCA1 mutated  breast  cancers 
confirmed  by  genetic  testing  is  shown  in  supplementary  table  S6.  All  patients  received 
surgery,  adjuvant  chemotherapy  and  radiotherapy  according  to  our  institutional  policy 
(supplementary treatment data 1). 
 
Tissue Microarrays (TMAs) and immunohistochemistry (IHC): Tumours were arrayed in 
tissue microarrays (TMAs) and immunohistochemically profiled for BRCA1, APE1, XRCC1, 
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Pol  β,  and  other  biological  markers  (Supplementary  Table  S2)  as  previously  described 
(Sultana et al., 2013). Supplementary Table S2 summarizes immunohistochemistry protocols 
for  the markers tested using the Bond Max automated staining machine and Leica Bond 
Refine Detection kit (DS9800) according to manufacturer instructions (Leica Microsystems). 
We have recently published optimisation and specificity of XRCC1 and pol β antibody used 
in the current study (Abdel-Fatah et al., 2014b; Sultana et al., 2013).  To validate the use of 
TMAs  for  immunophenotyping,  full-face  sections  of  40  cases  were  stained  and  protein 
expression  levels  of  the  different  antibodies  were  compared.   The  concordance  between 
TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of 
the primary antibody and IgG-matched serum) controls were included in each run. 
Evaluation of immune staining: The tumour cores were evaluated by specialist pathologists 
blinded to the clinicopathological characteristics of patients, in two different settings. There 
was excellent intra and inter-observer agreements (k > 0.8; Cohen’s κ and multi-rater κ tests, 
respectively).    Whole  field  inspection of  the  core  was  scored and intensities  of  nuclear 
staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 
= strong staining. The percentage of each category was estimated (0-100%).  H-scores (range 
0-300)  were  calculated  by  multiplying  intensity  of  staining  and  percentage  staining  as 
previously described (Sultana et al., 2013). Supplementary Table S2 summarizes cut-offs for 
individual markers.
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, Student’s t and ANOVA one 
way tests were used. Cumulative survival probabilities were estimated using the Kaplan–
Meier method, and differences between survival rates were tested for significance using the 
log-rank test. Multivariate analysis for survival was performed using the Cox proportional 
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hazard model. A p value < 0.05 considered significant.  For multiple comparisons, p values 
were adjusted according to Holm-Bonferroni correction method. 
Transcript  levels  in  the  METABRIC  (Molecular  Taxonomy  of  Breast  Cancer 
International Consortium) cohort: Investigation of the mRNA expression was performed 
in METABRIC cohort which refers to a set of 1980 breast cancer samples with a minimum of 
5 years of  clinical  follow up where mRNA expression data was available (Curtis  et  al.). 
Patient demographics are summarized in supplementary Table S9. ER positive and/or lymph-
node negative patients did not receive adjuvant chemotherapy. ER negative and/or lymph-
node positive patients received adjuvant chemotherapy.  All   the samples were analysed as 
triplicates. A sliding window analysis was used to identify a cut-off in gene expression values 
such that the resulting subgroups have significantly different survival courses. 
Artificial neural network (ANN) analysis in Uppsala cohort: The demographics of the 
Uppsala cohort is summarized in supplementary Table S10 and mRNA analysis has been 
described previously (Bergh et al.,  1995).   All  microarray data are accessible at  National 
Center  for  Biotechnology  Information  (NCBI)  Gene  Expression  Omnibus  (http://
www.ncbi.nlm.nih.gov/geo/,  accession number: GSE4922) (Pawitan et al.,  2005).  All data 
were normalized using the global mean method (MAS5), and probe set signal intensities were 
natural log transformed and scaled by adjusting the mean signal to a target value of log 500. 
The expression levels of the BRCA1, for the probe 204531_s_at located on the HG-U133A 
chip was utilized to generate the ANN based model as described previously (30) (Lancashire 
et al., 2010) (Lemetre, 2009). A non-linear, ANN modelling based, data mining approach was 
utilised to identify the best gene probes for sample classification as described previously (30). 
47,293  probes  were  screened  for  each  sample  in  the  test  set  (n=249).  The  data  mining 
algorithm comprised a three layer multilayer perception architecture modified with a feed 
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forward  back-propagation  algorithm  and  a  sigmoidal  transfer  function,  as  previously 
described  (Lancashire  et  al.,  2010).  The  network  momentum  and  learning  rate  were 
respectively set as 0.1 and 0.5. Two hidden nodes were utilised. The output node was coded 
as 0 if a case was low BRCA1 expression (<the median) and 1 if high BRCA1 expression 
(>median). Inputs were ranked in ascending order based on their classification error. The top 
50 predictive genes identified were merged with 150 gene probes  involved in the DNA repair 
process (Supplementary Table S11) and  then applied to an ANN based network inference 
algorithm as described in earlier studies (Lemetre, 2009).  This model predicted a weighted 
link (direction and magnitude) between each of the gene probe markers.  This weighting was 
based  on  the  non-linear  correlation  between  a  source  gene  and  a  target  gene  in  a 
multifactorial ANN model.  This approach defines a linkage or interaction with a magnitude 
between every possible pair of genes in the set presented to the algorithm.  The approach is 
data driven and unweighted by biological function.  The 100 strongest interactions were then 
visualised as a map with Cytoscape  (Smoot et al., 2011). In a second bioinformatics analysis 
step, we sought to obtain a robust ranking of genes that are differentially expressed between 
the mRNA BRCA1+  cases and the mRNA BRCA1-  and have high predictive power,  by 
applying an ensemble sample classification method within a leave-one-out cross-validation 
scheme.  For  this  purpose,  the  249  patient  samples  were  first  grouped  into  249  different 
training/test set partitions, using 248 samples for the training sets and the remaining sample 
as the test set. For each of the 248 training sets differentially expressed genes were selected 
independently with the "Empirical Bayes moderated t-statistic"  (Smyth, 2004) and used to 
train  a  machine  learning  model,  which  was  evaluated  based  on  the  left-out  sample  (a 
procedure  known  as  "external  cross-validation").  To  classify  the  left-out  sample,  the 
prediction results  of four algorithms (Support  Vector Machine,  Random Forest,  kNN and 
Prediction Analysis for Microarrays,  with all  parameters being optimised by using a grid 
   10
search  within  a  nested  cross-validation)  (Tibshirani  et  al.,  2002)  were  combined  to  a 
majority-vote  ensemble classifier  as  to  compensate  for  the  inevitable  inherent  biases  and 
variances that exists amongst each of these machine learning algorithms. In order to rank the 
genes  based  on  the  cross-validation  results,  their  frequency  of  occurrence  in  the  list  of 
significantly differentially expressed genes (p-value < 0.05) across different cross-validation 
cycles was recorded, and genes received higher scores the more often they had been selected. 
All steps of the analysis were conducted using an in-house web-application for microarray 
analysis, available at www.arraymining.net.
Pre-clinical study
Compounds  and  reagents:  ATM  inhibitors  (KU55933  and  KU60019)  and  DNA-PKcs 
inhibitors  (NU7441  and  NU7026)  were  purchased  from  Tocris  Bioscience,  UK.  The 
compounds were dissolved in 100% DMSO and stored at - 20ºC. Cisplatin was obtained from 
Nottingham University Hospitals. 
Cell lines and culture media: BRCA1 deficient HeLa SilenciX® cells and control BRCA 
proficient  HeLa  SilenciX®  cells  were  purchased  from  Tebu-Bio  (www.tebu-bio.com). 
SilenciX cells were grown in DMEM medium (with L-Glutamine 580mg/L, 4500 mg/L D19 
Glucose,  with  110mg/L Sodium  Pyruvate)  supplemented  with  10%  FBS,  1%  penicillin/
streptomycin and 125 μg/ml Hygromycin B. MDA-MB-436 (BRCA1 deficient human breast 
cancer cells) was grown in DMEM (Sigma, UK) and MCF7 (BRCA1 proficient human breast 
cancer cells) was grown in RPMI1640 (Sigma, UK). All media used to culture human cancer 
cell lines were supplemented with 10% FBS (PAA, UK) and 1% penicillin/streptomycin. 
Clonogenic survival assay: 200-500 hundred cells per well were seeded in six-well plates. 
Cells  were  allowed  to  adhere  for  4  hours.  Compounds  (ATM  inhibitors  or  DNA-PKcs 
inhibitors) were added at the indicated concentrations. For cisplatin combination studies, cells 
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were initially  treated with  cisplatin  for  16 hours  and then gently  washed twice  with  1X 
phosphate buffered saline and incubated in fresh media with or without ATM or DNA-PK 
inhibitors at indicated concentration. The plates were left in the incubator for 12-14 days. 
After incubation, the media was discarded, fixed (with methanol and acetic acid mixture) and 
stained with crystal violet and counted. Surviving Fraction = [No. of colonies formed/ (No. of 
cells seeded x Plating efficiency)] x100.  All clonogenic assays were done in triplicate.
Evaluation  of  drug  interaction  (Combination  index):  To  investigate  synergistic  and 
additive  activity,  combination  index  was  calculated  as  described  previously  (Berenbaum, 
1981). If D (combination index) is <1 the effect of the combination is synergistic, whereas if 
D=1 or D is >1 the effect is additive or antagonistic respectively.  
γH2AX  immunofluorescence  microscopy:  This  assay  was  performed  as  described 
previously(Sultana et al.,  2013). Briefly, cells were incubated in medium containing ATM 
inhibitor or DNA-PKCS inhibitor  for 48 hours. For cisplatin combination studies, cells were 
initially treated with cisplatin for 16 hours and then gently washed twice with 1X phosphate 
buffered saline and incubated in fresh media with or without ATM or DNA-PK inhibitors at 
indicated concentration for 48 hours.
Neutral COMET assay: COMET assay reagents were purchased from Trevigen and used 
according to the manufacturer’s neutral COMET protocol (Gaithersburg, MD, USA). Briefly, 
1 x 105 cells per well were seeded into a 6 well plate and treated with KU55933 (7.5µM) or 
NU7441 (0.75µM). After 48 hours treatment cells were resuspended in 250 µl PBS.  For 
COMET analysis 25 µl of cell suspension was mixed with 250 µl molten LMAgarose and 
then 75 µl of the mixture pipetted immediately onto COMET slides. Slides were allowed to 
set at 4oC for 20 minutes and then immersed in lysis buffer for 60 minutes at 4oC. Slides were 
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then subjected to electrophoresis at 20 V for 60 minutes in chilled electrophoresis buffer (0.5 
M  Tris,  1.5  M  sodium acetate).  Following  electrophoresis  slides  were  incubated  for  30 
minutes in DNA precipitation solution (5 M ammonium acetate in 95% ethanol) at room 
temperature  and subsequently  fixed in  70% ethanol  for  20 minutes  at  room temperature. 
Slides were left to dry overnight at 4oC and then each sample stained with 50 µl Sybr green 
and  scored  using  COMET  ASSAY  IV  software  (Perceptive  Instruments  Ltd,  Bury  St 
Edmonds, UK).  Treatments were performed in triplicate and 50 cells counted for each. 
Flow cytometric analyses (FACS): Cells grown to sub-confluence were exposed to ATM or 
DNA-PKcs inhibitors either alone or in combination with cisplatin for 48 hours and collected 
by  trypsinization  and  centrifugation  (1000  rpm for  5  minutes).  FACS was  performed as 
described previously (Sultana et al., 2013). 
Annexin V flow cytometric analyses: Cells grown to sub-confluence were exposed to ATM 
or  DNA-PKcs  inhibitors  either  alone  or  in  combination  with  cisplatin  for  48  hours  and 
collected  by  trypsinization  and  centrifugation  (1000  rpm for  5  minutes).  The  assay  was 
performed as described previously (Sultana et al., 2013).  
Quantitative real time PCR: RNA was extracted from cell lines using the RNeasy Mini Kit 
(Qiagen)  and  quantified  using  a  microvolume  spectrophotometer.  cDNA synthesis  was 
performed using the RT2 First Strand Kit (Qiagen). Primers used for RT-PCR for BER genes 
are shown in supplementary table S9. Quantitative PCR was performed on an ABI prism 
7700 (Applied Biosystems) using SYBR green detection (Applied Biosystems®, UK). The 
housekeeping gene GAPDH was used to standardise the samples.
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RT² Profiler™ PCR Array for global DNA Repair expression analysis: To evaluate the 
expression of 84 DNA repair genes simultaneously, real-time PCR was performed using the 
RT² Profiler™ PCR Array for global DNA Repair expression analysis in technical triplicates 
(ABI 7500 Fast Block Detection System; Applied Biosystems, Foster City, USA) and the data 
analysed as per manufacturer’s recommendation. GAPDH was used for normalization of the 
data. A 2 fold change or greater change in expression was considered significant. 
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RESULTS
Clinical studies
XRCC1, pol β, APE1 and SMUG1 are key BER proteins. Moreover, we have recently shown 
that XRCC1 (Sultana et al., 2013), pol β (Abdel-Fatah et al., 2014b), APE1 (Abdel-Fatah et 
al.,  2014a)  and  SMUG1 (Abdel-Fatah  et  al.,  2013b)  are  promising  biomarkers  in  breast 
cancer. To evaluate whether they also have prognostic and predictive significance based on 
BRCA1 status, we proceeded to immunohistochemical evaluation of XRCC1, pol β, APE1 
and SMUG1 in BRCA1 positive and BRCA1 negative breast tumours.
BRCA1 negativity is associated with impaired XRCC1 and pol β protein expression in 
human sporadic breast cancers: A total of 1602 breast tumours were suitable for BRCA1 
expression analysis.   1085/1602 (67.7%) of tumours were BRCA1 positive and 517/1602 
(32.3%) were negative for  BRCA1 expression (Figure 1A).   As shown in supplementary 
Table S3, BRCA1 negative tumours were highly significantly associated with low XRCC1 
(p<0.00001) and low polβ (p<0.000001). In the BRCA1 negative cohort we then evaluated 
clinicopathological associations of XRCC1 and pol β protein expression (Figure 1A). The 
data for XRCC1 and polβ are summarized in supplementary tables S4 and S5 respectively. 
Although no significant associations were seen with stage, tumour grade, tumour types or 
pleomorphism,  BRCA1 negative/ polβ low tumours were more likely to be Bcl2 negative 
(p=0.001) and BRCA1 negative/ XRCC1 low tumours were more likely to be p53 negative 
(p= 0.015). 
BRCA1 negative/low XRCC1 or BRCA1 negative/low polβ tumours are associated with 
poor  breast  cancer  specific  survival  (BCSS):   BRCA1  negativity  was  significantly 
associated with poor BCSS compared to BRCA1 positive tumours (p<0.000001) (Figure 1B) 
and  is  consistent  with  previous  studies  showing  poor  prognostic  significance  of  BRCA1 
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silencing in sporadic breast tumours (Hsu et al.,  2013; Wu et al.,  2013).   In the BRCA1 
negative group we investigated the prognostic influence of XRCC1 and pol β. As shown in 
Figure 1C1, BRCA1 negative/ low XRCC1 tumours had worse BCSS compared to BRCA1 
negative/ high XRCC1 tumours (p=0.001). Similarly, BRCA1 negative/ low polβ  tumours 
had worse BCSS compared to BRCA1 negative/ high polβ tumours (p=0.008) (Figure 1D1). 
As BRCA1 negativity is likely to be associated with ER negative tumours we conducted 
further analysis. In the BRCA1 negative/ER negative subgroup, low XRCC1 or low polβ 
remains associated with poor survival (p=0.033 and p=0.034 respectively, Figure 1C2 and 
1D2). In the BRCA1 negative/ER positive subgroup, similarly, low XRCC1 was associated 
with poor survival (p=0.003, Figure 1C3) and although not significant there was trend with 
low  polβ  (p=0.121,  Figure1D3).  In  multivariate  cox  regression  analysis  (Table  1),  low 
XRCC1  (p=0.005)  and  low  pol  β  (p=0.036)  were  independently  associated  with  poor 
survival. 
In the current study, APE1 and SMUG1 did not influence survival and was not associated 
with any clinicopathological parameters in BRCA1 negative breast tumours (data not shown).
XRCC1  and  pol  β  expression  in  germ-line  BRCA1  mutated  breast  cancers:  To 
investigate whether XRCC1 and polβ would also influence outcomes in germ-line BRCA1 
deficient  breast  cancer  we investigated  a  cohort  of  50  germ-line  BRCA1 mutated  breast 
cancers.   Demographics  are  summarised  in  supplementary  table  S6.  No  significant 
clinicopathological  correlations  were  observed  (supplementary  tables  S7  and S8).  In  this 
small  exploratory cohort,  low polβ  (5/34 tumours) was significantly associated with poor 
survival (p=0.007) in germ line BRCA1 mutated breast cancers (Figure 2A) compared to 
high polβ (29/34 tumours). Low XRCC1 expression did not influence survival in this cohort 
(Supplementary Figure S1A) 
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Low XRCC1 and low  pol  β  transcript  levels  have prognostic  significance in  BRCA1 
mRNA low sporadic breast cancers: To confirm whether the association between BRCA1 
and BER also operated at the mRNA level we investigated the Metabric cohort (n=1920, 
demographics  summarized  in  supplementary  table  S9)  and  the  Uppsala  cohort  (n=249, 
demographics summarized in supplementary table S10) - cohorts where mRNA expression 
data was available. In ER+ tumours (n=1485, Metabric), low BRCA1 (n=81) was associated 
with  poor  survival  compared  to  high  BRCA1  mRNA expressing  tumours  (n=  1404)  (p= 
0.0226, Figure 2B1). In the low BRCA1/ER+ group, low polβ (n=66) or low XRCC1 (n=42) 
remains associated with poor survival (ps= 0.038 and 0.0321 respectively) compared to high 
polβ (n=14) or high XRCC1 (n=38) mRNA expressing tumours (Figures 2B2 and 2B3). In 
the ER- tumours (n=435, metabric), high BRCA1 (n= 385) was associated with poor survival 
compared  to  low BRCA1 mRNA expressing  tumours  (n=50)  (p=  0.0365,  Supplementary 
Figure S2B).  In the low BRCA1/ER- group, low polβ (n=5) or low XRCC1 (n=17) remains 
associated with poor survival compared to high polβ (n=43) or high XRCC1 (n=31) mRNA 
expressing tumours [ps= 0.0224 and 0.0206 respectively) (Figures 2C1 and 2C2).  In the 
Uppsala cohort,  low polβ  mRNA (36/175 tumours)  was associated with poor survival  in 
BRCA1 low mRNA breast cancers (p=0.03, Supplementary Figure S1C) compared to high 
polβ mRNA tumours (139/175 tumours). XRCC1 mRNA expression levels did not influence 
survival in the Uppsala cohort (Supplementary Figure S1D). 
Artificial neural network (ANN), ensemble classification and cross-validation analysis 
for BRCA1 interacting DNA repair genes: The top 100 strongest are shown in Figure 2D. 
The biological functions of BRCA1 interaction genes are summarized in supplementary Table 
S12. The predominant interactions with genes involved in  BER, NER, HR, NHEJ, inter-
strand crosslink repair, MMR and transcription  is not only consistent with the previously 
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described functions of BRCA1 (Caestecker and Van de Walle, 2013; Huen et al., 2010; Silver 
and Livingston, 2012) but also reveals new BRCA1 interacting genes.  
Pre-clinical studies
The clinical and bioinformatics data presented above provides evidence that BRCA1 may 
influence the expression of multiple DNA repair genes. To provide additional pre-clinical 
evidence we investigated the expression of DNA repair in BRCA1 deficient and proficient 
cancer cell lines. 
BRCA1 deficient cancer cells exhibit impaired BER expression: BRCA1 deficient HeLa 
SilenciX  cells,  control  BRCA1 proficient  HeLa  SilenciX  cells,  BRCA1 deficient  MDA-
MB-436 breast cancer cells and BRCA1 proficient MCF7 breast cancer cells were initially 
examined for the expression of BRCA1, XRCC1 and pol β proteins.  BRCA1 deficiency was 
first confirmed at the protein level in BRCA1 deficient HeLa SilenciX and MDA-MB-436 
cells compared to control HeLa SilenciX cells and MCF7 cells (Figures 3A1, 3A2, 3B1, 
3B2). The relative expression of XRCC1 and pol β  was also found to be low in BRCA1 
deficient cells compared to BRCA1 proficient cells at the protein level (Figures 3A1, 3A2, 
3B1, 3B2).  Low mRNA expression of BRCA1, XRCC1 and pol β was confirmed by qRT-
PCR in MDA-MB-436 cells compared to MCF-7 cells and BRCA1 deficient HeLa SilenciX 
compared to control HeLa SilenciX cells (Figure 3A3, 3B3 respectively). The data is also 
summarized in supplementary Tables S14 and S15.  To provide additional evidence that low 
polβ  and low XRCC1 expression confers phenotypic consequence, we investigated MMS 
sensitivity in MDA-MB-436 and MCF-7 cells. As shown in supplementary Figure S3B, we 
found that MDA-MB-436 cells are sensitive to MMS. The data concurs with a recent study 
that showed a similar MMS sensitivity in BRCA1 deficient cells that was associated with 
impaired functional interaction between polβ and BRCA1(Masaoka et al., 2013).
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BRCA1  deficient  cells  have  deregulated  gene  expression  of  multiple  DNA  repair 
pathways: To investigate whether down regulation of DNA repair is restricted to polβ and 
XRCC1 or also includes additional DNA repair pathways, we profiled a panel of 84 DNA 
repair genes in BRCA1 deficient and BRCA1 proficient cells using the RT2 Profiler DNA 
Repair PCR array. All experiments were done in triplicates and DNA repair expression was 
compared between BRCA1 deficient and BRCA1 proficient cells [BRCA1 deficient HeLa 
SilenciX versus control BRCA1 proficient HeLa SilenciX cells and MDA-MB-436 versus 
MCF7 cells]. The data is summarized in Figure 3C (BRCA1 deficient and proficient HeLa 
SilenciX cells),  supplementary table S16 (BRCA1 deficient and proficient HeLa SilenciX 
cells),  Figure 3D (MDA-MB-436 and MCF7 cells),  and supplementary table S17 (MDA-
MB-436 and MCF7 cells).   In MDA-MB-436 cells as well  as in BRCA1 deficient HeLa 
SilenciX cells, we observed a consistent down regulation of several BER genes as well as 
genes involved in other pathways including base excision repair, nucleotide excision repair, 
homologous recombination, non-homologous end joining, inter-strand crosslink repair and 
mismatch repair.  
BRCA1  deficient  cancer  cells  are  sensitive  to  ATM  inhibitors  either  alone  or  in 
combination with cisplatin:  KU55933 (2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one) is 
an ATP-competitive potent ATM inhibitor with an IC50 of 13 nmol/L (Hickson et al., 2004). 
For  additional  validation  we  also  tested  KU60019  [(2R,6S-rel)-2,6-Dimethyl-N-[5-[6-(4-
morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-thioxanthen-2-yl-4-morpholineacetamide]  another 
ATP-competitive  potent  ATM inhibitor  (Golding  et  al.,  2009).  Treatment  with  KU55933 
resulted in reduced survival of BRCA1 deficient HeLa SilenciX cells compared to BRCA1 
proficient HeLa SilenciX cells (Figure 4A1). Similarly, MDA-MB-436 cells were sensitive to 
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KU55933 compared to MCF7 cells respectively (Figures 4B1). As an additional validation 
we  investigated  KU60019.  As  shown  in  supplementary  Figures  S3A and  S3E,  BRCA1 
deficient  HeLa  SilenciX  cells  and  MDA-MB-436  cells  were  also  sensitive  to  KU60019 
compared to BRCA1 proficient cells.  3-aminobenzamide,  a PARP inhibitor (Shekh et  al., 
2014) was used as  a  positive control.  As shown in supplementary Figure S2A and S2B, 
BRCA1 deficient cells, as expected, are sensitive to PARP inhibitor. 
To provide mechanistic evidence that ATM inhibition leads to a synthetic lethality effect in 
BRCA1 deficient  cells,  we investigated the functional  consequence of  ATM inhibition in 
BRCA1  proficient  and  BRCA1  deficient  cells.   Double  strand  breaks  (DSBs)  induce 
phosphorylation of H2AX at serine 139 (γH2AX), and accumulation of γH2AX foci in the 
nucleus is a marker of DSBs. Therefore, γH2AX immunocytochemistry was performed in 
BRCA1 deficient HeLa SilenciX cells and MDA-MB-436 cells and compared to BRCA1 
proficient control SilenciX or MCF7 cells (Supplementary Figure S3A). Nuclei containing 
more  than  six  γH2AX foci  were  considered  positive.  Cells  were  treated  with  KU55933 
(10µM)  for  48  hours.  The  percentage  of  cells  with  more  than  six  γH2AX  foci  was 
significantly  higher  in  BRCA1  deficient  cells  in  comparison  to  BRCA1  proficient  cells 
(Figures 4A2, 4B2). Similar results were observed with KU60019 (Supplementary Figures 
S4B and S4F). The data provides evidence that BRCA1 deficient cells accumulate DSBs at 
an increased rate after treatment with an ATM inhibitor relative to BRCA1proficient cells. As 
an  additional  validation  we performed neutral  COMET assays  after  ATM or  DNA-PKcs 
inhibitor treatment in cells. As shown in supplementary Figure S3C, BRCA1 deficient cells 
accumulated significantly more DSBs compared to BRCA1 proficient cells. Accumulation of 
DSBs may delay cell cycle progression. In BRCA1 deficient and BRCA1 proficient cells, cell 
cycle  progression  was  monitored  after  48  hours  of  treatment  with  KU55933  (10µM) 
(Supplementary Figure S4B). BRCA1 deficient cells were shown to be significantly arrested 
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in G2/M phase of the cell cycle compared to BRCA1 proficient cells (Figures 4A3, 4B3). 
Similar  results  were  observed  with  KU60019  (Supplementary  Figures  S5C  and  S5G). 
Accumulation of DSBs may result in eventual induction of apoptosis.  Apoptosis detection by 
FITC-annexin  V flow  cytometric  analysis  was  therefore  performed  in  cells  treated  with 
KU55933  (10µM)  for  48  hours  (Supplementary  Figure  S4C).   The  percentage  of  cells 
undergoing apoptosis following ATM inhibitor treatment was significantly higher in BRCA1 
deficient cells in comparison to BRCA1 proficient cells (Figures 4A4, 4B4). Similar results 
were  observed  with  KU60019  (Supplementary  Figures  S5D  and  S5H).   The  functional 
studies  together  provide  evidence  that  ATM  inhibition  can  induce  synthetic  lethality  in 
BRCA1  deficient  cells  by  causing  accumulation  of  DSBs,  G2M  cell  cycle  arrest  and 
induction  of  apoptosis.  However  the  level  of  synthetic  lethality  effect  seen  with  ATM 
inhibitor  was  modest  compared  that  demonstrated  previously  using  PARP inhibitors  in 
BRCA1 deficient cells (Lord and Ashworth, 2008). 
Cisplatin hypersensitivity has been well established in BRCA1 deficient cells (Tassone et al., 
2009).  We  investigated  whether  low  dose  cisplatin  could  potentiate  synthetic  lethality 
induced  by  KU55933.  Cells  were  treated  with  a  combination  of  low  dose  cisplatin 
(0.00001µM – 0.1 µM) and KU55933 (5µM).  As shown in Figure 4C1 and 4D1, KU55933 
treatment increased cytotoxicity of cisplatin in BRCA1 deficient HeLa SilenciX as well in 
MDA-MB-436  compared  to  BRCA1  proficient  control  SilenciX  and  MCF7  cells.  The 
interaction was synergistic [combination index= 0.6 (BRCA1 deficient HeLa SilneciX) and 
0.7 (MDA-MB-436), supplementary Figure S7A]. In BRCA1 deficient cells treated with a 
combination of cisplatin and KU55933, the observed increased cytotoxicity was associated 
with accumulation of DSBs (Figure 4C2 and 4D2), G2/M cell cycle arrest (Figure 4C3 and 
4D3) and increased apoptosis (Figure 4C4 and 4D4). 
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BRCA1 deficient cancer cells are sensitive to DNA-PKcs inhibitors either alone or in 
combination  with  cisplatin:  NU7441  (2-N-morpholino-8-dibenzothiophenyl-chromen-4-
one) is a potent and a specific inhibitor of DNA-PKcs with an IC50 of 14 nmol/L for DNA-PK 
inhibition (Tavecchio et al., 2012). NU7026 (2-(morpholin-4-yl)-benzo[h]chromen-4-one) is 
another DNA-PKcs inhibitor (Nutley et al., 2005).  
Treatment with NU7441 resulted in reduced survival of BRCA1 deficient HeLa SilenciX 
cells compared to BRCA1 deficient HeLa SilenciX cells (Figure 5A1). MDA-MB-436 cells 
were modestly sensitive to NU7441 compared to MCF7 cells respectively (Figures 5B1). As 
an additional validation we investigated NU7026. As shown in supplementary Figures S6A 
and S6E, BRCA1 deficient HeLa SilenciX cells and MDA-MB-436 cells were also sensitive 
to NU7026 compared to BRCA1 proficient cells. To provide mechanistic evidence that DNA-
PKcs inhibition leads to a synthetic lethality effect in BRCA1 deficient cells, we investigated 
the  functional  consequence  of  DNA-PKcs  inhibition  in  BRCA1  proficient  and  BRCA1 
deficient cells.  Cells were treated with NU7441 (1.5µM) for 48 hours. The percentage of 
cells with more than six γH2AX foci was significantly higher in BRCA1 deficient cells in 
comparison to BRCA1 proficient cells (Figures 5A2, 5B2). Similar results were observed 
with  NU7026  (supplementary  Figures  S6B  and  S6F).  In  BRCA1  deficient  and  BRCA1 
proficient  cells,  cell  cycle  progression  was  monitored  after  48  hours  of  treatment  with 
NU7441 (1.5µM). BRCA1 deficient cells were shown to be significantly arrested in G1 phase 
of the cell cycle compared to BRCA1 proficient cells (Figures 5A3, 5B3). Similar results 
were observed with NU7026 (supplementary Figures S6C and S6G).  Apoptosis detection by 
FITC-annexin  V flow  cytometric  analysis  was  therefore  performed  in  cells  treated  with 
NU7441 (1.5µM) for  48 hours.   The percentage of  cells  undergoing apoptosis  following 
DNA-PKcs  inhibitor  treatment  was  significantly  higher  in  BRCA1  deficient  cells  in 
comparison to BRCA1 proficient cells (Figures 5A4, 5B4). Similar results were observed 
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with  NU7026  (Supplementary  Figures  S6D  and  S6H).  The  functional  studies  together 
provide  evidence  that  DNA-PKcs  inhibition  can  induce  synthetic  lethality  in  BRCA1 
deficient  cells  by  causing  accumulation  of  DSBs,  G1  cell  cycle  arrest  and  induction  of 
apoptosis.  We  then  investigated  whether  low  dose  cisplatin  could  potentiate  synthetic 
lethality induced by NU7441. Cells were treated with a combination of cisplatin (0.00001µM 
– 0.1 µM) and NU7441 (0.75µM).  As shown in Figure 5C1 and 5D1, NU7441 treatment 
substantially increased cytotoxicity of low dose cisplatin in BRCA1 deficient HeLa SilenciX 
as well  as in MDA-MB-436 compared to BRCA1 proficient control  SilenciX and MCF7 
cells.  The  interaction  was  synergistic  [combination  index=  0.5  (BRCA1  deficient  HeLa 
SilneciX) and 0.6 (MDA-MB-436), supplementary figure S7B]. Increased cytotoxicity was 
associated with accumulation of DSBs (Figure 5C2 and 5D2), G2/M cell cycle arrest (Figure 
5C3 and 5D3) and increased apoptosis (Figure 5C4 and 5D4). 
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DISCUSSION 
We have shown, for the first time, that BRCA1 negative tumours have significantly lower 
expression of XRCC1 and Polβ, a feature that was also seen in BRCA1 deficient cancer cell 
lines.  Patients  with BRCA1 negative/  low XRCC1 or  BRCA1 negative /low Polβ  breast 
tumours  also  have worse  breast  cancer  specific survival  including in  ER+ and ER- sub-
groups. These new observations suggest that polβ/XRCC1 based sub-stratification may refine 
prognostication in BRCA1 deficient phenotypes. In addition, poor prognostic significance of 
pol β in a small cohort of germ-line BRCA1 mutated tumours is also consistent with a recent 
preclinical study linking BRCA1 and pol β in cancer cell line models (Masaoka et al., 2013). 
Additionally, at the mRNA level we conducted neural network analysis and demonstrated that 
the predominant BRCA1  interactions were with genes involved in BER, NHEJ, NER and 
MMR inter-strand crosslink repair and transcription.  To compliment clinical observations we 
DNA repair  profiled  BRCA1  proficient  and  deficient  cell  lines  and  also  demonstrated 
impairment in BER, NHEJ, NER and MMR. A surprising finding in the current study was 
that several genes involved in DDR were down regulated in BRCA1 deficient HeLa as well 
as  in  breast  cancer  cells  as  one  would  anticipate  that  this  would  reduce  survival  in  the 
absence of exogenous DNA damage. Moreover, as inhibition of BER (via PARP inhibition) is 
synthetically lethal in association with BRCA defects, we expected BRCA deficient cells to 
have compensatory up-regulation of BER pathway. In contrast we observed consistent down 
regulation of  BER implying a  complex regulation,  including transcriptional  regulation of 
BER by  BRCA1.   Although  in  BRCA deficient  cells  PARP1 may  be  up-regulated  as  a 
compensatory mechanism, in our cell line models we actually observed low expression of 
PARP1 mRNA, PARP2 mRNA and PARP3 mRNA in BRCA1 deficient HeLa cells and low 
expression of PARP1 mRNA and PARP2 mRNA in MDA-MB-436 cells.  Although these new 
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observations are intriguing, mechanism for down-regulation is currently unknown. However, 
we speculate that genomic instability in BRCA1 null cells may over a period of time, in the 
cell lines used in the current study, eventually lead to acquisition of new defects in other 
DNA repair pathways along with compensatory up-regulation of pro-survival pathways. In 
addition, recent studies implicating a role for BRCA1 in transcriptional regulation of BER 
(Saha et al., 2010) and NER(Hartman and Ford, 2002) suggests additional mechanisms may 
also  operate  for  the  observed  genomic  instability  in  BRCA1 deficient  cells.  The  altered 
expression of XRCC1 and polβ shown here also concurs to a large extent with a recent study 
by De Summa et  al.  who investigated the expression of APE1, NTHL1, OGG1, PARP1, 
XRCC1 and miR17 in BRCA1/2 mutated and sporadic breast cancers (De Summa et al., 
2014).  Down-regulation  of  XRCC1,  APE1  and  NTHL1  was  evident  in  that  study. 
Interestingly  overexpression  of  PARP1  and  miR17  were  observed  in  BRCA1  mutated 
tumours implying that they could be investigated as biomarker of BRCAness phenotype. In 
contrast, we observed PARP1 down regulation in BRCA1 deficient HeLa as well as in MDA-
MB-436 breast cancer cell line in our study.  Larger studies in human breast tumours are 
required to confirm these findings.
Although from preclinical studies we would expect DNA repair deficiency to be associated 
with chemosensitivity and improved survival in patient who received adjuvant chemotherapy, 
in the current clinical study we found that low BRCA1 or low BRCA1/low XRCC1 or low 
BRCA1/low Pol β was associated with poor survival. Our recent studies of DNA repair in 
breast cancer suggest that the relationship may be complex.  In previous studies we found 
that low XRCC1 (Sultana et al., 2013) and low DNA pol β (Abdel-Fatah et al., 2014b) to be 
associated with poor survival. As BER deficiency could lead to accelerated accumulation of 
mutations resulting in a mutator phenotype (Bielas et al., 2006) that is associated with an 
aggressive biology, we speculate that the observed effect for XRCC1 and pol β may reflect 
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this phenomenon.   On the other hand, high SMUG1 (Abdel-Fatah et al., 2013b) and high 
FEN1 (Abdel-Fatah et al., 2014c) was associated with poor survival in patients who have 
received adjuvant chemotherapy implying a DNA repair influenced  predictive significance 
for SMUG1 and FEN1 in breast cancer.  
We have demonstrated that a potential  synthetic lethality relationship also exists between 
BRCA1 deficiency and blockade of ATM or DNA-PKcs in cells.   A model for  synthetic 
lethality is shown in supplementary figure S8. We have concluded synthetic lethality for the 
following reasons: a) BRCA1 deficient cells have increased sensitivity to ATM or DNA-PKcs 
inhibitors;  b)  upon  ATM  inhibitor  treatment,  BRCA1  deficient  cells  accumulate  DSBs, 
exhibit G2/M cell cycle arrest and induction of apoptosis; and c) upon DNA-PKcs inhibitor 
treatment,  BRCA1  deficient  cells  accumulate  DSBs,  exhibit  G1  cell  cycle  arrest  and 
induction of apoptosis. Interestingly, BRCA1 deficient cells also exhibit low mRNA levels of 
ATM and DNA-PKcs but are sensitive to ATM and DNA-PKcs inhibitors. The data suggest a 
dose dependent effect where although ATM and DNA levels are low the cells are able to 
tolerate  genomic  instability  and  survive.  However,  with  additional  functional  inhibition 
through  small  molecule  inhibition,  pronounced  accumulation  of  DSBs  could  lead  to  a 
synthetic  lethality  effect.  Although  phosphorylation  of  H2AX  is  ATM  and  DNA-Pkcs 
dependent, we observed accumulation of γH2AX foci in BRCA1 deficient cells incubated in 
medium containing ATM inhibitor or DNA-PKcs inhibitor for 48 hours. Whether reflects a 
timing issue are whether H2AX phosphorylation may be contributed by other factors such as 
activated ATR is unclear. To confirm DSB accumulation we also performed neutral COMET 
assay and have demonstrated DSB accumulation in BRCA1 deficient cells treated with ATM 
or DNA-PKcs inhibitor. Moreover the effects on cell cycle progression, although significant, 
appear  to  be  modest.   In  the  current  study,  the  magnitude  of  synthetic  lethality  seen  in 
BRCA1  deficient  cells  treated  with  ATM  or  DNA-PKcs  inhibitor  alone  was  not  as 
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pronounced as that demonstrated for PARP inhibitors (Lord and Ashworth, 2008), we found 
that low dose cisplatin combination significantly enhanced synthetic lethality.   Of note, the 
dose of cisplatin used in our study was 1/10th the dose used in previous preclinical studies 
investigating cisplatin sensitivity in vitro in BRCA1 deficient cells (Husain et al., 1998). At 
higher doses of cisplatin similar to the doses used by Husain et al, BRCA1 deficient cells 
remain highly sensitive to platinum therapy (data not shown). We speculate that low dose 
cisplatin treatment generates low levels of DSBs.  In cells with proficient BRCA1 and BER, 
despite ATM or DNA-PKcs blockade, DSBs may be rapidly repaired in back-up DNA repair 
pathways and cells continue to survive. The back-up repair could operate at multiple levels 
including the complex interactions/overlap between HR, NHEJ, alternative NHEJ (B-NHEJ) 
(Chapman et  al.,  2012;  Schipler  and  Iliakis,  2013),  components  of  NER and ICL repair 
pathways.  On the other hand, in cells with deficient BRCA1 and low BER, the associated 
pharmacological  blockade  with  ATM  or  DNA-PKcs  inhibitors  may  lead  to  DSB 
accumulation  which  beyond a  threshold,  may severely  compromise  back-up  DNA repair 
machinery leading to DSB accumulation, cell cycle arrest and apoptosis. We have recently 
shown that XRCC1 deficient cells are cisplatin sensitive (Abdel-Fatah et al., 2013a) and ATM 
or DNA-PKcs inhibitors are also synthetically lethal in XRCC1 deficient cells (Sultana et al., 
2013).  Given the  potential  role  of  XRCC1 in  B-NHEJ (Mladenov and Iliakis,  2011)  we 
speculate that BRCA1 deficient cells that have low XRCC1 could also  have compromised B-
NHEJ in addition to BER resulting in increased genomic instability and  enhanced synthetic 
lethality with cisplatin treatment seen in the current study. Moreover, ATM or DNA-PKcs 
modulation has previously been shown to enhance cisplatin cytotoxicity (Dejmek et al., 2009; 
Yoshida et al., 2008).  Taken together, the data suggests that cisplatin combination may be 
more successful than ATM or DNA-PK monotherapy in BRCA1 negative tumours and would 
be consistent with a recent study showing enhancement of synthetic lethality with ABT-888 
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(PARP inhibitor) in combination with platinum chemotherapy in BRCA deficient cells (Clark 
et al., 2012).  
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Table 1. Multivariate analysis in BRCA1 negative sporadic breast cancers (Nottingham 
cohort).
  
Variables
Multivariate Model
Exp (B) CI 95% P Value
Pol beta expression 0.810 0.666-0.986 0.036
XRCC1 expression 0.831 0.731-0.945 0.005
Tumour stage 3.088 2.414-3.950 <0.0001
ER receptor status 0.522 0.328-0.833 0.006
Chemotherapy status 0.522 0.356-0.764 0.001
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FIGURE LEGENDS
Figure  1.  BRCA1  and  BER  protein  expression  in  human  breast  cancer.  A. 
Microphotographs of BRCA1 negative, BRCA1 positive, polβ positive and XRCC1 positive 
breast cancers. B. Kaplan Meier curves showing breast cancer specific survival (BCSS) in 
patients based on BRCA1 expression status.  C1. Kaplan Meier curves showing breast cancer 
specific  survival  (BCSS)  in  patients  with  BRCA1  negative  tumours  based  on  XRCC1 
expression status. C2. Kaplan Meier curves showing breast cancer specific survival (BCSS) 
in patients with BRCA1 negative/ER negative tumours based on XRCC1 expression status. 
C3. Kaplan Meier curves showing breast cancer specific survival (BCSS) in patients with 
BRCA1 negative/ER positive tumours based on XRCC1 expression status. D1. Kaplan Meier 
curves showing breast  cancer  specific survival  (BCSS) in  patients  with BRCA1 negative 
tumours based on polβ expression status. D2. Kaplan Meier curves showing breast cancer 
specific survival (BCSS) in patients with BRCA1 negative/ER negative tumours based on 
polβ  expression status.  D3.  Kaplan Meier  curves showing breast  cancer  specific survival 
(BCSS) in patients  with BRCA1 negative/ER positive tumours based on polβ  expression 
status.
Figure  2.  A.  Kaplan  Meier  curves  showing  overall  survival  in  patients  with  germ-line 
BRCA1mutated tumours based on polβ protein expression status. B1. Kaplan Meier curves 
showing  breast  cancer  specific  survival  (BCSS)  in  patients  based  on  BRCA1  mRNA 
expression  status  in  ER+  breast  cancer  (METABRIC  cohort).  B2.  Kaplan  Meier  curves 
showing breast cancer specific survival (BCSS) in patients with BRCA1 mRNA low/ER+ 
who received adjuvant endocrine therapy based on polβ mRNA status (METABRIC cohort). 
B3.  Kaplan Meier curves showing breast cancer specific survival (BCSS) in patients with 
BRCA1 mRNA low/ER+ who received adjuvant endocrine therapy based on XRCC1 mRNA 
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status  (METABRIC  cohort).  C1.  Kaplan  Meier  curves  showing  breast  cancer  specific 
survival  (BCSS)  in  patients  with  BRCA1  mRNA  low/ER-  who  received  adjuvant 
chemotherapy based on polβ mRNA status (METABRIC cohort). C2. Kaplan Meier curves 
showing breast cancer specific survival (BCSS) in patients with BRCA1 mRNA low/ER- 
who received adjuvant chemotherapy based on XRCC1 mRNA status (METABRIC cohort). 
D. The neural network illustrates the top genes that interact with BRCA1 and other DNA 
repair  genes.   In  addition,  the artificial  neural  network also reveals  how these top genes 
interact with each other. Top pair-wise interactions for gene probe markers associated with 
BRCA1 expression and the DNA repair process in 249 breast cancers is shown here. Each 
gene probe is represented by a node and the interaction weight between them as an edge, the 
width being defined by the magnitude of the weight. Interactions are directed from a source 
gene  to  a  target  gene  as  indicated  by  arrows.   Red  interactions  indicate  an  excitatory 
interaction and blue indicates an inhibitory interaction. Highly linked genes represent hubs 
that  are indicated to be highly influential  or  highly regulated in the BRCA1-DNA repair 
system. See supplementary data x for the biological functions of individual genes. 
Figure 3. DNA repair expression in BRCA1 deficient and BRCA1 proficient cells A1. 
Representative Western blots of BRCA1, XRCC1 and polβ in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells. A2. Protein quantification 
in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells 
are shown here. The Figure shows fold change in BRCA1 deficient cells in comparison to 
BRCA1 proficient cells. A3. mRNA expression in BRCA1 deficient HeLa SilenciX cells and 
control BRCA1 proficient HeLa SilenciX cells are shown here. The Figure shows fold 
change in BRCA1 deficient cells in comparison to BRCA1 proficient cells.  B1. 
Representative Western blots of BRCA1, XRCC1 and polβ in BRCA1 deficient MDA-
MB-436 cells and BRCA1 proficient MCF7 cells. B2. Protein quantification in MDA-
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MB-436 cells and MCF7 cells are shown here. The Figure shows fold change in BRCA1 
deficient cells in comparison to BRCA1 proficient cells.  B3. mRNA expression in MDA-
MB-436 cells and MCF7 cells are shown here. The Figure shows fold change in BRCA1 
deficient cells in comparison to BRCA proficient cells.   C. Scatter plots indicate up- and 
down-regulation of DNA repair mRNA expression in BRCA1 deficient HeLa SilenciX cells 
compared to BRCA1 proficient HeLa SilenciX cells. D. Scatter plots indicate up- and down-
regulation of DNA repair mRNA expression in MDA-MB-436 cells compared to MCF7 cells 
are shown here. Green circles show genes that are two-fold or more down-regulated. See also 
results section and supplementary table S16 and S17.
Figure 4. ATM inhibitors in BRCA1 deficient and BRCA1 proficient cells. A1. Clonogenic 
survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa 
SilenciX  cells  treated  with  KU55933.  A2.   уH2AX  immunohistochemistry  in  BRCA1 
deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with 
KU55933. A3. FACS analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient  HeLa  SilenciX  cells  treated  with  KU55933.  A4.  Annexin  V  flow  cytometric 
analysis  in  BRCA1  deficient  HeLa  SilenciX  cells  and  control  BRCA1  proficient  HeLa 
SilenciX cells treated with KU55933.B1. Clonogenic survival assays in MDA-MB-436 and 
MCF7 cells treated with KU55933. B2.  уH2AX immunohistochemistry in MDA-MB-436 
and MCF7 cells treated with KU55933.  B3. FACS analysis in MDA-MB-436 and MCF7 
cells treated with KU55933. B4. Annexin V flow cytometric analysis in MDA-MB-436 and 
MCF7 cells treated with KU55933. Inhibitors were added at the indicated concentrations (see 
methods for details).  C1.  Clonogenic survival  assays in BRCA1 deficient  HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
combination with KU55933. C2. уH2AX immunohistochemistry in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone 
   36
or in combination with KU55933. C3. FACS analysis in BRCA1 deficient HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
combination with KU55933. C4. Annexin V flow cytometric analysis in BRCA1 deficient 
HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin 
alone or in combination with KU55933. D1. Clonogenic survival assays in MDA-MB-436 
and MCF7 cells treated with cisplatin alone or in combination with KU55933. D2. уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in 
combination with KU55933. D3. FACS analysis in MDA-MB-436 and MCF7 cells treated 
with  cisplatin  alone  or  in  combination  with  KU55933.  D4.  Annexin  V flow  cytometric 
analysis in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in combination 
with KU55933. * p<0.05, ** p<0.01.
Figure  5.  DNA-PKcs  inhibitors  in  BRCA1  deficient  and  BRCA1  proficient  cells.  A1. 
Clonogenic survival assays in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient HeLa SilenciX cells treated with NU7441. A2.  уH2AX immunohistochemistry in 
BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells 
treated  with  NU7441.  A3.  FACS analysis  in  BRCA1 deficient  HeLa  SilenciX cells  and 
control BRCA1 proficient HeLa SilenciX cells treated with NU7441. A4. Annexin V flow 
cytometric analysis in BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient 
HeLa SilenciX cells treated with NU7441.B1. Clonogenic survival assays in MDA-MB-436 
and MCF7 cells treated with NU7441. B2. уH2AX immunohistochemistry in MDA-MB-436 
and MCF7 cells treated with NU7441.  B3. FACS analysis in MDA-MB-436 and MCF7 cells 
treated with NU7441. B4. Annexin V flow cytometric analysis in MDA-MB-436 and MCF7 
cells  treated  with  NU7441.  Inhibitors  were  added  at  the  indicated  concentrations  (see 
methods for details).  C1.  Clonogenic survival  assays in BRCA1 deficient  HeLa SilenciX 
cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone or in 
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combination with NU7441. C2. уH2AX immunohistochemistry in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin alone 
or in combination with NU7441. C3. FACS analysis in BRCA1 deficient HeLa SilenciX cells 
and  control  BRCA1  proficient  HeLa  SilenciX  cells  treated  with  cisplatin  alone  or  in 
combination with NU7441.  C4.  Annexin V flow cytometric analysis  in BRCA1 deficient 
HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with cisplatin 
alone or in combination with NU7441. D1. Clonogenic survival assays in MDA-MB-436 and 
MCF7  cells  treated  with  cisplatin  alone  or  in  combination  with  NU7441.  D2.  уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with cisplatin alone or in 
combination with NU7441. D3.  FACS analysis in MDA-MB-436 and MCF7 cells treated 
with cisplatin alone or in combination with NU7441. D4. Annexin V flow cytometric analysis 
in  MDA-MB-436  and  MCF7  cells  treated  with  cisplatin  alone  or  in  combination  with 
NU7441. * p<0.05, ** p<0.01.
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Highlights:
• BRCA1 may regulate base excision repair (BER). 
• BRCA1-BER deficient cells may be sensitive to blockade of ATM and DNA-PKcs. 
• We show that low XRCC1/low polβ have prognostic significance in BRCA1-/- 
tumours.
• ATM or DNA-PKcs inhibitors are synthetically lethal in BRCA1-BER deficient cells.
• Synthetic lethality is enhanced in combination with cisplatin.
Supplementary figure legends
Supplementary Figure S1: A. Kaplan Meier curves showing breast cancer specific survival 
(BCSS) in patients  with germ-line BRCA1 mutant  tumours based on XRCC1 expression 
status. B. Kaplan Meier curves showing breast cancer specific survival (BCSS) in patients 
with ER- negative tumours based on BRCA1 mRNA expression status.  C.  Kaplan Meier 
curves showing breast cancer specific survival (BCSS) in patients with BRCA1 low mRNA 
tumours based on pol β mRNA expression status. D. Kaplan Meier curves showing breast 
cancer  specific  survival  (BCSS)  in  patients  with  BRCA1 low mRNA tumours  based  on 
XRCC1 mRNA expression status. 
Supplementary  Figure  S2:  A.  Clonogenic  survival  assays  in  BRCA1  deficient  HeLa 
SilenciX  cells  and  control  BRCA1  proficient  HeLa  SilenciX  cells  treated  with  3-
aminobenzamide. B.  Clonogenic survival assays in MCF-7 cells  and MDA-MB-436 cells 
treated with 3-aminobenzamide.
Supplementary Figure S3: A.  Survival assay in MCF-7 and MDA-MB-436 cells treated 
with cisplatin. B. Survival assays in MCF-7 and MDA-MB-436 cells treated with MMS. C. 
Neutral  COMET  assay  in  MCF-7  and  MDA-MB-436  cells  treated  with  NU7441  or 
KU55933.
Supplementary  Figure  S4:  Functional  analysis  in  cells  (see  methods  section  for  more 
details).  A.  уH2AX immunohistochemistry  in  BRCA1 deficient  HeLa SilenciX cells  and 
control BRCA1 proficient HeLa SilenciX cells treated with KU55933. B. FACS analysis in 
BRCA1 deficient HeLa SilenciX cells and control BRCA1 proficient HeLa SilenciX cells 
treated with KU55933. C.  Annexin V flow cytometric analysis in BRCA1 deficient HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU55933.
   1
Supplementary  Figure  S5:  A.  Clonogenic  survival  assays  in  BRCA1  deficient  HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with KU60019.  B. 
уH2AX immunohistochemistry in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient HeLa SilenciX cells treated with KU60019. C. FACS analysis in BRCA1 deficient 
HeLa  SilenciX  cells  and  control  BRCA1  proficient  HeLa  SilenciX  cells  treated  with 
KU60019. D. Annexin V flow cytometric analysis in BRCA1 deficient HeLa SilenciX cells 
and control BRCA1 proficient HeLa SilenciX cells treated with KU60019. E.  Clonogenic 
survival  assays  in  MDA-MB-436  and  MCF7  cells  treated  with  KU60019.  F.  уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with KU60019. G. FACS 
analysis  in  MDA-MB-436  and  MCF7  cells  treated  with  KU60019.  H.  Annexin  V flow 
cytometric analysis in MDA-MB-436 and MCF7 cells treated with KU60019. * p<0.05, ** 
p<0.01.
Supplementary  Figure  S6:  A.  Clonogenic  survival  assays  in  BRCA1  deficient  HeLa 
SilenciX cells and control BRCA1 proficient HeLa SilenciX cells treated with NU7026.  B. 
уH2AX immunohistochemistry in BRCA1 deficient HeLa SilenciX cells and control BRCA1 
proficient HeLa SilenciX cells treated with NU7026. C. FACS analysis in BRCA1 deficient 
HeLa  SilenciX  cells  and  control  BRCA1  proficient  HeLa  SilenciX  cells  treated  with 
NU7026. D. Annexin V flow cytometric analysis in BRCA1 deficient HeLa SilenciX cells 
and control  BRCA1 proficient  HeLa SilenciX cells  treated with  NU7026.  E.  Clonogenic 
survival  assays  in  MDA-MB-436  and  MCF7  cells  treated  with  NU7026.  F.  уH2AX 
immunohistochemistry in MDA-MB-436 and MCF7 cells treated with NU7026. G. FACS 
analysis  in  MDA-MB-436  and  MCF7  cells  treated  with  NU7026.  H.  Annexin  V  flow 
cytometric analysis in MDA-MB-436 and MCF7 cells treated with NU7026. * p<0.05, ** 
p<0.01.
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Supplementary Figure S7: Combination index for synergism (see results section for more 
details). A. ATM inhibitor (KU55933). B.  DNA-PKcs inhibitor (NU7441).  
Supplementary Figure S8: A model for synthetic lethality in BRCA1 deficient cells using 
ATM or DNA-PKcs inhibitors either alone or in combination with cisplatin chemotherapy is 
shown here. See discussion section for details.
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Figure	S8
Probe Id Probe Set ID Gene SymbolGene Title go biological process term go molecular func:on termgo cellular co ponent term
218527_at 218527_at APTX aprataxin single strand break repair /// DNA liga:on /// DNA repair /// double-strand break repair /// response to DNA damage s:mulus /// metabolic process /// cell death /// regula:on of protein stability /// response to hydrogen peroxideDNA binding /// chroma:n binding /// amaged DNA binding /// double-str nded DNA binding /// double-stranded RNA binding / cataly:c ac:vity /// prote n binding /// zinc ion bindi g /// phosphoglycolate phosphatase ac:vity /// hydrolase ac:vity /// DNA 5'-adenosine monophosphate hydrolase ac:vity /// polynucleo:de 3'-phosphatase ac:vity /// metal ion binding /// protein N-terminus binding /// phosphoprotein bindingchroma:n /// uclear chrom :n /// nucleus /// nucleoplasm /// ucleolus /// cytoplasm
208442_s_at 208442_s_at ATM ataxia telangiectasia mutatedcell cycle checkpoint /// DNA damage checkpoint /// telomere maintenance /// double-strand break repair via homologous recombina:on /// response to hypoxia /// somitogenesis /// pre-B cell allelic exclusion /// DNA repair /// double-strand break repair /// protein phosphoryla:on /// protein phosphoryla:on /// apopto:c process /// response to DNA damage s:mulus /// DNA damage induced protein phosphoryla:on /// DNA damage response, signal transduc:on by p53 class mediator resul:ng in cell cycle arrest /// cell cycle /// cell cycle arrest /// mito:c spindle assembly checkpoint /// reciprocal meio:c recombina:on /// signal transduc:on /// female gamete genera:on /// brain development /// heart development /// cell death /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to ionizing radia:on /// phosphoryla:on /// histone phosphoryla:on /// pep:dyl-serine phosphoryla:on /// nega:ve regula:on of B cell prolifera:on /// G2 DNA damage checkpoint /// histone-serine phosphoryla:on /// phospha:dylinositol-3-phosphate biosynthe:c process /// lipoprotein catabolic process /// posi:ve regula:on of apopto:c process /// nega:ve regula:on of apopto:c process /// posi:ve regula:on of DNA damage response, signal transduc:on by p53 class mediator /// posi:ve regula:on of neuron apopto:c process /// protein autophosphoryla:on /// neuron apopto:c process /// regula:on of cell cycle /// histone mRNA catabolic process /// cellular response to gamma radia:on /// replica:ve senescencenucleo:de binding /// DNA binding /// protein kinase ac:vity /// prote n serine/threonine kinase ac vity / DNA-d pendent protein kinase ac:vity /// binding /// protein binding /// TP binding /// kina e c:vity /// 1-phospha:dyli ositol-3-kin se ac:vity /// transferase ac:vity /// transferase a :vity, transferring phosphorus-containing groups /// phosphotransferase ac:vity, alcohol group as acceptor /// protein complex bi ding /// histone serine kinase ac:vity /// protein dime iza:on ac:vity //  protein N-te minus bindingchromosome, t lomeric region / n cl u  /// nucl o lasm /// cytoplasm /// spi dle /// cytoplasmic membrane-bounded vesicl  /// cytoplasmic vesicl
209903_s_at 209903_s_at ATR ataxia telangiectasia and Rad3 relatedcell cycle checkpoint /// DNA damage checkpoint /// DNA replica:on /// DNA repair /// protein phosphoryla:on /// response to DNA damage s:mulus /// cell cycle /// mul:cellular organismal development /// nega:ve regula:on of DNA replica:on /// phosphoryla:on /// pep:dyl-serine phosphoryla:on /// cellular response to UV /// regula:on of protein binding /// posi:ve regula:on of DNA damage response, signal transduc:on by p53 class mediator /// protein autophosphoryla:on /// cellular response to gamma radia:on /// replica:ve senescencenucleo:de binding /// DNA bindi g / protein kinase ac:v ty /// protein seri e threoni e kinase ac:vity /// binding  protein binding /// ATP binding /// kinase ac:vity /// transferase ac:vity /// transferase c:vity, transferring ph sphorus-containing groups /// phosphotransferase ac:vity, alcohol g oup s acceptor /// MutLalpha complex binding /// MutSalpha complex bindingXY body / nucleus /// nucleoplasm /  ch mosome /// PML body
214727_at 214727_at BRCA2 breast cancer 2, early onsetdouble-strand break repair via homologous recombina:on /// double-strand break repair via homologous recombina:on /// cytokinesis /// oocyte matura:on /// inner cell mass cell prolifera:on /// DNA repair /// nucleo:de-excision repair /// double-strand break repair /// double-strand break repair /// DNA recombina:on /// response to DNA damage s:mulus /// DNA damage response, signal transduc:on by p53 class mediator resul:ng in transcrip:on of p21 class mediator /// cell cycle /// male meiosis I /// spermatogenesis /// brain development /// cell aging /// cell prolifera:on /// female gonad development /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to X-ray /// response to UV-C /// response to gamma radia:on /// hemopoiesis /// regula:on of cytokinesis /// nega:ve regula:on of mammary gland epithelial cell prolifera:on /// intrinsic apopto:c signaling pathway in response to DNA damage by p53 class mediator /// chordate embryonic development /// histone H3 acetyla:on /// histone H4 acetyla:on /// posi:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of mito:c cell cycle /// replica:on fork protec:on /// chromosome organiza:on /// centrosome duplica:onprotease binding /// DNA binding /// single-stranded DNA binding /// histone acetyltransferase ac:vity /// pro in binding //  H3 histone acetyltransferase ac:vity /// H4 histone acetyltransferase ac:vity //  gamma-tubulin bindingucleus /// nucle plasm /// nucleolus /// cytoplas  //  centroso e /// secreto y gr nule BRCA2-MAGE-D1 complex /// prot in om l x
214816_x_at 214816_x_at C19orf40 chromosome 19 open reading frame 40DNA repair /// response to DNA damage s:mulusDNA binding /// chroma:n binding /// protein bindingn cleus /// nucleoplasm / nucleolus /// intracellular membrane-bounded organelle /// Fanconi anaemia nuclear complex
228693_at 228693_at CCDC50 coiled-coil domain containing 50--- protein bindingcytoplasm
204093_at 204093_at CCNH cyclin H regula:on of cyclin-dependent protein serine/threonine kinase ac:vity /// G1 phase of mito:c cell cycle /// G1/S transi:on of mito:c cell cycle /// S phase of mito:c cell cycle /// G2/M transi:on of mito:c cell cycle /// mito:c cell cycle /// nucleo:de-excision repair, DNA damage removal /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// transcrip:on from RNA polymerase I promoter /// transcrip:on ini:a:on from RNA polymerase I promoter /// transcrip:on elonga:on from RNA polymerase I promoter /// termina:on of RNA polymerase I transcrip:on /// transcrip:on from RNA polymerase II promoter /// transcrip:on from RNA polymerase II promoter /// transcrip:on ini:a:on from RNA polymerase II promoter /// transcrip:on elonga:on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla:on /// cell cycle /// gene expression /// viral reproduc:on /// phosphoryla:on /// viral reproduc:ve process /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// posi:ve regula:on of viral transcrip:on /// regula:on of cell cycleprotein kinase ac:vity /// protein binding /// DNA-dependent ATPas ac:vity /// RNA polymerase II carboxy-terminal domain kinase ac:vity  kinase ac:vity /// cyclin-dependent prote n serine/threonine kinase r gulator ac:vity /// protein kinase bindingnucleus /// nucl oplasm  holo TFIIH co plex /// DNA-directed RNA polymerase II, holoenzyme / cyc in-dependent protein kinase ac:v : g kinase hol enzyme com lex /// TFIIK complex
210021_s_at 210021_s_at CCNO cyclin O regula:on of cyclin-dependent protein serine/threonine kinase ac:vity /// DNA repair /// base-excision repair /// base-excision repair /// base-excision repair, AP site forma:on /// cell cycle /// depyrimidina:on /// cell division /// regula:on of cell cycleuracil DNA N-glycosylase c:vity /// protein kinase bindingnucleu  /// nucl oplasm  nucleopl sm
204775_at 204775_at CHAF1B chroma:n assembly factor 1, subunit B (p60)DNA replica:on /// DNA repair /// DNA replica:on-dependent nucleosome assembly /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// protein complex assembly /// response to DNA damage s:mulus /// cell cycle /// chroma:n assemblychroma:n binding /// protei  binding /// protein binding /// hist e binding /// unfolded protein bindingnucleus / nucleus /// ucl o las  /// ucleolus /// cytoplasm /  cytosol // CAF-1 complex
208619_at 208619_at DDB1 damage-speciﬁc DNA binding protein 1, 127kDacell cycle checkpoint /// nucleo:de-excision repair, DNA damage removal /// DNA repair /// nucleo:de-excision repair /// response to DNA damage s:mulus /// Wnt receptor signaling pathway /// protein ubiqui:na:on /// virus-host interac:on /// protein ubiqui:na:on involved in ubiqui:n-dependent protein catabolic process /// proteasomal ubiqui:n-dependent protein catabolic processnucleic acid binding /// DNA binding /// damaged DNA binding /// prote n bindingnucleus /// nucleoplasm  cytoplasm /// Cul4A-RING ubiqu :n ligase compl x /// Cul4B-RING ubiqui:n ligase complex /// Cul4-RING ubiqui:n ligase complex
203409_at 203409_at DDB2 damage-speciﬁc DNA binding protein 2, 48kDaprotein polyubiqui:na:on /// nucleo:de-excision repair, DNA damage removal /// DNA repair /// nucleo:de-excision repair /// pyrimidine dimer repair /// response to DNA damage s:mulus /// response to UV /// protein ubiqui:na:on /// protein autoubiqui:na:onDNA binding /// damaged DNA binding /// ubiqui:n-protein ligase ac:vity /// pr tein bindingnucleus /// nucleopl sm /// prote n compl x
208382_s_at 208382_s_at DMC1 DNA meio:c recombinase 1pachytene /// ovarian follicle development /// oocyte matura:on /// DNA metabolic process /// DNA repair /// cell cycle /// meiosis /// synapsis /// reciprocal meio:c recombina:on /// male meiosis I /// gamete genera:on /// spermatogenesis /// sperma:d development /// female gamete genera:on /// SOS responsenucleo:de binding /// DNA bi ding /// single-stranded DNA binding /// protein binding / ATP binding /// DNA-dependent ATPase ac:vity /// nucleoside-triphosphatase ac:vitychromosome, tel meric region /// condens d nuclear chromosom  /// nucleus /// chromosome
208955_at 208955_at DUT deoxyuridine triphosphatasenucleobase-containing compound metabolic process /// pyrimidine nucleobase metabolic process /// dUMP biosynthe:c process /// DNA replica:on /// nucleo:de metabolic process /// small molecule metabolic process /// dUTP metabolic process /// pyrimidine nucleoside biosynthe:c process /// nucleobase-containing small molecule metabolic processdUTP diphosphatase ac:vity /// protein inding /// hydrolas  ac:vitynucleu  / nucleoplasm /// mitochondrion
202176_at 202176_at ERCC3 excision repair cross-complemen:ng rodent repair deﬁciency, complementa:on group 3cell cycle checkpoint /// nucleo:de-excision repair, DNA duplex unwinding /// nucleo:de-excision repair, DNA damage removal /// response to hypoxia /// ATP catabolic process /// DNA topological change /// DNA repair /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// transcrip:on from RNA polymerase I promoter /// transcrip:on ini:a:on from RNA polymerase I promoter /// transcrip:on elonga:on from RNA polymerase I promoter /// termina:on of RNA polymerase I transcrip:on /// transcrip:on from RNA polymerase II promoter /// transcrip:on from RNA polymerase II promoter /// transcrip:on from RNA polymerase II promoter /// transcrip:on ini:a:on from RNA polymerase II promoter /// transcrip:on elonga:on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla:on /// apopto:c process /// induc:on of apoptosis /// induc:on of apoptosis /// response to DNA damage s:mulus /// response to oxida:ve stress /// protein localiza:on /// response to UV /// UV protec:on /// gene expression /// viral reproduc:on /// virus-host interac:on /// viral reproduc:ve process /// nucleo:de-excision repair, DNA incision /// hair cell diﬀeren:a:on /// posi:ve regula:on of apopto:c process /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// posi:ve regula:on of viral transcrip:onnu leo:de bi ding /// nucleic acid bi ding /// DNA binding /// damaged DNA binding /// ATP-dependent DNA helic se ac:vity /// helicase ac:vity /// protein kinase c:vity /// protein binding /// ATP binding /// GTP binding /// protein C term nus binding /// DNA-dependent ATPase ac vity /// DNA-depende t ATPase ac:vity /// tr nscrip:on factor bind ng /// RNA polymerase II carboxy-terminal domain kinase ac:vity /// hydrolase ac:vity /// ATPase ac:vity /// dATP binding /// pep:de binding / 3'-5' DNA helicase ac:vity /// 3'-5' DNA helicase ac:vity protein N-terminus bindingcore TFIIH c mplex /// SSL2-core TFIIH complex nucleus /// nucleoplasm // holo TFIIH complex /// holo TFIIH compl x
210158_at 210158_at ERCC4 excision repair cross-complemen:ng rodent repair deﬁciency, complementa:on group 4m io:c mismatch repair /// resolu:on of m io:c rec mbina:on intermediates /// nucleo:de-excision repair, DNA damage removal /// telomere maintenance /// double-strand break repair via homologous recombina:on /// DNA metabolic process /// DNA repair /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair, DNA incision, 3'-to lesion /// nucleo:de-excision repair, DNA incision, 5'-to lesion /// response to DNA damage s:mulus /// response to UV /// UV protec:on /// telomere maintenance via telomere shortening /// nega:ve regula:on of telomere maintenance /// nucleo:de-excision repair, DNA incision /// nucleic acid phosphodiester bond hydrolysissingle-stranded DNA speciﬁc endodeoxyribonuclease ac:vity /// TFIID-class transcrip:on fact r binding /// nucleic acid binding /// DNA binding /// dam ged DNA binding /// single-stranded  binding /// nu lease ac:vity /// endonuclease ac:vity /// endodeoxyribonuclease ac:vity /// p ote n binding /// protein C-terminus bi ding /// hydrolase ac:v ty / structur -speciﬁc DNA binding /// protein N-terminus bindingnucl o:de- xcision repair complex // nucleo:d -excision repair f cto  1 c mplex /// chromosome, telomeric region /// nucle r chromoso e, telomeric region /// ucleus /// nucleoplasm /// tra s rip:on facto TFIID complex
225861_at 225861_at FAM195A family with sequence similarity 195, member A--- protein binding---
203678_at 203678_at FAN1 FANCD2/FANCI-associated nuclease 1ouble-strand break repair via homologous recombina:on /// DNA repair /// nucleo:de-excision repair /// response to DNA damage s:mulus /// nucleo:de-excision repair, DNA incision /// nucleo:de-excision repair, DNA incisionmagnesium i n i ding /// A binding / nuclease ac:vity /// endonucl ase ac:vity /// exonuclease ac:vity /// ph sphodie teras  I ac:vity /// pr tein binding /// 5'-3' exonuclease ac:vity /// hydrolase ac:vity /// hydrolase ac:vity, ac:ng on ester bonds /// 5'-ﬂap endonuclease ac:vity /// ubiqui:n binding /// metal ion bindingnucleus
205189_s_at 205189_s_at FANCC Fanconi anemia, complementa:on group Cyeloid cell homeostasis /// DNA repair /// nucleo:de-excision repair /// protein complex assembly /// response to DNA damage s:mulus /// gamete genera:on /// germ cell development /// removal of superoxide radicalsprotein bi dingchr ma:n /// nucl us //  nucleoplasm /// cytoplasm /  cytos l /// Fanconi naemia nuclear complex
203564_at 203564_at FANCG Fanconi anemia, complementa:on group Gcell cycle check oint /// phosphorelay signal transduc:on system /// ovarian follicle development /// DNA repair /// response to DNA damage s:mulus /// mitochondrion organiza:on /// sperma:d development /// response to radia:ond ma ed DNA binding /// signal transducer ac:vity /// prot i  bindingnucle s /// nucl oplasm /// cyt plasm /  mit chondrio  /// Fanconi anaemia nuclear complex
218397_at 218397_at FANCL Fanconi anemia, complementa:on group LDNA repair /// DNA repair /// protein monoubiqui:na:on /// response to DNA damage s:mulus /// gamete genera:on /// protein ubiqui:na:on /// regula:on of cell prolifera:onubiqui:n-prote n ligase ac:vity /// ubiqui:n-protein ligase ac:vity /// ubiqui:n-pr tein ligase ac:vity /// protein binding /// zinc ion binding /// ligase ac:vity /// ubiqui:n protein ligase binding /// metal ion bindingnucleus /// nuclear e v lope /// nucl op as  /// cytoplasm /// Fa coni anaemia nuclear com lex
200895_s_at 200895_s_at FKBP4 FK506 binding protein 4, 59kDaprotein pep:dyl-prolyl isomeriza:on /// protein pep:dyl-prolyl isomeriza:on /// protein folding /// steroid hormone receptor complex assembly /// copper ion transport /// embryo implanta:on /// nega:ve regula:on of neuron projec:on development /// pep:dyl-proline modiﬁca:on /// androgen receptor signaling pathway /// prostate gland development /// nega:ve regula:on of microtubule polymeriza:on or depolymeriza:on /// nega:ve regula:on of microtubule polymeriza:on /// protein complex localiza:on /// male sex diﬀeren:a:on /// reproduc:ve structure development /// chaperone-mediated protein foldingpep:dyl-prolyl cis-trans isomerase ac:vity /// ep:dyl-prolyl cis-trans somerase ac:vity /// protein binding /// ATP binding /// GTP binding /// FK506 binding //  FK506 bindin  /// isomerase ac:vity /// prot in binding, bridging /// heat shock protein binding /// copp r-dependent protein binding /// glucocor:coid r ceptor bindi g /// tau protein binding /// phosphoprotein bindingi tracellular /// nucleus /// nucleolus /// cytop asm // mitoc ndrion /// c sol /// cytoskeleton  microtubule /// membrane /// neuron projec:on /// neuro al cell body /// protein com lex /// axonal growth cone /// perinuclear r gion of cytoplasm
221540_x_at 221540_x_at GTF2H2 general transcrip:on factor IIH, polypep:de 2, 44kDanucleo:de-excision repair, DNA damage removal /// G-protein coupled receptor internaliza:on /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// transcrip:on from RNA polymerase I promoter /// transcrip:on ini:a:on from RNA polymerase I promoter /// transcrip:on elonga:on from RNA polymerase I promoter /// termina:on of RNA polymerase I transcrip:on /// transcrip:on from RNA polymerase II promoter /// transcrip:on from RNA polymerase II promoter /// transcrip:on ini:a:on from RNA polymerase II promoter /// transcrip:on elonga:on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// transla:on /// protein phosphoryla:on /// response to DNA damage s:mulus /// response to UV /// gene expression /// viral reproduc:on /// viral reproduc:ve process /// posi:ve regula:on of viral transcrip:onnucl ic acid binding /// s quence-speciﬁc DNA binding transcrip:on factor ac:vity /// protein kinase ac:vity /// prote n binding  DNA-dep ndent ATPase ac:vi y /// transla:on factor ac:vity, nucleic cid binding /// zinc ion bin ing /// RNA polyme ase II carboxy-terminal domain kinase ac:vi y /// metal io  bindi g /// protein N-terminus bindingcore TFIIH compl x /// nu leus /// ucleopl sm /  holo TFIIH complex
222104_x_at 222104_x_at GTF2H3 general transcrip:on factor IIH, polypep:de 3, 34kDanucleo:de-excision repair, DNA damage removal /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// transcrip:on from RNA polymerase I promoter /// transcrip:on ini:a:on from RNA polymerase I promoter /// transcrip:on elonga:on from RNA polymerase I promoter /// termina:on of RNA polymerase I transcrip:on /// transcrip:on from RNA polymerase II promoter /// transcrip:on from RNA polymerase II promoter /// transcrip:on ini:a:on from RNA polymerase II promoter /// transcrip:on elonga:on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// transla:on /// protein phosphoryla:on /// response to DNA damage s:mulus /// gene expression /// viral reproduc:on /// viral reproduc:ve process /// posi:ve regula:on of viral transcrip:ondamag d DNA binding /// sequence-speciﬁc DNA bin i g transcrip:on factor ac:vity /// protein kinase ac:vity DNA-dep ndent ATPase ac:vi y /// transla:on factor ac:vity, nucleic cid binding /// RNA polymeras  II carboxy-terminal domain kinase ac:vity /// metal ion binding /// rotein N-terminus bindingcore TFIIH complex // nucl us /// nucleoplasm /// holo TFIIH c mplex / ho o TFIIH complex
202983_at 202983_at HLTF helicase-like transcrip:on factorATP catabolic process /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// regula:on of transcrip:on from RNA polymerase II promoter /// metabolic process /// protein ubiqui:na:on /// chroma:n modiﬁca:onnucleo:de binding /// nucleic cid binding /// DNA binding /// cataly:c ac:vity /// helic se ac:vity /// protein binding /// ATP binding /// zinc ion binding //  hydr lase ac:vity /// hydrolase ac:vity, ac:ng on acid anhydrides, in phosphorus-containing anhydrides /// ligase ac:vity /// ATPase ac:vity /// metal ion bindingnucleus  nucleoplasm /// ucleolus /// cytoplasm
204883_s_at 204883_s_at HUS1 HUS1 checkpoint homolog (S. pombe)cell cycle checkpoint /// DNA damage checkpoint /// double-strand break repair via homologous recombina:on /// regula:on of protein phosphoryla:on /// DNA replica:on /// DNA repair /// protein phosphoryla:on /// response to DNA damage s:mulus /// mito:c cell cycle checkpoint /// nega:ve regula:on of DNA replica:on /// response to UV /// embryo development /// cellular response to ionizing radia:onprotein bindi gnucleus /// nucleoplasm /// nucleolus /// cytopla m /// Golgi apparatus /// checkpoin  clamp complex
209580_s_at 209580_s_at MBD4 methyl-CpG binding domain protein 4DNA epair /// base-excision repair /// base-excision repair, AP site forma:on /// response to DNA damage s:mulus /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to radia:on /// G2 DNA damage checkpoint /// depyrimidina:onDNA binding /// sat llite DNA binding /// cataly:c ac:vity /// en odeoxyribonuclease ac:vity /// r tein bindi  /// pyrimidine-speciﬁc mismatch base pair DNA N-glycosylase ac:vity /// hydrolase ac:vityhr ma:n /// nucleus /// nucleop asm /// nucleolus /// cytoplasm
204880_at 204880_at MGMT O-6-methylguanine-DNA methyltransferaseDNA liga:on /// DNA repair /// DNA methyla:on /// DNA dealkyla:on involved in DNA repair /// response to DNA damage s:mulus /// response to toxic substance /// response to organic cyclic compound /// methyla:on /// cellular response to oxida:ve stress /// response to drug /// regula:on of cysteine-type endopep:dase ac:vity involved in apopto:c process /// response to ethanol /// posi:ve regula:on of DNA repair /// response to folic acid /// nega:ve regula:on of cell death /// mammary gland epithelial cell diﬀeren:a:on /// cellular response to organic cyclic compound /// cellular response to ionizing radia:onDNA binding /// cataly:c c:vity /// methylated-DNA-[ rotein]-cystein  S-methyltransf rase ac:vity /// calcium ion binding /// methyltransf rase ac:vity /// DNA-methyltransf rase ac:vity /// transf rase ac:vity /// m tal ion bindingnucleus /// nuc eoplasm
202520_s_at 202520_s_at MLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)pa hytene /// nuclear-transcribed mRNA poly(A) tail shortening /// resolu:on of meio:c recombina:on intermediates /// response to hypoxia /// soma:c recombina:on of immunoglobulin genes involved in immune response /// ATP catabolic process /// DNA repair /// mismatch repair /// double-strand break repair via nonhomologous end joining /// response to DNA damage s:mulus /// cell cycle /// male meiosis chromosome segrega:on /// meiosis /// synapsis /// reciprocal meio:c recombina:on /// male meiosis /// spermatogenesis /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to toxic substance /// soma:c hypermuta:on of immunoglobulin genes /// soma:c recombina:on of immunoglobulin gene segments /// response to drug /// meio:c metaphase I plate congression /// meio:c chromosome segrega:on /// isotype switching /// nega:ve regula:on of mito:c recombina:on /// oogenesis /// spindle midzone assembly involved in meiosis /// cellular response to organic cyclic compoundsingle-stranded DNA binding /// protein bi ding /// ATP binding /// ATPase ac:vi y /  mismatched DNA binding /// guanine/thymine mispair bi ding /// MutSalpha complex bindi g /// structure-speciﬁc DNA bindingcondensed chromosome /// con ens d nuclear chrom some /// synaptonemal complex /// m le germ cell u leus /// nucleus /// chromosome /// chi sma /// mis atch re air omplex /// MutLal ha complex /// MutLbeta complex
203686_at 203686_at MPG N-methylpurine-DNA glycosylaseDNA repair /// base-excision repair /// base-excision repair, AP site forma:on /// DNA dealkyla:on involved in DNA repair /// response to DNA damage s:mulus /// depurina:onDNA binding /// damaged DNA binding /// cataly:c ac:vity /// alkylbase DNA N-glycosylase ac:vity /// protein binding /// DNA-3-methyl denine glycosylase ac:vity /// hydrolase ac:vity /// DNA-7-methylguanine glycosylase ac:vity /// DNA-7-methyladenine glycosylase ac:vity /// DNA-3-methylguanine glycosylase ac:vitynucleus /// nucleoplasm
217942_at 217942_at MRPS35 mitochondrial ribosomal protein S35DNA damage response, detec:on of DNA damage /// pep:de biosynthe:c process--- mitochondrion /// mitochond ial small ribosomal subunit /// mitochondrial small ribosomal subunit /// ribosome /// ribonucleoprotein complex
209421_at 209421_at MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)meio:c mismatch repair /// in utero embryonic development /// soma:c recombina:on of immunoglobulin genes involved in immune response /// oxida:ve phosphoryla:on /// ATP catabolic process /// DNA repair /// mismatch repair /// postreplica:on repair /// double-strand break repair /// meio:c gene conversion /// apopto:c process /// response to DNA damage s:mulus /// cell cycle arrest /// germ cell development /// spermatogenesis /// determina:on of adult lifespan /// male gonad development /// response to X-ray /// response to X-ray /// response to UV-B /// response to UV-B /// response to organic cyclic compound /// soma:c hypermuta:on of immunoglobulin genes /// soma:c recombina:on of immunoglobulin gene segments /// B cell mediated immunity /// B cell diﬀeren:a:on /// intra-S DNA damage checkpoint /// response to drug /// intrinsic apopto:c signaling pathway in response to DNA damage by p53 class mediator /// nega:ve regula:on of apopto:c process /// response to amino acid s:mulus /// nega:ve regula:on of neuron apopto:c process /// maintenance of DNA repeat elements /// nega:ve regula:on of reciprocal meio:c recombina:on /// isotype switching /// isotype switching /// nega:ve regula:on of DNA recombina:on /// nega:ve regula:on of DNA recombina:on /// posi:ve regula:on of helicase ac:vitynucleo:de binding /// magnesiu  ion binding /// f ur-way junc:on DNA binding /// Y-form DNA binding /// loop DNA binding /// double-strand/single-strand DNA junc:on binding  DNA binding /// damaged DNA binding /// double-stranded DNA binding single-stra ded DNA bi ding /// r tein binding // ATP binding /// protein C-terminus binding /// DNA-dependent ATPas  ac:vity /  ATPase ac:vity /// centromeric DNA binding /// enzyme binding /// protein kinase binding /// mismatched DNA binding /// guanine/thymine mispair binding /// guanine thymine mispai  bi ding /// dinucleo:de inser:on or d le:on binding /// si gle guanin  inser:on binding /// single thymine inser:on binding /// dinucleo:de repeat inser:on bindi g /  oxidize  pu ine DNA bindi g /// MutLalph  complex bi ding /// rot in homodimeriza:on ac:vity /// ADP bindingnuclear chromosome /// ucleus /// MutSalpha complex /// MutSbeta complex
210947_s_at 210947_s_at MSH3 mutS homolog 3 (E. coli) meio:c mismatch repair /// DNA repair /// mismatch repair /// response to DNA damage s:mulus /// reciprocal meio:c recombina:on /// soma:c recombina:on of immunoglobulin gene segments /// maintenance of DNA repeat elements /// nega:ve regula:on of DNA recombina:on /// posi:ve regula:on of helicase ac:vitynucleo:de binding /// Y-form DNA binding /// loop DNA binding /// double-strand/single-strand DNA junc:on binding /// DNA binding /// damaged DNA binding //  single-stranded DNA binding /// protein binding /// ATP binding /// DNA-dependent ATPase ac ity /// centromeric DNA binding /// enzyme binding /// mismatched DNA binding /// guanine/thymine mispair binding /// dinucleo:de inser:on or dele:on binding /// single guanine inser:on binding /// dinucleo:de repeat inser:on binding /// oxidized purine DNA binding /// protein homodimeriza:on ac:vitynuclear chromosome /// ucleus // MutSbeta complex
221406_s_at 221406_s_at MSH5 /// MSH5-SAPCD1 /// SAPCD1mutS homolog 5 (E. coli) /// MSH5-SAPCD1 readthrough (NMD candidate) /// suppressor APC domain containing 1meio:c mismatch repair /// mismatch repa r /// meiosis /// reciprocal meio:c recombina:on /// meio:c prophase II /// maintenance of ﬁdelity involved in DNA-dependent DNA replica:on /// homologous chromosome segrega:on /// chiasma assemblynucleo:de binding /// DNA binding /// damaged DNA binding /// protein binding /  ATP binding /// DNA-dependent ATPase ac:vity /// mismatched DNA bindingsynaptonemal c mplex /// mis at h repair complex
211449_at 211449_at MSH6 mutS homolog 6 (E. coli) meio:c mismatch repair /// meio:c mismatch repair /// ATP catabolic process /// DNA repair /// mismatch repair /// mismatch repair /// response to DNA damage s:mulus /// reciprocal meio:c recombina:on /// determina:on of adult lifespan /// intrinsic apopto:c signaling pathway in response to DNA damage /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to UV /// response to UV /// soma:c hypermuta:on of immunoglobulin genes /// soma:c hypermuta:on of immunoglobulin genes /// soma:c recombina:on of immunoglobulin gene segments /// maintenance of DNA repeat elements /// isotype switching /// isotype switching /// nega:ve regula:on of DNA recombina:on /// posi:ve regula:on of helicase ac:vity /// intrinsic apopto:c signaling pathwaynucleo:de binding /// magnesium ion binding /// four-way junc:on DNA binding // DNA binding //  chroma:n binding /// d maged DNA binding /// double-stranded DNA binding /// protein binding /// ATP binding /// DNA-dependent ATPase c:vit  /// ATPase ac:vity /// ismatched DNA binding /// u nine/thymine mispair binding /// single guanine inser:on binding /// single thymine inser on binding /// oxidized purine DNA binding / MutLalpha co plex binding /// methylated histone residue binding /// pr tein ho odimeriza:on ac:vity /// ADP bindingnuclear chromosome /// u lear chroma:n /// nucleus /// chromosome /// MutSal ha complex
223112_s_at 223112_s_at NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDamitochondrial lectron transport, NADH to ubiquinone /// electron transport chain /// respiratory electron transport chain /// cellular metabolic process /// small molecule metabolic process /// oxida:on-reduc:on processprotein binding /// NADH dehydrogenase (ubiquinon ) ac:vitymitochondrion /// mi ochondrial n er m mb ne /// mit chondrial espiratory hain co plex I /// mitochondrial respiratory chain com lex I /// membrane /// respirato y hain
219502_at 219502_at NEIL3 nei endonuclease VIII-like 3 (E. coli)DNA repair /// base-excision repair /// nucleo:de-excision repair /// response to DNA damage s:mulus /// metabolic processbubble DNA binding /// nucleic acid binding /// DNA binding /// damaged DNA binding /// double-stranded DNA binding /// single-stranded DNA binding /// cataly:c ac:vity /// DNA-(apurinic or apyrimidinic site) lyase ac:vity /// zinc ion binding /// hydrolase ac:vity /// hydrolase ac:vity, ac:ng on glycosyl bonds /// hydrolase ac:vity, hydrolyzing N-glycosyl compounds /// lyase ac:vity /// DNA N-glycosylase ac:vity /// DNA N-glycosylase ac:vity /// metal ion bindingintracellular /// nu leus
209731_at 209731_at NTHL1 nth endonuclease III-like 1 (E. coli)DNA repair /// base-excision repair /// base-excision repair, AP site forma:on /// base-excision repair, AP site forma:on /// nucleo:de-excision repair, DNA incision, 5'-to lesion /// response to DNA damage s:mulus /// metabolic process /// depyrimidina:onDNA binding /// double-strand d DNA binding /// cataly:c ac:vity /// DNA-(apurinic or apyrimidinic site) lyas  ac:vity /// endonucleas  ac:vity /// rot in binding /// hydrolase ac:vity /// hydrolase ac:vity, ac:ng on glycosyl bonds /// lyase ac:vity /// DNA N-glycosylase ac:vity /// metal ion binding /// iron-sulfur cluster binding /// 4 iron, 4 sulfur cluster bindingnucleus /// nucleoplasm /// mitochondrion
204766_s_at 204766_s_at NUDT1 nudix (nucleoside diphosphate linked moiety X)-type mo:f 1GTP catabolic process /// urine nucleo:de catabolic process /// ATP catabolic process /// dGTP catabolic process /// DNA repair /// response to oxida:ve stress /// nucleobase-containing small molecule catabolic process /// DNA protec:on /// small molecule metabolic process /// nucleobase-containing small molecule metabolic processRNA binding /// GTPase ac:vity /// 8-oxo-7,8-dihydroguanosine riphos hat  pyrophosphat se ac:vity /// hydrolase ac:vity /// s oRNA inding /// 8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase ac:vity /// metal ion binding ATP diphosphatase ac:vity /// m7G(5')pppN diphosphatase ac:vitynucleus /// cytoplasm // mitochondrion /// mitochondrial matrix /// cyt ol
205760_s_at 205760_s_at OGG1 8-oxoguanine DNA glycosylaseacut  inﬂammatory response /// DNA repair /// base-excision repair /// base-excision repair, AP site forma:on /// nucleo:de-excision repair /// regula:on of transcrip:on, DNA-dependent /// response to DNA damage s:mulus /// response to oxida:ve stress /// metabolic process /// response to radia:on /// response to estradiol s:mulus /// regula:on of protein import into nucleus, transloca:on /// response to drug /// depurina:on /// response to ethanol /// response to folic acid /// cellular response to cadmium iondamaged DNA binding /// cataly:c ac:vity /// DNA-(a urinic or apyri idinic site) lyase ac:vity /// endonuclease ac:vity /// protein binding /// microtubule binding /// xidize  purin  nucleobase lesion DNA N-glycosylase ac:vity /// hydrolase ac:vity /// hydrolase ac:vity, ac:ng  glycosyl bonds /// lyase ac:vity /// DNA N-glycosylase ac:vity /// 8-oxo-7,8-dihydroguanine DNA N-glycosylase ac:vitynucleus /// nucleo lasm /// nucleoplasm /// nu leolus /// mit hondrion /// nuclear matrix //  nucle r speck
202239_at 202239_at PARP4 poly (ADP-ribose) polymerase family, member 4DNA repair /// cellular protein modiﬁca:on process /// protein ADP-ribosyla:on /// transport /// inﬂammatory response /// response to DNA damage s:mulus /// cell death /// response to drugDNA binding /// NAD+ ADP-ribosyltransferase ac:vity /// NAD+ ADP-ribosyltransferas  ac:vity /// pr tein binding /// transferase ac:vity //  tran fera  ac:vity, transferring glycosyl groups /// enzyme bindingnucleus /// cytoplasm /// pindle /  cytoskele on /// spindle mic otubule /// ribonucl oprotein co pl x
201202_at 201202_at PCNA prolifera:ng cell nuclear an:genDNA damage checkpoint /// G1/S transi:on of mito:c cell cycle /// regula:on of transcrip:on involved in G1/S phase of mito:c cell cycle /// S phase of mito:c cell cycle /// mito:c cell cycle /// telomere maintenance via recombina:on /// telomere maintenance /// DNA replica:on /// DNA strand elonga:on involved in DNA replica:on /// regula:on of DNA replica:on /// DNA repair /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// base-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair, DNA gap ﬁlling /// mismatch repair /// response to DNA damage s:mulus /// heart development /// cell prolifera:on /// translesion synthesis /// posi:ve regula:on of deoxyribonuclease ac:vity /// telomere maintenance via semi-conserva:ve replica:on /// response to lipid /// response to cadmium ion /// phospha:dylinositol-mediated signalingpurine-speciﬁc mismatch base pair DNA N-glycosylase ac:vity /// DNA binding /// prote n binding /// DNA polym rase processivit  factor ac:vity /// re eptor yr sine kin se binding /// dinucleo:de inser:on or d le:on binding /// MutLal ha c mplex binding /// iden:cal protein bindingnucleus /// nu opl sm /// DNA replic :on factor C complex // nucl olus /// cytop asm /// microtubule cyt skel ton /// checkpoint clamp compl x /// nuclear r plica:on fork /// PCNA compl x /// PCNA-p21 complex
219317_at 219317_at POLI polymerase (DNA directed) iotaDNA replica:on /// DNA repair /// response to DNA damage s:mulusDNA binding /// damaged DNA binding /// DNA-directed DNA polymerase ac:vity /// protein binding /// transferase ac:vity /// nucleo:dyltransferase ac:vity /// metal ion bindingintracellular /// nucleus /// nucleoplasm /// intracellular membrane-bounded organelle
203103_s_at 203103_s_at PRPF19 pre-mRNA processing factor 19protein polyubiqui:na:on /// spliceosomal complex assembly /// mRNA splicing, via spliceosome /// mRNA splicing, via spliceosome /// inner cell mass cell prolifera:on /// DNA repair /// mRNA processing /// response to DNA damage s:mulus /// RNA splicing /// lipid biosynthe:c process /// protein ubiqui:na:on /// nega:ve regula:on of neuron diﬀeren:a:on /// posi:ve regula:on of mRNA splicing, via spliceosome /// posi:ve regula:on of astrocyte diﬀeren:a:onDNA binding /// ubiqui:n-protein ligase a :vity /// rotein binding /// ubiqu : -ubiqui:n ligase ac:vity /// id n:c l protein bindingubiq i:n ligase c mplex /// Prp19 complex /// nucleus /// nucleoplasm /// spliceosomal complex /// cytoplasm /// lipid par:cle /// spindle // cytoskeleton /// nucl ar speck /// cataly:c step 2 spliceosome
37793_r_at 37793_r_at RAD51D RAD51 homolog D (S. cerevisiae)DNA metabolic process /// DNA replica:on /// DNA repair /// DNA recombina:on /// response to DNA damage s:mulus /// reciprocal meio:c recombina:onnucle :de binding /// DNA binding /// DNA helicase ac:vity /// protein binding /// ATP binding /// DNA-dependent ATPase ac:vity /// nucleoside-triphosphatase ac:vitynucleus
203344_s_at 203344_s_at RBBP8 re:noblastoma binding protein 8cell cycle checkpoint /// G1/S transi:on of mito:c cell cycle /// nega:ve regula:on of transcrip:on from RNA polymerase II promoter /// double-strand break repair via homologous recombina:on /// blastocyst hatching /// DNA repair /// regula:on of transcrip:on from RNA polymerase II promoter /// response to DNA damage s:mulus /// cell cycle /// mitosis /// meiosis /// DNA double-strand break processing involved in repair via single-strand annealing /// G2 DNA damage checkpoint /// cell divisionsingle-stranded DNA sp ciﬁc endodeoxyribonuclease ac:v ty /// RNA polymerase II repressing transcrip:on fac or binding /// RNA polymerase II transcrip:on corepressor ac:vity /// DNA binding /// damaged DNA binding /// nuclease ac:vity /// endonuclease ac:vity /// rot in binding /// hydrolase ac:vitynu leus /// transcrip:onal repressor complex
205091_x_at 205091_x_at RECQL RecQ protein-like (DNA helicase Q1-like)DNA trand renatura:on /// DNA replica:on /// DNA repair /// DNA recombina:on /// DNA duplex unwinding /// DNA duplex unwindingnucleo:de binding /// nucleic acid binding /// DNA binding /// DNA helicase ac:vity /// ATP-dependent DNA helicase ac:vity /// helicase ac:vity /// protein binding /// ATP binding /// ATP-dependent helicase ac:vity /// hydrolase ac:vity /// ATP-dependent 3'-5' DNA helicase ac:vitynucleus / nucleolus /// microtubule cytoskeleton
208021_s_at 208021_s_at RFC1 replica:on factor C (ac:vator 1) 1, 145kDaS phase of mito:c cell cycle /// mito:c cell cycle /// telomere maintenance via recombina:on /// telomere maintenance /// DNA replica:on /// DNA-dependent DNA replica:on /// DNA strand elonga:on involved in DNA replica:on /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair, DNA gap ﬁlling /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// telomere maintenance via telomerase /// telomere maintenance via semi-conserva:ve replica:on /// posi:ve regula:on of cataly:c ac:vitynu leo:de binding /// DNA binding /// DNA clamp loader ac:vity /// protein bindi g /  ATP binding /// enzyme ac:vator ac:vity /// nu leoside-tripho phatase ac:vitynucleus / nucleoplasm / DNA replica:on factor C c l x
212696_s_at 212696_s_at RNF4 ring ﬁnger protein 4 transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// protein ubiqui:na:on /// androgen receptor signaling pathway /// proteasomal ubiqui:n-dependent protein catabolic process /// posi:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// response to arsenic-containing substance /// protein autoubiqui:na:on /// protein K63-linked ubiqui:na:on /// protein K48-linked ubiqui:na:on /// protein K11-linked ubiqui:na:on /// protein K6-linked ubiqui:na:on /// regula:on of spindle assembly /// regula:on of kinetochore assemblyDNA binding /// sequence-speciﬁc DNA binding transcrip:on factor ac:vity /// tra scrip:on coac:vator ac:vity / ubiqui:n-protein ligase ac:vity /// protein binding /// transcrip:on factor binding /// zi c ion bi ding /// ligase ac:vity /// estrogen receptor bi ding /// nucleosome binding /// SUMO polyme  binding /// progesterone receptor bi ding // m tal ion binding /// androgen r ceptor bindingnucleus /// nucleoplasm /// cy oplasm /// micr tubule cytoskeleton /// PML b dy
203160_s_at 203160_s_at RNF8 ring ﬁnger protein 8, E3 ubiqui:n protein ligaseDNA repai  /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// ubiqui:n-dependent protein catabolic process /// response to DNA damage s:mulus /// cell cycle /// mitosis /// sperma:d development /// response to ionizing radia:on /// protein ubiqui:na:on /// chroma:n modiﬁca:on /// histone H2A ubiqui:na:on /// histone H2B ubiqui:na:on /// interstrand cross-link repair /// histone exchange /// isotype switching /// posi:ve regula:on of DNA repair /// nega:ve regula:on of transla:onal elonga:on /// cell division /// protein autoubiqui:na:on /// protein K63-linked ubiqui:na:on /// histone H2A K63-linked ubiqui:na:on /// histone H2A K63-linked ubiqui:na:on /// protein K48-linked ubiqui:na:onchroma:n binding /// ubiqui:n-protein ligase ac:vity /// protein binding /// zinc ion binding /// ligase a :vity /// acid-amino acid ligase ac:vity /// ubiqui:n protein ligase binding /// histon  binding /// protein homodimeriza: n ac:vity /// metal ion bindingubiqui:n ligase com lex /// chr mosome, telomeric region //  nucleus /// chromosome /// mid dy /// site of double-strand break
201529_s_at 201529_s_at RPA1 replica:on protein A1, 70kDacell cycle checkpoint /// G1/S transi:on of mito:c cell cycle /// S phase of mito:c cell cycle /// mito:c cell cycle /// nucleo:de-excision repair, DNA damage removal /// telomere maintenance via recombina:on /// telomere maintenance /// double-strand break repair via homologous recombina:on /// DNA recombinase assembly /// in utero embryonic development /// DNA replica:on /// DNA-dependent DNA replica:on /// DNA strand elonga:on involved in DNA replica:on /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair, DNA gap ﬁlling /// double-strand break repair /// DNA recombina:on /// response to DNA damage s:mulus /// meiosis /// posi:ve regula:on of cell prolifera:on /// hemopoiesis /// telomere maintenance via semi-conserva:ve replica:on /// homeostasis of number of cells within a :ssue /// chromosome organiza:onnucleic acid binding /// DNA binding /// chroma:n binding /// single-strand d DNA binding /// pr tein binding /// etal ion bindingco nsed chromosom ondensed nuclear chr mosome /// lateral element / male germ cell nucleus /// nucleus // nucl oplasm /// DNA replica:on factor A complex /// nucleolus /// cytoplasm /// ac:n cytoskeleton /// PML b dy
201756_at 201756_at RPA2 replica:on protein A2, 32kDacell cycle checkpoint /// G1/S transi:on of mito:c cell cycle /// S phase of mito:c cell cycle /// mito:c cell cycle /// nucleo:de-excision repair, DNA damage removal /// telomere maintenance via recombina:on /// telomere maintenance /// double-strand break repair via homologous recombina:on /// DNA recombinase assembly /// DNA replica:on /// DNA-dependent DNA replica:on /// DNA strand elonga:on involved in DNA replica:on /// DNA repair /// transcrip:on-coupled nucleo:de-excision repair /// nucleo:de-excision repair /// nucleo:de-excision repair, DNA gap ﬁlling /// double-strand break repair /// DNA recombina:on /// response to DNA damage s:mulus /// regula:on of double-strand break repair via homologous recombina:on /// telomere maintenance via semi-conserva:ve replica:onnucleic acid binding /// DNA binding /// single-stranded DNA binding /// protein binding /// protein phosphatase binding /// protein N-terminus b di gnu leus /// nucleo lasm  DNA replica:on factor A comp ex /// nucleolus /// PML b dy
227108_at 227108_at STARD9 StAR-related lipid transfer (START) domain containing 9microtubule-b sed movement /// metabolic process /// spindle assemblynucleo:de binding / microtubule motor ac:vity /// protein binding /// ATP binding /// microtubule bindingnucleus / / cytopl m /// centriole /// cytoskeleton /// microtubule associated omplex
202633_at 202633_at TOPBP1 topoisomerase (DNA) II binding protein 1DNA metabolic process /// DNA repair /// response to DNA damage s:mulus /// response to ionizing radia:onDNA binding /// protein bindin  /// protein C-t rmi us bindi g /// isomerase ac:vity /// iden:cal protein bindingcondensed nuclear chro some /// ndle pole /// male germ cell nucleus /// nucleus /// chromosome /// cytoplasm /// microtubule organizing center /// cytoskeleton /// PML body
211300_s_at 211300_s_at TP53 tumor protein p53 protein import into nucleus, transloca:on /// cell cycle checkpoint /// nega:ve regula:on of transcrip:on from RNA polymerase II promoter /// nega:ve regula:on of transcrip:on from RNA polymerase II promoter /// nega:ve regula:on of transcrip:on from RNA polymerase II promoter /// DNA strand renatura:on /// in utero embryonic development /// somitogenesis /// release of cytochrome c from mitochondria /// T cell prolifera:on involved in immune response /// B cell lineage commitment /// T cell lineage commitment /// response to ischemia /// base-excision repair /// nucleo:de-excision repair /// double-strand break repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// protein complex assembly /// apopto:c process /// induc:on of apoptosis /// response to DNA damage s:mulus /// DNA damage response, signal transduc:on by p53 class mediator resul:ng in cell cycle arrest /// DNA damage response, signal transduc:on by p53 class mediator resul:ng in transcrip:on of p21 class mediator /// response to oxida:ve stress /// ER overload response /// cell cycle /// cell cycle arrest /// cell cycle arrest /// transforming growth factor beta receptor signaling pathway /// Ras protein signal transduc:on /// mul:cellular organismal development /// gastrula:on /// nega:ve regula:on of neuroblast prolifera:on /// central nervous system development /// cell aging /// blood coagula:on /// protein localiza:on /// nega:ve regula:on of DNA replica:on /// cell prolifera:on /// nega:ve regula:on of cell prolifera:on /// determina:on of adult lifespan /// rRNA transcrip:on /// response to UV /// response to salt stress /// embryo development ending in birth or egg hatching /// response to X-ray /// response to gamma radia:on /// posi:ve regula:on of cardiac muscle cell apopto:c process /// virus-host interac:on /// cell diﬀeren:a:on /// nega:ve regula:on of cell growth /// DNA damage response, signal transduc:on by p53 class mediator /// DNA damage response, signal transduc:on by p53 class mediator /// nega:ve regula:on of transforming growth factor beta receptor signaling pathway /// posi:ve regula:on of histone deacetyla:on /// chroma:n assembly /// mito:c G1 DNA damage checkpoint /// posi:ve regula:on of protein oligomeriza:on /// T cell diﬀeren:a:on in thymus /// regula:on of :ssue remodeling /// cellular protein localiza:on /// cellular response to UV /// mul:cellular organism growth /// cellular response to drug /// regula:on of cell prolifera:on /// cellular response to glucose starva:on /// response to drug /// intrinsic apopto:c signaling pathway in response to DNA damage by p53 class mediator /// regula:on of apopto:c process /// posi:ve regula:on of apopto:c process /// nega:ve regula:on of apopto:c process /// nega:ve regula:on of apopto:c process /// regula:on of neuron apopto:c process /// posi:ve regula:on of neuron apopto:c process /// nega:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// response to an:bio:c /// regula:on of mitochondrial membrane permeability /// nega:ve regula:on of ﬁbroblast prolifera:on /// posi:ve regula:on of pep:dyl-tyrosine phosphoryla:on /// nega:ve regula:on of helicase ac:vity /// protein tetrameriza:on /// chromosome organiza:on /// neuron apopto:c process /// regula:on of cell cycle /// posi:ve regula:on of thymocyte apopto:c process /// posi:ve regula:on of cell cycle arrest /// cellular response to hypoxia /// cellular response to ionizing radia:on /// mito:c cell cycle arrest /// intrinsic apopto:c signaling pathway by p53 class mediator /// posi:ve regula:on of release of cytochrome c from mitochondria /// posi:ve regula:on of cell aging /// replica:ve senescence /// oxida:ve stress-induced premature senescence /// intrinsic apopto:c signaling pathway /// oligodendrocyte apopto:c process /// nega:ve regula:on of macromitophagy /// nega:ve regula:on of reac:ve oxygen species metabolic process /// posi:ve regula:on of reac:ve oxygen species metabolic process /// posi:ve regula:on of intrinsic apopto:c signaling pathwayRNA polymerase II core promo er proximal region sequence-spec ﬁc DNA binding transcrip:on factor ac:vity involved in posi ve regula:on of transcrip:on /// RNA polymerase II transcrip:on factor binding /// RNA p lymerase II transcrip:on regulat ry region seque ce-speciﬁc DNA binding transcrip:on factor ac:vity involved in posi:ve regula:on of transcrip:on /// protease binding // p53 binding /// DNA bin ing /// chroma:n binding /// damaged DNA bindi g sequenc -speciﬁc DNA binding transcrip:on factor ac:vity /// copper ion binding /// protein binding /// ATP binding /// transcrip:on factor binding /// zinc ion binding /// enzyme binding /// protein kinase binding /// rece t r tyrosine kinase binding /// ubiqui:n protein ligase bindi g /// his ne deacetylase regulator c:vity /// histone acetyltransferase bi ding /// iden:cal protein binding /// transcrip:on regulatory region DNA binding /// etal ion binding /// protein heterodimeriza:on ac:vi y /// protein N-terminus binding /// chaperone binding /// protein phosphatase 2A binding /// MDM2/MDM4 famil  protein bindingchroma:n /// nuclea chro a:n /// ucle s /// nucleoplasm /// nucleoplasm /// replica: n fork /// transc ip:on fact r TFIID complex /// nucleolus /// cytoplasm /// mitochondrion /// mitochondrial matrix /// endoplasmi  re culum /// cytosol /// cytosol /// u le r matrix /// nucl ar body /// PML body //  prot in complex
203050_at 203050_at TP53BP1 tumor protein p53 binding protein 1double-strand break repair via homologous recombina:on /// DNA repair /// double-strand break repair /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// response to DNA damage s:mulus /// posi:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of transcrip:on from RNA polymerase II promoter /// posi:ve regula:on of sequence-speciﬁc DNA binding transcrip:on factor ac:vityRNA polymerase II c:va:ng transcrip:on factor bindi g /// RNA polymerase II transcrip:on cofactor ac:vity /// p53 binding /// DNA binding /// damaged DNA binding /// protein binding /// methylated histone residue binding /// telom ric DNA bindingchromosome, centromeric region /// k etocho  /// condensed chromosome kineto h e //  chromosome, telomeric regio  /// nucleus /// nucleopla m //  re lica:on fork //  chrom om  /// cytopla m
34689_at 34689_at TREX1 three prime repair exonuclease 1DNA metabolic process /// DNA replica:on /// DNA repair /// mismatch repair /// DNA recombina:on /// response to DNA damage s:mulus /// cell death /// regula:on of type I interferon produc:on /// posi:ve regula:on of type I interferon produc:on /// cellular response to interferon-beta /// innate immune response /// nucleic acid phosphodiester bond hydrolysisnucleic acid binding /// double-stranded DNA binding /// single-stranded DNA binding /// nuclease ac:vity / xonuclease ac:vity /// 3'-5'-exodeoxyribonuclease ac:vity /// 3'-5' exonuclease ac:vity /// 3'-5' ex n clease ac:vity /// exodeoxyribonuclease III c:v ty /// hydrolase ac:vity /  M tLalpha complex binding /// MutSalpha complex binding /// adenyl deoxyribonucleo:de binding /// protein homodimeriza:on ac:vity /// protein homodimeriza:on ac:vity /// metal ion binding /// metal ion bindingintracellula   nucleus /// nuclear envelope /// cytopl sm /// endoplasmic re:cu um membrane
211788_s_at 211788_s_at TREX2 three prime repair exonuclease 2DNA metabolic process /// DNA repair /// response to DNA damage s:mulus /// nucleic acid phosphodiester bond hydrolysismagnesium ion binding /// nucl ic acid binding /// nuclease ac:vity /// xonuclease ac:vity /// 3'-5'-exodeoxyribonuclease ac:vity /// exodeoxyribonuclease III ac:vity /// hydrolase ac:vity /// protein homodimeriza:on ac:vity /// metal ion bindingintracellular  l us
201523_x_at 201523_x_at UBE2N ubiqui:n-conjuga:ng enzyme E2Ndouble-strand break repair via homologous recombina:on /// DNA double-strand break processing /// toll-like receptor signaling pathway /// MyD88-dependent toll-like receptor signaling pathway /// DNA repair /// regula:on of DNA repair /// postreplica:on repair /// cellular protein modiﬁca:on process /// proteolysis /// ubiqui:n-dependent protein catabolic process /// response to DNA damage s:mulus /// Toll signaling pathway /// protein ubiqui:na:on /// protein ubiqui:na:on /// histone ubiqui:na:on /// cytokine-mediated signaling pathway /// posi:ve regula:on of histone modiﬁca:on /// regula:on of histone ubiqui:na:on /// toll-like receptor 1 signaling pathway /// toll-like receptor 2 signaling pathway /// toll-like receptor 4 signaling pathway /// toll-like receptor 5 signaling pathway /// toll-like receptor 9 signaling pathway /// toll-like receptor 10 signaling pathway /// nucleo:de-binding domain, leucine rich repeat containing receptor signaling pathway /// Fc-epsilon receptor signaling pathway /// toll-like receptor TLR1:TLR2 signaling pathway /// toll-like receptor TLR6:TLR2 signaling pathway /// posi:ve regula:on of I-kappaB kinase/NF-kappaB cascade /// posi:ve regula:on of I-kappaB kinase/NF-kappaB cascade /// innate immune response /// posi:ve regula:on of DNA repair /// T cell receptor signaling pathway /// T cell receptor signaling pathway /// posi:ve regula:on of NF-kappaB transcrip:on factor ac:vity /// posi:ve regula:on of ubiqui:n-protein ligase ac:vity /// nucleo:de-binding oligomeriza:on domain containing signaling pathway /// protein K63-linked ubiqui:na:onnucle :de binding /// ubiqui:n-pr tein ligase ac:vity /// protein binding /// ATP binding /// ligase ac:vity /// acid-amino acid ligase ac:vity /// ubiqu :n bindingubiqui:n ligase complex /// nucleus /// c toplasm /// cytop asm /// cy sol //  UBC13-MMS2 complex /// UBC13-UEV1A complex
205667_at 205667_at WRN Werner syndrome, RecQ helicase-liketelomere maintenance /// DNA synthesis involved in DNA repair /// replica:ve cell aging /// nucleobase-containing compound metabolic process /// ATP catabolic process /// DNA metabolic process /// DNA replica:on /// DNA repair /// base-excision repair /// double-strand break repair /// DNA recombina:on /// response to DNA damage s:mulus /// response to oxida:ve stress /// aging /// cell aging /// metabolic process /// cellular response to starva:on /// response to UV-C /// mul:cellular organismal aging /// replica:on fork processing /// replica:on fork processing /// nucleolus to nucleoplasm transport /// DNA duplex unwinding /// DNA duplex unwinding /// regula:on of growth rate /// regula:on of apopto:c process /// cellular metabolic process /// posi:ve regula:on of hydrolase ac:vity /// cellular response to gamma radia:on /// nucleic acid phosphodiester bond hydrolysisnucleo:de bin i g /// magnesium ion binding /// Y-form DNA binding /// bubble DNA binding /// nucleic acid binding /// DNA binding /// DNA helicase ac:vity /// DNA helicase ac vity /// cataly:c ac:vity /// ATP-dep ndent DNA helicase ac:vity /// helicase ac:vity /// nuclease ac:vity /// exonuclease c:vity /// protein binding /// ATP binding //  ATP-depend nt helicase ac:vity /// 3'-5' exonu lease ac:vity /// four-w y junc:on helicase ac:vity / hydrolase ac:vity /// ATPase ac:vity /// manganese ion binding /// protein com lex binding // protein h modimeriza:on ac:vity /// 3'-5' DNA helicase ac:vity /// TP-d pendent 3'-5' DNA helicase ac:vity /// metal ion binding /// G-quadruplex DNA bindingintracellular /// nucleus /// nucleop asm //  nucleolus /// e trosome /// M tLalpha complex
205672_at 205672_at XPA xeroderma pigmentosum, complementa:on group Anucleo:de- xcisi  repair, DNA damage removal /// DNA repair /// nucleo:de-excision repair /// response to DNA damage s:mulus /// response to oxida:ve stress /// intrinsic apopto:c signaling pathway in response to DNA damage /// response to UV /// response to toxic substance /// mul:cellular organism growthnucl o:de binding /// DNA bindi g /// damaged DNA binding /// rotein binding /// protein domain speciﬁc binding /// pro ein homodimeriz : n ac:vity /// met l ion bi dingnucleus / nucleoplasm
207598_x_at 207598_x_at XRCC2 X-ray repair complemen:ng defec:ve repair in Chinese hamster cells 2double-strand break repair via o ologous recombina:on /// in utero embryonic development /// DNA metabolic process /// DNA repair /// DNA recombina:on /// response to DNA damage s:mulus /// meiosis /// response to X-ray /// response to gamma radia:on /// nega:ve regula:on of neuron apopto:c process /// posi:ve regula:on of neurogenesisDNA binding /// protei binding /// ATP binding /// DNA-dependent ATPase ac:vitynucleus
216299_s_at 216299_s_at XRCC3 X-ray repair complemen:ng defec:ve repair in Chinese hamster cells 3DNA m tabolic rocess /// DNA repair /// DNA recombina:on /// transcrip:on, DNA-dependent /// response to DNA damage s:mulus /// response to organic substancenucleo:de binding /// DNA binding /// DNA-directed RNA polyme a e ac:vity /// protein binding /// ATP binding /// DNA-depende t ATPase ac:vitynucleus / cytoplasm //  mitochondrion /// perinucl ar region of cytopl sm
210812_at 210812_at XRCC4 X-ray repair complemen:ng defec:ve repair in Chinese hamster cells 4i  utero embryonic development /// p o-B cell diﬀeren:a:on /// DNA liga:on /// DNA repair /// double-strand break repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina:on /// response to DNA damage s:mulus /// central nervous system development /// response to X-ray /// response to ionizing radia:on /// response to gamma radia:on /// viral reproduc:on /// viral reproduc:ve process /// T cell diﬀeren:a:on in thymus /// V(D)J recombina:on /// immunoglobulin V(D)J recombina:on /// nega:ve regula:on of neuron apopto:c process /// isotype switching /// posi:ve regula:on of ﬁbroblast prolifera:on /// posi:ve regula:on of neurogenesis /// DNA liga:on involved in DNA repair /// posi:ve regula:on of ligase ac:vity /// cellular response to lithium ion /// establishment of integrated proviral latencyDNA binding /// protein binding /// protei C-terminus b nding /// ligase ac:vitycondensed chromosome /// nucleus /// nucleus /// n c opl sm /// cytosol /// DNA-dependent protein kinase-DNA liga e 4 complex /// DNA ligase IV complex /// n nhomolog s end joining complex
208643_s_at 208643_s_at XRCC5 X-ray repair complemen:ng defec:ve repair in Chinese hamster cells 5 (double-strand-break rejoining)telomere maintenance /// DNA repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina:on /// transcrip:on, DNA-dependent /// regula:on of transcrip:on, DNA-dependent /// response to DNA damage s:mulus /// cell prolifera:on /// viral reproduc:on /// viral reproduc:ve process /// posi:ve regula:on of type I interferon produc:on /// nega:ve regula:on of apopto:c process /// innate immune response /// nega:ve regula:on of transcrip:on, DNA-dependent /// posi:ve regula:on of neurogenesis /// hematopoie:c stem cell diﬀeren:a:on /// establishment of integrated proviral latencynucleo:de inding /// DNA inding / damaged DNA binding /// double-stranded DNA bindi g /// double-stranded t lom ric DNA binding /// ATP-d pendent DNA helicase ac:vity /// helic se ac:vity /// prot in binding /// ATP binding /// protein C-terminus bindi g /// hydrolase ac:vity /// hydrolase ac:vity, ac:ng on acid anhydrides /// biqui:n protein ligase binding /// telomeric DNA binding /// transcrip:on egulatory region DNA binding /// 5'-deoxyribose-5-phosphate lyase ac:vitynuclear telomere c p complex /// nuclear chromosome, telome ic re ion /// nucleus / n cleoplasm /// chromosome /// ucle lus /// cytoplasm //  cytosol /// DNA-dependent protein kinase-DNA ligas  4 complex /// Ku70:Ku80 complex /// onhomologous end joining complex


Supplementary Table S1: Clinicopathological characteristics of whole breast cancer cohort
Variable n* Cases          (%)
Menopausal status 1650
Pre-menopausal 612          (37.0)
postmenopausal 1038        (63.0)
Tumour Grade (NGS) 1650
G1  306          (18.5)
G2 531          (32.2)
G3  813          (49.3)
Lymph node stage 1650
Negative  1056         (64.0)
Positive (1-3 nodes) 486          (29.5)
Positive (>3 nodes) 108           (6.5)
Tumour size (cm) 1650
T1 a + b (≤1.0) 187         (11.0)
T1 c (>1.0 -2.0) 868         (53.0)
T2 (>2.0-5) 579      (35.0)
T3 (>5) 16         (1.0)
Tumour type 1650
IDC-NST 941         (57)
Tubular 349         (21)
ILC 160        (10)
Medullary (typical/atypical) 41          (2.5)
Others 159        (9.5)
NPI subgroups 1650
Excellent PG(2.08-2.40) Low risk 207         (12.5)
Good PG(2.42-3.40) 331          (20.1)
Moderate I PG(3.42 to 4.4) High risk 488         (29.6)
Moderate II PG(4.42 to 5.4) 395         (23.9)
Poor PG(5.42 to 6.4) 170         (10.3)
Very poor PG(6.5–6.8) 59         (3.6)
Survival at 20 years 1650
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* Number of cases for which data were available.
NPI; Nottingham prognostic index, PG; prognostic group
Alive and well 1055         (64.0)
Dead from disease 468          (28.4)
Dead from other causes 127         (7.6)
Adjuvant systemic therapy (AT)
No AT 665         (42.0)
Hormone therapy (HT) 642         (41.0)
Chemotherapy 307         (20.0)
Hormone + chemotherapy 46         (3.0)
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Supplementary treatment data 1:
Patients received standard surgery (mastectomy or wide local excision) with radiotherapy.  Prior to 1989, 
patients did not receive systemic adjuvant treatment (AT). After 1989, AT was scheduled based on prognostic 
and predictive factor status, including NPI, oestrogen receptor-α (ER-α) status, and menopausal status. Patients 
with NPI scores of <3.4 (low risk) did not receive AT. In pre-menopausal patients with NPI scores of ≥3.4 (high 
risk), classical Cyclophosphamide, Methotrexate, and 5-Flourouracil (CMF) chemotherapy was given; patients 
with ER-α positive tumours were also offered HT. Postmenopausal patients with NPI scores of ≥3.4 and ER-α 
positivity were offered HT, while ER-α negative patients received classical CMF chemotherapy.
Median follow up was 111 months (range 1 to 233 months).  Survival data, including overall survival, disease-
free survival (DFS), and development of loco-regional and distant metastases (DM), was maintained on a 
prospective basis.  DFS was defined as the number of months from diagnosis to the occurrence of local 
recurrence, local lymph node (LN) relapse or DM relapse.  Breast cancer specific survival (BCSS) was defined 
as the number of months from diagnosis to the occurrence of BC related-death. Local recurrence free survival 
(LRS) was defined the number of months from diagnosis to the occurrence of local recurrence. DM-free 
survival was defined as the number of months from diagnosis to the occurrence of DM relapse.  Survival was 
censored if the patient was still alive at the time of analysis, lost to follow-up, or died from other causes.
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Supplementary Table S2. Antigens, primary antibodies, clone, source, optimal dilution and scoring system 
used for each immunohistochemical marker.
Marke
r Antibody Clone
Manufact
urer
Antigen 
retrieval
Dilution 
/  
Incubati
on Time
Distributi
on
Scoring 
system Cut-offs
BRCA
1
Mouse 
MAb anti-
BRCA1
MS 110 Calbiochem
Citrate 
buffer pH6 
20 minutes
1:100
60 min
Nuclear
% of 
positive 
cells
<25% 
(negative
)
Pol β Rabbit Polyclonal ab26343 Abcam
Citrate 
buffer pH6 
20 minutes
1:200
60 min
Nuclear H-score ≤100 (low)
XRCC
1
Mouse 
MAb anti-
XRCC1 
33-2-5 Thermo Scientific
Citrate 
buffer pH6 
20 minutes
1:200 Nuclear H-score ≤100 (low)
APE1 Rabbit polyclonal
NB100-10
1
Novus 
Biologicals
Citrate 
buffer pH6 
20 minutes
1:500
60 min
Nuclear H-score ≤100 (low)
SMUG
1
Goat MAb 
anti-
SMUG1 
AP08884P
U-N
Acris 
Antibody 
GmbH
Citrate 
buffer pH6 
20 minutes
1:200 Nuclear H-score ≤35 (low)
Viment
in
Mouse 
MAb anti-
vimentin
Vim 3B4
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:250
60 min
Cytoplas
m
% of 
positive 
cells
≥10% 
(positive
)
CK18
Mouse 
MAb anti-
Ck18
DC10
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:100
60 min
Cytoplas
m
% of 
positive 
cells
≥10% 
(positive
)
ER
Mouse 
MAb anti-
ER-α
SP1
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:150
30 min
Nuclear Allred score
≥3 
(positive
)
ER
Mouse 
MAb anti-
ER-α
EP1
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:80
30 min
Nuclear
% of 
positive 
cells
≥1% 
positive
PR
Mouse 
MAb anti-
PR
PgR636
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:125
30 min
Nuclear
% of 
positive 
cells
≥1% 
positive
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All sections were pre-treated with microwave antigen retrieval using 0.1% citrate buffer (pH 6).
AR: Androgen Receptor; MAb: Monoclonal antibody; BRCA1: BC 1, ER: oestrogen receptor; PR: 
progesterone receptor; TOP2A: Topoisomerase II alpha; CK: cytokeratin; Bax: BCL2-associated X 
protein.
p53
Mouse 
MAb anti 
p53
DO7 Novocastra
Citrate 
buffer pH6 
20 minutes
1: 50
60 min
Nuclear
% of 
positive 
cells
≤20% 
(negative
)
>20% 
(High)
p21
Mouse 
MAb anti-
p21
SW118
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:50
60 min
Nuclear
% of 
positive 
cells
≥10% 
(positive
)
Bax Rabbit anti-Bax Polyclonal Abcam
Citrate 
buffer pH6 
20 minutes
1:1000
60 min
Cytoplas
m
% 
positive 
cells
≥10% 
(positive
)
Bcl2
Mouse 
MAb anti-
Bcl2
124
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:100
60 min
Cytoplas
m
% of 
positive 
cells
>10% 
(positive
TOP2A
Mouse 
MAb
TOP2A
KiS1
Dako-
Cytomatio
n
Citrate 
buffer pH6 
20 minutes
1:100
60 min Nuclear
% of 
positive 
cells
>25% 
(positive
)
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Supplementary Table S3. BRCA1 and DNA base excision repair protein expression in breast cancers cancers.
BRCA1 
(Negative)
BRCA1 (Positive)       P value
DNA base excision repair  Number (%) Number (%)
Pol β Low 276 (61.2) 278 (34.8) 1.8 x 10-19
High 175 (38.8) 521 (65.2)
XRCC1 Low 98 (22.5) 101 (13.0) 1.6 x 10-5
High 337 (77.5) 678 (87.0)
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Supplementary Table S4. Clinicopathological significance of  XRCC1 expression in BRCA1 negative 
tumours.
Variable
XRCC1
X2
Adjusted p value
Low
N (%)
    High 
N (%)
A) Pathological    Parameters
Stage 
I 59 (60.2) 208 (61.7) 0.864
II 29 (29.6) 91 (27.0)
III 10 (10.2) 38 (11.3)
Tumour Size 
T1 a + b (≤1.0) 2 (2.1) 27 (8.2) 0.079
T1 c (>1.0 -2.0) 40 (41.7) 141 (42.9)
T2 (>2.0-5) 52 (54.2) 146 (44.4)
T3 (>5) 2 (2.1) 15 (4.6)
LVI 
Negative 48 (49.0) 136 (40.6) 0.140
Positive 50 (51.0) 199 (59.4)
Grade
G1 3 (3.1) 9 (2.7) 0.353
G2 9 (9.2) 50 (14.8)
G3 86 (87.8) 278 (82.5)
Tumour Types
IDC-NST 78 (79.6) 298 (88.7) 0.162
Tubular 7 (7.1) 9 (2.7)
ILC 2 (2.0) 5 (1.5)
Medullary 5 (5.1) 11 (3.3)
Others 6 (6.1) 13 (3.9)
Mitotic Index
M1 (low; mitoses < 10) 7 (7.2) 34 (10.1) 0.290
M2 (medium; mitoses 10-18) 13 (13.4) 62 (18.5)
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M3 (high; mitosis >18) 77 (79.4) 239 (71.3)
Pleomorphism
1 (small-regular uniform) 0 (0.0) 0 (0.0) 0.480
2 (Moderate variation) 7 (7.2) 32 (9.6)
3 (Marked variation) 90 (92.8) 303 (90.4)
Tubule formation
1 (>75% of definite tubule) 2 (2.1) 5 (1.5) 0.700
2 (10%-75% definite tubule) 16 (16.5) 67 (20.0)
3 (<10% definite tubule) 79 (81.4) 263 (78.5)
B) Aggressive phenotype
Her2 overexpression (No) 85 (86.7) 267 (79.5) 0.106
                                     (Yes) 13 (13.3) 69 (20.5)
Triple negative (No)       37 (37.8) 133 (39.6) 0.744
                          (Yes) 61 (62.2) 203 (60.4)
Basal like          (No) 44 (81.5) 95 (76.6) 0.470
                          (Yes) 10 (18.5) 29 (23.4)
Vimentin (Negative) 29 (85.3) 75 (80.6) 0.547
                  (Positive) 5 (14.7) 18 (19.4)
CK18         (Negative) 38 (40.4) 146 (47.2) 0.245
                  (Positive) 56 (59.6) 163 (52.8)
C) Hormonal receptors
ER   (Negative) 71 (72.4) 264 (78.3) 0.223
        (Positive) 27 (27.6) 73 (21.7)
PgR (Negative) 79 (84.0) 261 (82.1) 0.659
        (Positive) 15 (16.0) 52 (17.9)
D) DNA Repair Pathway
APE1 (Low)
          (High)
34 (79.1) 57 (56.4) 0.010
9 (20.9) 44 (43.6)
SMUG1 (Low) 46 (55.4) 94 (31.4) 0.000006
             (High) 37 (44.6) 205 (68.6)
PolB    (Low) 59 (67.8) 178 (58.7) 0.127
             (High) 28 (32.2) 125 (41.3)
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TOP2A (Low) 66 (77.6) 168 (57.9) 0.001
             (High) 19 (22.4) 122 (42.1)
E) Cell cycle/apoptosis regulators
p53      (Negative) 58 (59.8) 150 (45.7) 0.015
            (Positive) 39 (40.2) 178 (54.3)
Bax     (Negative) 34 (89.5) 68 (76.4) 0.090
           (Positive) 4 (10.5) 21 (23.6)
Bcl2   (Negative) 56 (60.9) 219 (66.4) 0.328
          (Positive) 36 (39.1) 111 (33.6)
p16    (Low) 35 (83.3) 94 (87.0) 0.557
          (High) 7 (16.7) 14 (13.0)
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Supplementary Table S5. Clinicopathological significance of  pol β expression in BRCA1 negative tumours.
Variable
Pol Beta
X2
Adjusted p value
Low
N (%)
    High 
N (%)
A) Pathological    Parameters
Stage 
I 172 (62.3) 112 (64.0) 0.332
II 70 (25.4) 49 (28.0)
III 34 (12.3) 14 (8.0)
Tumour Size 
T1 a + b (≤1.0) 20 (7.4) 13 (7.6) 0.627
T1 c (>1.0 -2.0) 120 (44.1) 69 (40.6)
T2 (>2.0-5) 121 (44.5) 84 (49.4)
T3 (>5) 11 (4.0) 4 (2.4)
LVI
Negative 116 (42.3) 78 (44.6) 0.641
Positive 158 (57.7) 97 (55.4)
Grade
G1 5 (1.8) 7 (4.0) 0.331
G2 39 (14.1) 27 (15.4)
G3 232 (84.1) 141 (80.6)
Tumour Types
IDC-NST 236 (86.1) 147 (84.0) 0.740
Tubular 11 (4.0) 11 (6.3)
ILC 6 (2.2) 2 (1.1)
Medullary 9 (3.3) 6 (3.4)
Others 12 (4.4) 9 (5.1)
Mitotic Index
M1 (low; mitoses < 10) 23 (8.4) 24 (13.9) 0.184
M2 (medium; mitoses 10-18) 43 (15.7) 26 (15.0)
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M3 (high; mitosis >18) 208 (75.9) 123 (71.1)
Pleomorphism
1 (small-regular uniform) 2 (0.7) 0 (0.0) 0.133
2 (Moderate variation) 19 (6.9) 20 (11.6)
3 (Marked variation) 253 (92.3) 153 (88.4)
Tubule formation
1 (>75% of definite tubule) 2 (0.7) 4 (2.3) 0.366
2 (10%-75% definite tubule) 54 (19.7) 33 (19.1)
3 (<10% definite tubule) 218 (79.6) 136 (78.6)
B) Aggressive phenotype
Her2 overexpression (No) 225 (81.8) 140 (80.5) 0.719
                                     (Yes) 50 (18.2) 34 (19.5)
Triple negative (No)       101 (36.7) 75 (43.1) 0.178
                          (Yes) 174 (63.3) 99 (56.9)
Basal like          (No) 76 (76.8) 67 (75.3) 0.811
                          (Yes) 23 (23.2) 22 (24.7)
Vimentin   (Negative) 61 (89.7) 48 (81.4) 0.178
                  (Positive) 7 (10.3) 11 (18.6)
CK18         (Negative) 125 (48.8) 68 (41.2) 0.126
                  (Positive) 131 (51.2) 97 (58.8)
C) Hormonal receptors
ER   (Negative) 218 (79.0) 123 (70.3) 0.036
        (Positive) 58 (21.0) 52 (29.7)
PgR (Negative) 221 (84.4) 130 (77.4) 0.069
        (Positive) 41 (15.6) 38 (22.6)
D) DNA Repair Pathway
APE1 (Low) 67 (72.0) 47 (56.0) 0.026
          (High) 26 (28.0) 37 (44.0)
SMUG1 (Low) 79 (34.6) 59 (41.5) 0.182
             (High) 149 (65.4) 83 (58.5)
XRCC1 (Low) 59 (24.9%) 28 (18.3) 0.127
             (High) 178 (75.1) 125 (81.7)
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TOP2A (Low) 149 (64.2) 87 (58.8) 0.286
             (High) 83 (35.8) 61 (41.2)
E) Cell cycle/apoptosis regulators
p53      (Negative) 123 (45.6) 90 (52.6) 0.147
            (Positive) 147 (54.4) 81 (47.4)
Bax     (Negative) 52 (77.6) 50 (84.7) 0.309
           (Positive) 15 (22.4) 9 (15.3)
Bcl2   (Negative) 187 (70.6) 94 (55.3) 0.001
          (Positive) 78 (29.4) 76 (44.7)
p16    (Low) 69 (87.3) 61 (87.1) 0.971
          (High) 10 (12.7) 9 (12.9)
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Supplementary  Table  S6:  Clinicopathological  characteristics  of  BRCA1 germ line  mutated  breast 
cancer cohort (N=50)
Variables N (%)
Age (years) at diagnosis [Mean, Median (range)] [40.66, 38.5(26-64)]
Tumour Size (cm) [Mean (range)]
T1 a + b (≤1.0)
T1 c (>1.0 -2.0)
T2 (>2.0-5)
T3 (>5)
[2.03 (0.4-5.2)]
7   (22)
22 (44)
20 (40)
1   (2)
Pathological Type
Ductal/NST
Lobular/Miixed
Medullary (Typical/Atypical)
Basal
Spindle
Tubular/Mixed
40 (80)
1   (2)
6   (12)
1   (2)
1   (2)
1   (2)
Lymph node involvement
No
LN (1-3)
LN (>3)
Unknown
32  (64)
15  (30)
1   (2)
2  (4)
Grade
1
2
3
1  (2)
5  (10)
44 (88)
Stage
1
2
3
Unknown
32 (64)
15 (30)
1  (20)
2  (4)
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Vascular Invasion
No
Yes
Unknown
29 (58)
17 (34)
4 (8)
NPI
Excellent PG(2.08-2.40)
Good PG(2.42-3.40)
Moderate I PG(3.42 to 4.4)
Moderate II PG(4.42 to 5.4)
Poor PG(5.42 to 6.4)
Very poor PG(6.5–6.8)
Unknown
1 (2)
2 (4)
19 (38)
15 (30)
9 (18)
1 (2)
3 (6)
Oestrogen receptor (ER) 
Negative 
Positive
Unknown
40 (80)
9  (18)
1 (2)
Her2
Negative 
Positive
Unknown
47 (94)
2 (4)
1 (2)
Triple Negativity
Non TN
TN
Unknown
18 (36)
31 (62)
1 (2)
Recurrence
No
Yes
40 (80)
10 (20)
Survival in months [Mean, Median (range)]
Alive
Dead
[122.06, 118 (9 - 274)]
36 (72)
14 (28)
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Type of Surgery
WLE
Mastectomy
18 (36)
32 (64)
Bilateral Cancer
No
Yes
34 (68)
16 (32)
Prophylactic Mastectomy
No
Yes 
30 (60)
20  (40)
Prophylactic Oophorectomy
No
Yes
16 (32)
34 (68)
Prophylactic Oophorectomy for Cancer
No
Yes
44 (88)
6   (12)
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Supplementary Table S7: Clinicopathological significance of pol β expression in germ-line BRCA1 
mutated breast cancers (n=50).  
Markers POL-B (Low) POL-B (High)
P valuePathological parameters Number (%) Number (%)
Tumour Size (Cm) T1 a + b (≤1.0) 0 (0) 4 (13.8) 0.708
T1 c (>1.0 -2.0) 2 (40) 13 (44.8)
T2 (>2.0-5) 3 (60) 11 (37.9)
T3 (>5) 0 (0) 1 (3.4)
Histological Type A t y p i c a l 
Medullary
0 (0) 4 (13.8) 0.135
Ductal/NST 4 80) 22 (75.9)
Lobular 0 (0) 1 (3.4)
Medullary/NST 0 (0) 2 (6.9)
Spindle 1 (20) 0 (0)
LN Status Negative 4 (80) 17 (60.7) 0.409
Positive 1 (20) 11 (39.3)
Grade 1 1 (20) 0 (0) 0.042
2 0 (0) 3 (10.3)
3 4  (80) 26 (89.7)
Stage 1 4 (80) 17 (60.7) 0.409
2 1 (20) 11 (33.9)
Vascular Invasion Absent 2 (40) 16 (59.3) 0.425
Present 3 (60) 11 (40.7)
ER Status Negative 4 (80) 24 (82.8) 0.881
Positive 1 (20) 5 (17.2)
HeR2 Status Negative 5 (100) 27 (93.1)      0.545
Positive 0 (0) 2 (6.9)
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Triple Negativity No 2 (40) 11 (37.9)      0.958
Yes 3 (60) 18 (62.1)
Recurrence No 3 (60.0) 23 (79.3)     0.347
Yes 2 (40.0) 6 (20.7)
   17
Supplementary Table S8: Clinicopathological significance of XRCC1 expression in germ-line 
BRCA1 mutated breast cancers (n=50).  
Markers XRCC1 (Low) XRCC1 (High)
P valuePathological parameters Number (%) Number (%)
Tumour Size (cm) T1 a + b (≤1.0) 2 (22.2) 3 (12) 0.824
T1 c (>1.0 -2.0) 4 (44.4) 11 (44)
T2 (>2.0-5) 3 (33.3) 10 (40)
T3 (>5) 0 (0) 1 (4)
Histological Type Atypical Medullary 1 (11.1) 3 (12) 0.891
Ductal/NST 7 (77.8) 18 (72)
Lobular 0 (0) 1 (4)
Medullary/NST 1 (11.1) 1 (4)
Spindle 0 (0) 1 (4)
Tubular/Mixed 0 (0) 1 (4)
LN Status Negative 8 (88.9) 14 (58.3) 0.097
Positive 1 (11.1) 10 (41.7)
Grade 1 0 (0) 1 (4) 0.442
2 0 (0) 3 (12)
3 9 (100) 21 (84)
Stage 1 8 (88.9) 14 (58.3) 0.097
2 1 (11.1) 10 (41.7)
Vascular Invasion Absent 6 (75) 12 (52.2) 0.260
Present 2 (25) 11 (47.8)
ER Status Negative 8 (88.9) 19 (76) 0.412
Positive 1 (11.1) 6 (24)
HeR2 Status Negative 9 (100) 23 (92) 0.382
Positive 0 (0) 2 (8)
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Triple Negativity No 3 (33.3) 10 (40) 0.724
Yes 6 (66.7) 15 (60.0)
Recurrence No 6 (66.7) 19 (76) 0.586
Yes 3 (33.3) 6 (24)
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Supplementary Table S9. Patient demographics (METABRIC cohort)
Variables N
Age at diagnosis [Median (range)] 61.8 (21.93-96.29)
Tumour size [Median (range (mm))] 23 (1- 182mm)
NPI [Median (95% CI)] 4.04 (3.99-4.09)
Survival [Median (Months, 95% Cl)] 149 (141-159)
Lymph nodes status
0
1
2
3
>3
1012
336
170
112
316
ER status
Positive
Negative
1485
437
PAM50 subtype
Basal 
HER2 
Luminal A 
Luminal B 
Normal 
Not classified
322
238
714
484
188
6
Adjuvant systemic therapy (AT)
No AT 290
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Hormone therapy (HT) 1014
Chemotherapy 226
Hormone + chemotherapy 192
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Supplementary Table S10: Clinicopathological characteristics of the Uppsala Cohort 
(n=249) 
Variables N (%)
Age (years) at diagnosis [Mean, Median (range)] [62.1, 63.02 (28-93)]
Tumour Size (cm) [Mean (range)]
T1 a + b (≤1.0)
T1 c (>1.0 -2.0)
T2 (>2.0-5)
T3 (>5)
[2.24 (0.2-13.0)]
22 (8.8)
104 (41.8)
117 (47.0)
6 (2.4)
Lymph node involvement
No
Yes
159 (66.3)
81   (33.7)
Grade
1
2
3
68   (27.3)
126 (50.6)
55   (22.1)
Oestrogen receptor (ER) 
Negative 
Positive
34   (13.9)
211 (86.1)
Recurrence
No
Yes
160 (64.3)
89   (35.7)
Survival in months [Mean, Median (range)]
Alive
Dead
[85.7, 119 (0-153)]
160 (64.3)
89 (35.7)
Hormone therapy (Tamoxifen)
No
Yes
183 (73.5)
66   (26.5)
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Chemotherapy
No
Yes [Cyclophosphamide, Methotrexate, 5-Fluorouracil)
208 (83.5)
41   (16.5)
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Supplementary Table S13. QuantiTect® Primers used in RT-PCR analysis.  
Gene Symbol Source Catalog  no.
APE1 Qiagen QT00012474
XRCC1 Qiagen QT00016688
SMUG1 Qiagen QT00002317
POLB Qiagen QT00088655
BRCA1 Qiagen QT00039305
GAPDH Qiagen QT00079247
   24
Supplementary Table S14. DNA repair mRNA expression in MDA-MB-436 compared to MCF7 
cells for qPCR.
All significant p values are shown in bold.  
Fold down-regulation P Value
APE1 -7.02 0.0006
XRCC1 -15.22 0.01
SMUG1 -9.54 0.001
POLB -2.56 0.05
BRCA1 -44.07 0.002
   25
Supplementary Table S15. DNA repair mRNA expression in BRCA1 knockdown cells compared to 
Control cells for qPCR.
All significant p values are shown in bold.  
Fold down-regulation P Value
APE1 -1.22 0.065
XRCC1 -4.21 0.002619
SMUG1 -1.60 0.033851
POLB -4.53 0.0676
BRCA1 -15.80 0.000455
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Supplementary Table S16. DNA repair mRNA expression profiling in BRCA1 knockdown HeLa 
SilenciX cells compared to control HeLa SilenciX cells.
Fold Change P Value
BER
APEX1 -1.06 0.856990
APEX2 1.32 0.001814
PARP1 -1.15 0.724495
PARP2 -1.94 0.262235
PARP3 -1.62 0.350824
POLB -2.08 0.213085
SMUG1 -1.18 0.374608
NTHL1 -1.36 0.440362
UNG -1.66 0.351472
FEN1 -1.04 0.759157
OGG1 -1.11 0.558876
NEIL1 -5.57 0.263241
NEIL2 1.05 0.932681
NEIL3 -1.31 0.416592
XRCC1 -2.17 0.051321
CCNO -1.57 0.104014
LIG3 -1.92 0.271431
MUTYH -1.84 0.201311
MPG -1.27 0.262867
HR
BRCA1 -3.50 0.036557
BRCA2 -1.24 0.239570
RAD21 -1.34 0.061085
RAD50 -1.67 0.345218
RAD51 -2.30 0.277572
RAD51B -1.77 0.336811
RAD51C -1.54 0.233420
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RAD51D -4.14 0.355474
RAD54L -1.76 0.208675
RAD52 -2.05 0.347470
XRCC2 -1.50 0.220340
XRCC3 -1.63 0.370900
ATM -1.54 0.128451
DMC1 -6.44 0.231080
MRE11A -1.36 0.177377
NHEJ
DNA-PKcs -2.54 0.000942
XRCC4 -1.28 0.336954
XRCC5 -1.10 0.586375
XRCC6 -1.04 0.716075
XRCC6BP1 1.20 0.622443
LIG4 -1.18 0.303680
NER
BRIP1 -1.64 0.120475
LIG1 -1.24 0.257076
ATXN3 -1.88 0.098094
RAD23A -3.00 0.348902
RAD23B 1.17 0.693343
RPA1 -1.15 0.557166
CCNH -1.19 0.361003
CDK7 -1.06 0.972071
DDB1 -1.00 0.789882
DDB2 -1.66 0.144235
PNKP -1.95 0.337396
POLL -2.92 0.333463
RPA3 -3.16 0.350940
SLK -1.46 0.180509
ERCC1 -2.28 0.023598
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All significant p values are shown in bold.  
ERCC2 -1.73 0.066389
ERCC3 -1.12 0.529309
ERCC4 -1.48 0.006281
ERCC5 -1.32 0.164452
ERCC6 -1.40 0.140431
ERCC8 -1.46 0.165440
XAB2 -1.33 0.338438
XPA -1.17 0.523245
XPC -1.59 0.285955
MMR
POLD3 -1.64 0.141055
PMS1 -2.25 0.254384
PMS2 -1.38 0.141756
MLH1 -1.38 0.356310
MSH2 -1.18 0.599644
MLH3 -1.61 0.132913
MSH3 -1.29 0.327005
MSH4 -3.04 0.012337
MSH5 -2.93 0.222323
MSH6 -1.58 0.322960
TREX1 -1.16 0.605905
Others
ATR -1.23 0.270260
EXO1 -1.27 0.418162
MGMT -2.62 0.224041
RAD18 -1.32 0.433195
RFC1 -1.30 0.285465
TOP3A -1.37 0.370190
TOP3B -1.53 0.364182
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Supplementary Table S17. DNA repair mRNA expression profiling in MDA-MB-436 compared to 
MCF7 cells.
Fold Change P Value
BER
APEX1 -2.68 0.108045  
APEX2 -2.37 0.447471  
PARP1 -2.89 0.024987  
PARP2 -2.20 0.026338  
LIG3 -4.43 0.086662  
POLB -2.85 0.018010  
SMUG1 -3.08 0.348467  
NTHL1 -5.74 0.063845  
UNG -7.32 0.062112  
FEN1 -2.71 0.401000  
OGG1 -3.71 0.093199  
NEIL1 -7.79 0.059311  
NEIL2 -2.18 0.080271  
NEIL3 -5.81 0.049842  
XRCC1 -4.63 0.090248  
CCNO -1.85 0.056339  
PARP3 -1.35 0.119678  
MUTYH -3.32 0.088049  
MPG -4.09 0.055673
HR
BRCA1 -9.08 0.016911
BRCA2 -5.30 0.092852
RAD21 -3.00 0.011678
RAD50 -2.41 0.080741
RAD51 -5.08 0.033865
RAD51C -27.35 0.089201
RAD51D -3.91 0.092264
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RAD52 -1.74 0.241065
RAD54L -6.55 0.027788
RAD51B -288.98 0.099145
XRCC2 -6.87 0.042262
XRCC3 -4.02 0.142791
ATM -3.78 0.114557
DMC1 -9.53 0.126028
MRE11A 0.049906 -6.20
NHEJ
DNA-PKcs -7.06 0.025294
XRCC4 -5.11 0.038131
XRCC5 -3.84 0.102412
XRCC6 -3.30 0.078772
XRCC6BP1 -8.08 0.095138
LIG4 -4.44 0.06401
NER
BRIP1 -48.33 0.110474
LIG1 -7.24 0.105516
ATXN3 -5.99 0.111505
RAD23A -2.88 0.08335
RAD23B -2.77 0.133763
RPA1 -3.28 0.077981
CCNH -3.13 0.043847
CDK7 -2.93 0.099967
DDB1 -2.25 0.131174
DDB2 -10.74 0.094882
PNKP -4.23 0.118640
POLL -3.02 0.178876
RPA3 -3.42 0.04816
SLK -2.49 0.11911
ERCC1 -2.51 0.037378
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All significant p values are shown in bold. 
ERCC2 -2.46 0.068755
ERCC3 -4.61 0.057429
ERCC4 -5.68 0.014286
ERCC5 -1.27 0.673253
ERCC6 -3.18 0.007035
ERCC8 -3.64 0.042008
XAB2 -2.50 0.074802
XPA -3.69 0.124376
XPC -2.87 0.143832
MMR
POLD3 -4.69 0.047055
PMS1 -3.76 0.100986
PMS2 -3.13 0.128963
MLH1 -4.47 0.071532
MSH2 -3.05 0.069132
MLH3 -4.19 0.121674
MSH3 -3.57 0.045203
MSH4 -1.43 0.587442
MSH5 -6.04 0.077756
MSH6 -2.81 0.064770
TREX1 -1.34 0.139725
Others
ATR 0.088050 -6.57
EXO1 0.038277 -6.99
MGMT 0.123066 -3.74
RAD18 0.099833 -4.23
RFC1 0.137648 -2.14
TOP3A 0.096444 -3.61
TOP3B 0.107455 -2.51
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Probe Set IDGene SymbolGene Title go biological process termgo molecular func9on termgo cellular co ponent term
210027_s_atAPEX1 APEX nuclease (mul9func9onal DNA repair enzyme) 1DNA repair /// DNA repair /// base-excision repair /// DNA recombina9on /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// aging /// response to organic nitrogen /// nega9ve regula9on of smooth muscle cell migra9on /// response to drug /// regula9on of mRNA stability /// cell redox homeostasis /// posi9ve regula9on of DNA repair /// oxida9on-reduc9on process /// cellular response to hydrogen peroxide /// cellular response to cAMP /// cellular response to pep9de hormone s9mulus /// cellular response to organic nitrogen /// DNA demethyla9on /// nucleic acid phosphodiester bond hydrolysisDNA binding /// damag d DNA binding / transcrip9on coac9vato  ac9vity /// transcrip9on corepressor c9vity /// RNA binding /// DNA-(apurinic or apyrimidinic site) ly s ac9vity /  DNA-(apurinic r apyrimidinic site) lyase ac9vity /// nucle se ac9vity /// endonuclease ac9vity /  endodeoxyribonucleas  ac9vity /// endoribonuclease ac9vity /// ribonuclease H ac9vity /// exonuclease ac9vity /// phosphodiesterase I ac9vity /  uracil DNA N-glycosylase ac9vity /// protein binding /// phosphoric diester hydrolase ac9vity /// 3'-5' exonuclease ac9vity /// 3'-5' exonuclease ac9vity /// oxidoreductase ac9vity /// hydrolase ac9vity /// lyase ac9vity /// site-speciﬁc endodeoxyribonuclease ac9vity, speciﬁc for altered base /// chroma9n DNA binding /// protein complex binding /// metal ion binding /// NF-kappaB bindingntrac llular /// nucl us //  nucleoplas  /// nucleoplasm /// ranscrip9on factor complex /// nucleolus /// cytoplasm / mitochondrion /// endoplasmic re9culum /// centrosome ibosome /// nuclear speck /// perinuclea  region of cytoplasm
204408_at APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2DNA repa r // DNA recombina9on /// response to DNA damage s9mulus /// cell cycle /// nucleic acid phosphodiester bond hydrolysisDNA binding /// DNA-(apu inic r apyrimidinic site) lyase ac9vity /// nu ase ac9vity /// end nuclease ac9vity /// ex nuclease ac9vity /// zinc ion binding /// hydrolase ac9vity /// lyase ac9vity /// metal ion bindingintracellu r // nucleus /// cytoplasm /// itochondrion /// mitochondri l nner membran
218527_at APTX aprataxin single strand break repair /// DNA liga9on /// DNA repair /// double-strand break repair /// response to DNA damage s9mulus /// metabolic process /// cell death /// regula9on of protein stability /// response to hydrogen peroxideDNA binding /  chroma9n binding /// damaged DNA binding /// double-st anded DNA binding /// double-stranded RNA binding /// cataly9  ac9vity /  p otein bi ding /// zi c ion binding /// phosphoglycolate ph sphatase ac9vity /// hydrolase ac9vity /// DNA 5'-adenosine monophosphate hydrolase ac9vity /// polynucleo9de 3'-phosphatase ac9vity /// metal ion binding /// protein N-terminus binding /// phosphoprotein bindingchroma9n /// nuclear chroma9n  nucleus /// nucle plasm //  nucleolus /// cytoplas
208442_s_atATM ataxia telangiectasia mutatedc ll cycle checkpoint /// DNA damage checkpoint /// telomere maintenance /// double-strand break repair via homologous recombina9on /// response to hypoxia /// somitogenesis /// pre-B cell allelic exclusion /// DNA repair /// double-strand break repair /// protein phosphoryla9on /// protein phosphoryla9on /// apopto9c process /// response to DNA damage s9mulus /// DNA damage induced protein phosphoryla9on /// DNA damage response, signal transduc9on by p53 class mediator resul9ng in cell cycle arrest /// cell cycle /// cell cycle arrest /// mito9c spindle assembly checkpoint /// reciprocal meio9c recombina9on /// signal transduc9on /// female gamete genera9on /// brain development /// heart development /// cell death /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to ionizing radia9on /// phosphoryla9on /// histone phosphoryla9on /// pep9dyl-serine phosphoryla9on /// nega9ve regula9on of B cell prolifera9on /// G2 DNA damage checkpoint /// histone-serine phosphoryla9on /// phospha9dylinositol-3-phosphate biosynthe9c process /// lipoprotein catabolic process /// posi9ve regula9on of apopto9c process /// nega9ve regula9on of apopto9c process /// posi9ve regula9on of DNA damage response, signal transduc9on by p53 class mediator /// posi9ve regula9on of neuron apopto9c process /// protein autophosphoryla9on /// neuron apopto9c process /// regula9on of cell cycle /// histone mRNA catabolic process /// cellular response to gamma radia9on /// replica9ve senescencenucleo9de binding /// DNA binding //  protein kinase ac9vity /// protein serine/threonine kinase ac9vity /// DNA-dependent protein kinase ac9vity /// binding /// protein binding /// ATP binding /// kinase ac9vity /  1-phospha9dylinositol-3-k nase ac9vity /// transfer se ac9vity /// transferase ac vity, transferring hosphorus-containing groups /// phosphotransferase ac9vity, alcohol group as acce tor /// protein complex binding /// histone se ine kinase ac9vity /// prot in dimeriza9on ac9vity /// prot in N-terminus bindingchromosom , telomeric region /// nucleus /// nu leoplasm /// cytoplasm /// s indl  /// cytoplasmic m mbr ne-bounded ve icle /// c toplasm c vesicle
209903_s_atATR ataxia telangiectasia and Rad3 relatedc ll cycle checkpoint /// DNA damage checkpoint /// DNA replica9on /// DNA repair /// protein phosphoryla9on /// response to DNA damage s9mulus /// cell cycle /// mul9cellular organismal development /// nega9ve regula9on of DNA replica9on /// phosphoryla9on /// pep9dyl-serine phosphoryla9on /// cellular response to UV /// regula9on of protein binding /// posi9ve regula9on of DNA damage response, signal transduc9on by p53 class mediator /// protein autophosphoryla9on /// cellular response to gamma radia9on /// replica9ve senescencenucleo9de binding /// DNA binding //  protein kinase ac9vity /// protein serine/threonine kinase ac9vity /// binding /// protein binding /// ATP binding kinase ac9vity /// transferas  ac9vity /  transferase ac9vity, transferring phosphorus-c ntaining groups /// phosphotransferase ac9vity, alcohol group as acc ptor //  MutLalpha c mplex binding /// MutSalpha complex bindingXY body // nucleus /// nucle plasm /// chromosome /// PML body
205733_at BLM Bloom syndrome, RecQ helicase-likeregula9on of cyclin-dependent protein serine/threonine kinase ac9vity /// G2 phase of mito9c cell cycle /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA double-strand break processing /// DNA strand renatura9on /// ATP catabolic process /// DNA replica9on /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// response to X-ray /// replica9on fork processing /// G2 DNA damage checkpoint /// cellular metabolic process /// posi9ve regula9on of transcrip9on, DNA-dependent /// nega9ve regula9on of DNA recombina9on /// nega9ve regula9on of mito9c recombina9on /// alpha-beta T cell diﬀeren9a9on /// posi9ve regula9on of alpha-beta T cell prolifera9on /// replica9on fork protec9on /// regula9on of binding /// protein oligomeriza9on /// chromosome organiza9on /// nega9ve regula9on of cell division /// cellular response to ionizing radia9on /// cellular response to hydroxyurea /// cellular response to camptothecinnu leo9de bi i g /// bubble DNA binding /// p53 binding nucleic acid binding /// DNA binding /// single-s randed DNA binding /// cataly9c ac9vity /// ATP-depend nt DNA helicase ac9vity /// ATP-dependent DNA helicase ac9vity /// h licase ac9vity /// pro ein binding /// ATP binding /// ATP-dependent helicase ac9vity /// four-way junc9on helicase ac9vity /// hydrolase ac9vity /// hyd olase ac9vity, ac9ng on a id a hydrides, in phosphorus-contai ing anhydrides /// ATPase ac9vity // annealing helicase ac9vity /// ATP-dependent 3'-5' DNA helicase ac9vity /// G-quadruplex DNA bindi guclear chromosome /// chromosom , telomeric region /// lateral element /// male erm cell nucl us /// intracellular /  nucl us /// replic 9 n f rk /// nu leolus /// cytopl sm /// nuclear matrix /// PML body pronucleus
204531_s_atBRCA1 breast cancer 1, early onsetcell cyc e checkpoint /// double-strand break repair via homologous recombina9on /// double-strand break repair via homologous recombina9on /// DNA replica9on /// DNA repair /// postreplica9on repair /// double-strand break repair /// double-strand break repair /// DNA recombina9on /// regula9on of gene expression by gene9c imprin9ng /// regula9on of transcrip9on from RNA polymerase II promoter /// regula9on of transcrip9on from RNA polymerase III promoter /// lipid metabolic process /// fady acid metabolic process /// fady acid biosynthe9c process /// apopto9c process /// response to DNA damage s9mulus /// DNA damage response, signal transduc9on by p53 class mediator resul9ng in transcrip9on of p21 class mediator /// cell cycle /// chromosome segrega9on /// centrosome cycle /// intrinsic apopto9c signaling pathway in response to DNA damage /// dosage compensa9on by inac9va9on of X chromosome /// response to ionizing radia9on /// protein ubiqui9na9on /// androgen receptor signaling pathway /// posi9ve regula9on of protein ubiqui9na9on /// G2 DNA damage checkpoint /// substrate adhesion-dependent cell spreading /// posi9ve regula9on of histone acetyla9on /// nega9ve regula9on of histone acetyla9on /// regula9on of cell prolifera9on /// regula9on of apopto9c process /// chordate embryonic development /// response to estrogen s9mulus /// regula9on of DNA methyla9on /// nega9ve regula9on of fady acid biosynthe9c process /// posi9ve regula9on of DNA repair /// nega9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// nega9ve regula9on of centriole replica9on /// posi9ve regula9on of histone H3-K4 methyla9on /// nega9ve regula9on of histone H3-K4 methyla9on /// nega9ve regula9on of histone H3-K9 methyla9on /// posi9ve regula9on of histone H3-K9 methyla9on /// protein autoubiqui9na9on /// posi9ve regula9on of histone H4-K20 methyla9on /// posi9ve regula9on of cell cycle arrest /// cellular response to indole-3-methanol /// protein K6-linked ubiqui9na9on /// regula9on of cell mo9lity /// posi9ve regula9on of histone H3-K9 acetyla9on /// posi9ve regula9on of histone H4-K16 acetyla9onDNA binding /// damaged DNA binding /// transcrip9on coac9vator ac9vity /// RNA bi ing /// ubiqui9n-protein ligase a 9vity /// protein binding /// zi c ion binding /// tubulin binding /// lig se ac9vity /// enzyme binding /// ubiqui9n protein ligase binding // trans rip9o  regulato y region DNA binding /// metal ion binding /// a drogen receptor bindi gubiqui9n ligase complex /// condensed chromosome /// ondensed nuclear chromosome /// ruﬄe /// nucl us /// ucle plasm /// chrom some /// cytoplasm /// plasma membrane /// f cal adhesion /// gamma-tubulin ri g c mplex /// ibonucleoprotein complex /// BRCA1-BARD1 complex /// ﬁlament us ac9  /// protein complex /// BRCA1-A complex
214727_at BRCA2 breast cancer 2, early onsetdouble-strand break repair via homologous recombina9on /// double-strand break repair via homologous recombina9on /// cytokinesis /// oocyte matura9on /// inner cell mass cell prolifera9on /// DNA repair /// nucleo9de-excision repair /// double-strand break repair /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// DNA damage response, signal transduc9on by p53 class mediator resul9ng in transcrip9on of p21 class mediator /// cell cycle /// male meiosis I /// spermatogenesis /// brain development /// cell aging /// cell prolifera9on /// female gonad development /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to X-ray /// response to UV-C /// response to gamma radia9on /// hemopoiesis /// regula9on of cytokinesis /// nega9ve regula9on of mammary gland epithelial cell prolifera9on /// intrinsic apopto9c signaling pathway in response to DNA damage by p53 class mediator /// chordate embryonic development /// histone H3 acetyla9on /// histone H4 acetyla9on /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of mito9c cell cycle /// replica9on fork protec9on /// chromosome organiza9on /// centrosome duplica9onprotease binding /// DNA binding /// single-stranded DNA binding /// histone acetyltransfera e ac9vity /// protein binding //  H3 his one acetyltransferas  a 9vity /// H4 histone acetyltransferase ac9vity /// gamma-tubulin bindingnucleus /// nucleoplasm /// nucleolus /// cytopl sm /  centr some /// secretory granule /  BRCA2-MAGE-D1 complex /// protein complex
221703_at BRIP1 BRCA1 interac9ng protein C-terminal helicase 1DNA damage checkpoint /// nucleobase-containing compound metabolic process /// DNA repair /// double-strand break repair /// regula9on of transcrip9on from RNA polymerase II promoter /// response to DNA damage s9mulus /// small molecule metabolic processucl o9de bindi g /// nucl i  acid b ding /// DNA binding /// ATP-dependent DNA helicase ac9vity /// h licase c9vity /// protein binding /// ATP binding /// ATP-dep ndent helicase ac9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on acid anhydrides /// hydrolase ac9vity, ac9ng on acid anhydrides, in phosphorus-containing anhydrides /// metal ion binding /// iron-sulfur cluster binding /// 4 iron, 4 sulfur cluster bindingnucle s /// nucleus /// cytoplasm /// nuclear membrane
204093_at CCNH cyclin H regula9on of cyclin-dependent protein serine/threonine kinase ac9vity /// G1 phase of mito9c cell cycle /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// G2/M transi9on of mito9c cell cycle /// mito9c cell cycle /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla9on /// cell cycle /// gene expression /// viral reproduc9on /// phosphoryla9on /// viral reproduc9ve process /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of viral transcrip9on /// regula9on of cell cycleprotein kinase ac9vity /// protein binding /// DNA-dependent ATPase ac9vity /// RNA polymerase II ca boxy-terminal domain kinase ac9vity /// kinase ac9vity /// cyclin-dependent protein serine/threonine kinase regulator ac9vity /// prot in kinase bindingucleus //  nucleoplasm /// holo TFIIH complex /// DNA-directed RNA po ymerase II, holoenzyme /// cyclin-dependent prote n kinase c9va ng kinase holoenzyme complex /// TFIIK compl x
210021_s_atCCNO cyclin O regula9on of cyclin-dependent protein serine/threonine kinase ac9vity /// DNA repair /// base-excision repair /// base-excision repair /// base-excision repair, AP site forma9on /// cell cycle /// depyrimidina9on /// cell division /// regula9on of cell cycleura il DNA N-glycosylas  ac9vity // pr tein i s  bindingucleus /// nucleoplasm /// nucleoplasm
209194_at CETN2 centrin, EF-hand protein, 2G2/M transi9on of mito9c cell cycle /// mito9c cell cycle /// DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// cell cycle /// mitosis /// centriole replica9on /// spermatogenesis /// regula9on of cytokinesis /// cell divisionnucleic acid binding /// calcium ion binding /  protein binding /// ATP binding /// microtubule binding /// ATP- ependent helicase ac9vity //  G-prote n beta/gamma-subunit complex bindin  /// heterotrimeric G-protein binding /// metal i  bindingintracellu ar / nucleus /// cytoplasm /// ce trosome /// ce trosome /// centriol  /// cytosol /// cytoskel ton /// cilium /// microtubule basal body /// photoreceptor connec9 cilium / XPC complex
214426_x_atCHAF1A chroma9n assembly factor 1, subunit A (p150)DNA replica9on /// DNA repair /// DNA replica9on-dependent nucleosome assembly /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// protein complex assembly /// response to DNA damage s9mulus /// cell cycle /// chroma9n assemblychroma9n binding /// protein binding /// iden9cal prot in binding /// unfolded protein binding /// chromo shadow domain bindingucleus // C F-1 complex /// WINAC complex
204775_at CHAF1B chroma9n assembly factor 1, subunit B (p60)DNA replica9on /// DNA repair /// DNA replica9on-dependent nucleosome assembly /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// protein complex assembly /// response to DNA damage s9mulus /// cell cycle /// chroma9n assemblychroma9n binding /// protein binding /// rotei  binding /// histone binding /// unfolded protein bindingucleus // nucl us /// nucl oplasm /// nucle lus /// cytoplasm cyt sol /// CAF 1 complex
205394_at CHEK1 checkpoint kinase 1cell cycle checkpoint /// DNA damage checkpoint /// DNA damage checkpoint /// G2/M transi9on of mito9c cell cycle /// DNA replica9on /// DNA repair /// protein phosphoryla9on /// response to DNA damage s9mulus /// DNA damage induced protein phosphoryla9on /// cell cycle /// regula9on of gene expression /// regula9on of double-strand break repair via homologous recombina9on /// regula9on of transcrip9on from RNA polymerase II promoter in response to UV-induced DNA damage /// phosphoryla9on /// pep9dyl-threonine phosphoryla9on /// G2 DNA damage checkpoint /// regula9on of S phase /// histone H3-T11 phosphoryla9on /// regula9on of cell prolifera9on /// nega9ve regula9on of mitosis /// regula9on of mito9c centrosome separa9on /// chroma9n-mediated maintenance of transcrip9on /// cellular response to mechanical s9mulus /// cellular response to organic substance /// cellular response to caﬀeine /// replica9ve senescence /// regula9on of histone H3-K9 acetyla9onnucleo9de binding /// protein inase ac9vity /// prot in serine/threonine kinase ac9vity /// protein tyrosine kinase ac9vity /// protein binding // ATP binding /// kinase ac9vity /// transferase ac9vity /// transferase ac9vity, transferring phosphorus-cont ini g groups /// histone kinase ac9vity (H3-T11 speciﬁc) /// iden9cal protein bindingchromosom , telomeric region /  ch ma9n /// cond nsed nuclear chromosome /// ucleus / ucl o lasm replica9on fork  cytoplasm //  centrosome /// microtubule org nizing center /  cytosol /// cytoskeleton
210416_s_atCHEK2 checkpoint kinase 2cell cycle checkpoint /// DNA damage checkpoint /// G2/M transi9on of mito9c cell cycle /// DNA repair /// double-strand break repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// protein phosphoryla9on /// apopto9c process /// response to DNA damage s9mulus /// response to DNA damage s9mulus /// DNA damage induced protein phosphoryla9on /// cell cycle /// mitosis /// intrinsic apopto9c signaling pathway in response to DNA damage /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to gamma radia9on /// phosphoryla9on /// regula9on of protein catabolic process /// signal transduc9on in response to DNA damage /// cellular protein catabolic process /// posi9ve regula9on of transcrip9on, DNA-dependent /// protein autophosphoryla9on /// protein stabiliza9on /// cell division /// signal transduc9on involved in intra-S DNA damage checkpoint /// spindle assembly involved in mitosis /// replica9ve senescencenucleo9de binding /// protein inase ac9vity /// protein serine/threonine kinase ac9vity /// protein serine/threonine kinase ac9vity /// protein tyrosine kinase ac9vity /// protein binding /// ATP binding /// kinase ac9vity /// transferase ac9vity /// transferase ac9vity, transferring phosphor s-containing groups /// protein kinase binding /// ubiqui9n protein ligase binding /// iden9cal protein binding /// protein homodimeriza on ac9vity /// metal ion bindingchromosom , telomeric region nucleus /// nucleoplasm /// PML body
203229_s_atCLK2 CDC-like kinase 2protein phosphoryla9on /// response to ionizing radia9on /// phosphoryla9on /// pep9dyl-tyrosine phosphoryla9on /// response to re9noic acid /// response to chemical s9mulus /// regula9on of RNA splicing /// nega9ve regula9on of gluconeogenesis /// protein autophosphoryla9onnucleo9de binding /// pro ein k nase c9vity /  protein se ine/threonine kinase ac9vity /// protein serine/threonin / yrosi e kinase ac9vity /// pr tein tyrosine kinase ac9vity /// pr tein binding //  ATP binding /// kinase ac9vity /// transferase ac9v ty /// transferase c9vity, transferring phosphorus-containing groupsnucl us /// nuclear speck
209804_at DCLRE1A DNA cross-link repair 1ADNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// cell cycle /// mitosis /// cell divisionhydrolase ac9vitynucleus /// nucleolus
219490_s_atDCLRE1B DNA cross-link repair 1Bcell cycle checkpoint /// telomere maintenance /// DNA repair /// response to DNA damage s9mulus /// telomeric loop forma9on /// protec9on from non-homologous end joining at telomere /// telomeric 3' overhang forma9on /// nucleic acid phosphodiester bond hydrolysisnuclease ac9vity /// xonuclease ac9vity /// protein binding /// 5'-3' exonuclease ac9vity /// hydrolase ac9vitychromoso e, lomeric region /// nucleus /// chromosome /// cytoplasm //  centrosom /// microtubule organizing center /// cytoskeleton
222233_s_atDCLRE1C DNA cross-link repair 1Ctelomere maintenance /// DNA repair /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// response to ionizing radia9on /// B cell diﬀeren9a9on /// chromosome organiza9on /// nucleic acid phosphodiester bond hydrolysissi gle-stranded DNA s eciﬁc endod oxyribonucleas  c9vity /// nu lease ac vity / ndonuclease ac9vity /// exonuclease ac9vity /// 5'-3' exonuclease ac9vity /// hydrolase ac9vitynucleus
208619_at DDB1 damage-speciﬁc DNA binding protein 1, 127kDaell cycle checkpoint /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// Wnt receptor signaling pathway /// protein ubiqui9na9on /// virus-host interac9on /// protein ubiqui9na9on involved in ubiqui9n-dependent protein catabolic process /// proteasomal ubiqui9n-dependent protein catabolic processnucleic acid binding /// DNA bi ding /// damaged DNA binding // prot in bindi gl us /// nucleoplasm / cytoplasm /// Cul4A-RING ubiqui9n ligase compl x /// Cul4B-RING ubiqui9  ligase complex /// Cul4-RING ubiqui9n ligase complex
203409_at DDB2 damage-speciﬁc DNA binding protein 2, 48kDaprotein polyubiqui9na9on /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// nucleo9de-excision repair /// pyrimidine dimer repair /// response to DNA damage s9mulus /// response to UV /// protein ubiqui9na9on /// protein autoubiqui9na9onDNA binding /// dam ged DNA b ndi g /// ubiqui9n-prot in ligase ac9vity /// rotein bindingucleus /// nucleoplasm //  protein com lex
208382_s_atDMC1 DNA meio9c recombinase 1pa hytene /// ovarian follicle development /// oocyte matura9on /// DNA metabolic process /// DNA repair /// cell cycle /// meiosis /// synapsis /// reciprocal meio9c recombina9on /// male meiosis I /// gamete genera9on /// spermatogenesis /// sperma9d development /// female gamete genera9on /// SOS responsenucleo9de binding /// DNA binding /// single-st nded DNA binding /// protein binding /// ATP binding /// DNA-dependent ATP se ac9vity /// nucleoside-t iphosphatase ac9vitychromosome, t lomeric reg on /// co nsed nuclear chromosome  nucleus /// chromosome
208955_at DUT deoxyuridine triphosphatasenucleobase-containing compound metabolic process /// pyrimidine nucleobase metabolic process /// dUMP biosynthe9c process /// DNA replica9on /// nucleo9de metabolic process /// small molecule metabolic process /// dUTP metabolic process /// pyrimidine nucleoside biosynthe9c process /// nucleobase-containing small molecule metabolic processdUTP diphosphatase ac9vity /// protein binding /// hydrolas  ac9vitynucle s /// nucleoplasm /// mitochon rion
203719_at ERCC1 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 1 (includes overlapping an9sense sequence)nu leo9de-excision repair, DNA damage removal /// pyri idine dime  re air by nucle 9de-exc sion repair /// replica9ve cell aging /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA incision, 3'-to lesion /// nucleo9de-excision repair, DNA incision, 5'-to lesion /// double-strand break repair /// DNA recombina9on /// mito9c recombina9on /// syncy9um forma9on /// response to DNA damage s9mulus /// response to oxida9ve stress /// germ cell development /// spermatogenesis /// response to nutrient /// cell prolifera9on /// male gonad development /// response to abio9c s9mulus /// UV protec9on /// response to sucrose s9mulus /// response to X-ray /// mul9cellular organismal aging /// nega9ve regula9on of telomere maintenance /// post-embryonic hemopoiesis /// mul9cellular organism growth /// nega9ve regula9on of apopto9c process /// isotype switching /// cell development /// oogenesis /// embryonic organ development /// chromosome organiza9onsingle-stranded DNA s eciﬁc ndodeoxyribonuclease ac9vity /// TFIID- lass transcrip9o  factor binding /// DNA binding // damaged DNA binding /// single-strand d DNA binding /// nuclease ac9vity /// endonuclease ac9vity /// protein binding  prot in C-term nus binding / hydr las  ac9vity /// TBP-class protei  binding /// protein domain spec ﬁc binding /// structure-speciﬁc DNA bindingnucleo9de-excisio  repair complex /// nucl a  chromosome, telomeric region /// nucl s /  nu leoplasm  transcrip9on factor TFIID complex /// ucleolus /// cytoplasm
213468_at ERCC2 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 2cell cycle checkpoint /// nucleo9de-excision repair, DNA damage removal /// response to hypoxia /// in utero embryonic development /// nucleobase-containing compound metabolic process /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla9on /// apopto9c process /// induc9on of apoptosis /// response to DNA damage s9mulus /// response to oxida9ve stress /// chromosome segrega9on /// aging /// cell prolifera9on /// response to UV /// UV protec9on /// post-embryonic development /// gene expression /// viral reproduc9on /// virus-host interac9on /// spinal cord development /// hair cycle process /// viral reproduc9ve process /// extracellular matrix organiza9on /// bone mineraliza9on /// central nervous system myelin forma9on /// nucleo9de-excision repair, DNA incision /// mul9cellular organism growth /// hair cell diﬀeren9a9on /// embryonic cleavage /// nega9ve regula9on of apopto9c process /// erythrocyte matura9on /// posi9ve regula9on of DNA binding /// skin development /// small molecule metabolic process /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// hair follicle matura9on /// posi9ve regula9on of viral transcrip9on /// hematopoie9c stem cell diﬀeren9a9onnucleo9de bin ing /// nucleic acid binding /// DNA binding //  ATP-dependent DNA helicase ac9vity /// helicase ac9vity /// protein kinase ac9vity /// protein binding /// ATP binding // prot in C-termi us bindi g /// ATP-dep ndent helicase ac9vity // DNA-dependent ATPase ac9vity /// DNA-dependent ATPase ac9v ty /// RNA polymerase II carboxy-terminal domain kinas  ac9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on acid anhydrides /// hydrolase ac9vity, ac9ng on acid anhydrides, in pho pho us-containing anhydrides /// 5'-3' DNA helicase ac9vity /// metal ion binding /// protein N-terminus binding /// iron- ulfu  clust r binding /// 4 iron, 4 sulfur cluster bindingSSL2-core TFIIH mplex /// nucleus /// nucle p asm /// holo TFIIH c mplex /// hol TFIIH c mplex /// cy oplasm /// spindle /// cytoskeleton /// cyclin-dependent protein kinas  ac9va9ng kinase holoenzyme complex /// MMXD complex
202176_at ERCC3 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 3cell cycle checkpoint /// nucleo9de-excision repair, DNA duplex unwinding /// nucleo9de-excision repair, DNA damage removal /// response to hypoxia /// ATP catabolic process /// DNA topological change /// DNA repair /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla9on /// apopto9c process /// induc9on of apoptosis /// induc9on of apoptosis /// response to DNA damage s9mulus /// response to oxida9ve stress /// protein localiza9on /// response to UV /// UV protec9on /// gene expression /// viral reproduc9on /// virus-host interac9on /// viral reproduc9ve process /// nucleo9de-excision repair, DNA incision /// hair cell diﬀeren9a9on /// posi9ve regula9on of apopto9c process /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of viral transcrip9onnucleo9de bin ing /// nucleic acid binding /// DNA bind g /// damaged DNA bind ng /// ATP-dependent DNA helicase ac9vity /// helicase ac9vity /// pr tein kina e ac9vity /// pr tein binding /// ATP binding GTP binding / protein C-terminus bi ding /// DNA-dependent ATPase ac9vity /// DNA-dependent ATPa e ac9vity /  transcrip9on fact r binding / RNA polymera e II carboxy-terminal domain kinas  ac9vity /// hydrolase ac9vity /// ATPase ac9vity /// dATP bindi g /// pep9de binding /// 3'-5' DNA helicase ac9vity /// 3'-5' DNA helicase ac9vity /// protein N-terminus bindi gc r  TFIIH complex /// SSL2-core TFIIH c mplex  nucleus /// nucleoplasm /// holo TFIIH complex /// holo TFIIH complex
210158_at ERCC4 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 4meio9c mismatch repair /// resolu9on of m io9c recombina9on inte mediates /// nucleo9de-excision repair, DNA damage removal /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA metabolic process /// DNA repair /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA incision, 3'-to lesion /// nucleo9de-excision repair, DNA incision, 5'-to lesion /// response to DNA damage s9mulus /// response to UV /// UV protec9on /// telomere maintenance via telomere shortening /// nega9ve regula9on of telomere maintenance /// nucleo9de-excision repair, DNA incision /// nucleic acid phosphodiester bond hydrolysissingle-stranded DNA s eciﬁc end deoxyribonuclease ac9vity /// TFIID-class transcrip9on factor binding /// nucleic acid binding /// DNA binding /// damaged DNA binding /// single-stranded DNA binding /// nuclease ac9vi y /// endonuclease ac9vity //  endodeoxyribonuclease ac9vity /// protein binding /// protein C-terminus binding /// hydrol se ac9vity /// structure-sp ciﬁc DNA binding /// protein N-terminus bindingnucl o9de-excisio  repai  co plex /// nucl o9de-excision repair factor 1 c mplex /// chromosome, tel mer c r gion /// nuclear chromosome, telomer c gion /// nucleus /// nucleoplas  //  tra scrip9on fac or TFIID c mp x
202414_at ERCC5 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 5nu leo9de-excision repair, DNA damage removal /// DNA r pair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA incision, 3'-to lesion /// nucleo9de-excision repair, DNA incision, 3'-to lesion /// response to DNA damage s9mulus /// determina9on of adult lifespan /// response to UV /// response to UV /// UV protec9on /// response to UV-C /// mul9cellular organism growth /// nega9ve regula9on of apopto9c process /// nucleic acid phosphodiester bond hydrolysisbubbl  DNA binding /// DNA binding doubl -s randed DNA binding /// single-stran d DNA binding /// cataly9c ac9vity /// nuclease ac9vity /// endonuclease ac9vity /// endodeoxy ibonuclease ac9vity /// protein bind g /// hydrolase ac9vity /// hydrolase ac9vity, c9ng on ester bonds /// protein homodimeriza9on ac9vity /// metal ion bindi g /// protein N-t rmi us bindingnucleus nucleoplasm /// h lo TFIIH c mplex /// DNA directed RNA polym ra e II, holoenzyme
207347_at ERCC6 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 6resp nse to superoxide /// DNA repair /// tra scrip9on-coupled nucle 9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair /// nucleo9de-excision repair /// pyrimidine dimer repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase II promoter /// response to DNA damage s9mulus /// response to oxida9ve stress /// ac9va9on of JNKK ac9vity /// ac9va9on of JUN kinase ac9vity /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to UV /// response to toxic substance /// response to X-ray /// response to UV-B /// response to gamma radia9on /// regula9on of DNA-dependent transcrip9on, elonga9on /// posi9ve regula9on of DNA-dependent transcrip9on, elonga9on /// mul9cellular organism growth /// photoreceptor cell maintenancen cle 9de bin ing /// nucleic acid binding /// DNA binding /// DNA helicase ac9vity /// chroma9n binding /// helicase ac9vity /// protein binding /// ATP binding /// prot in C-terminus binding /// DNA-dependent ATPase ac9vity /// hydrolase ac9vity /// protei  complex bindi g /// protei  N-terminus bindingnucleus /// nucleoplasm /// nu leo lasm /// n cl olus /// tr nsc ip9on elonga  factor compl x
205162_at ERCC8 excision repair cross-complemen9ng rodent repair deﬁciency, complementa9on group 8p otein p lyubiqui9na9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// response to oxida9ve stress /// response to oxida9ve stress /// response to UV /// response to UV /// response to X-ray /// protein ubiqui9na9on /// proteasomal ubiqui9n-dependent protein catabolic process /// posi9ve regula9on of DNA repair /// protein autoubiqui9na9onDNA helicase ac9vity /// ubiqui9 -prote n ligas  ac vity /// rotein binding /// DNA-dependent ATPase ac9vity /// prot in c mplex bindingu leo9de- xcision re air complex /// nucle s /// nucleoplasm /// nuclear matrix /// Cul4A-RING ubiqui9n ligase complex /// prote n c mplex
204603_at EXO1 exonuclease 1humoral immune response mediated by circula9ng immunoglobulin /// DNA repair /// mismatch repair /// mismatch repair /// mismatch repair /// mismatch repair /// DNA recombina9on /// response to DNA damage s9mulus /// meiosis /// soma9c hypermuta9on of immunoglobulin genes /// isotype switching /// nucleic acid phosphodiester bond hydrolysisDNA binding /// cataly9c ac9vity /// uclease ac9vity /// endonuclease ac9vity /// ribonuclease H ac9vity /// exonuclease ac9vity //  protein binding /// 5'-3' exonuclease c9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on ester bonds /// 5'-3' exodeoxyribonuclease ac9vity /// structure-speciﬁc DNA binding /// single-stranded DNA speciﬁc 5'-3' exodeoxyribonuclease ac9vity /// metal ion binding /// ﬂap endonuclease ac9vity /// double-stranded DNA speciﬁc 5'-3' exodeoxyribonuclease ac9vitynucleus
203678_at FAN1 FANCD2/FANCI-associated nuclease 1double-stran  break r pair via homologous recombina9on /// DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// nucleo9de-excision repair, DNA incision /// nucleo9de-excision repair, DNA incisionmagnesium ion binding /// DNA binding /// nuclease ac9vity /  e donuclease ac9vity /// exonuclease ac9vity /// phosphodiesterase I a 9vity /// protein binding /// 5'-3' exonucleas  ac9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on ester bonds /// 5'-ﬂap endonuclease ac9vity /// ubiqui9n binding /// metal ion bindingnucleus
203806_s_atFANCA Fanconi anemia, complementa9on group ADNA repair /// protei  com lex assembly /// response to DNA damage s9mulus /// male meiosis /// male gonad development /// female gonad development /// regula9on of cell prolifera9onprotein bindingc us /// nucleoplasm /// cyt plasm /// Fanconi anaemia nuclear complex
205189_s_atFANCC Fanconi anemia, complementa9on group Cyeloid cell homeostasis /// DNA repair /// nucleo9de-excision repair /// protein complex assembly /// response to DNA damage s9mulus /// gamete genera9on /// germ cell development /// removal of superoxide radicalsprotein bindingchroma9n /// nucleus /// nucleoplasm /// cytoplasm /// ytosol /// Fanconi ana mia nuclear complex
220255_at FANCE Fanconi anemia, complementa9on group EDNA repair /// resp se to DNA damage s9mulusprotein bindingcleus /// nucleoplasm /// Fanconi anaemia nuclear complex
218689_at FANCF Fanconi anemia, complementa9on group FDNA repair /// resp se to DNA damage s9mulusprotein bindingcleus /// nucleoplasm /// Fanconi anaemia nuclear complex
203564_at FANCG Fanconi anemia, complementa9on group Gcell cycle checkpoint /// phosphorelay signal transduc9on system /// ovarian follicle development /// DNA repair /// response to DNA damage s9mulus /// mitochondrion organiza9on /// sperma9d development /// response to radia9ondamaged DNA binding /// er ac9vity //  pr tein bindingn cleus //  nucleoplasm /// cytopla m mitocho drion /// Fanconi a aemia nucl ar complex
213007_at FANCI Fanconi anemia, complementa9on group IDNA repair /// resp se to DNA damage s9mulus /// cell cycle /// posi9ve regula9on of protein ubiqui9na9onDNA binding /// protein bindingn cleus /// nucleoplasm /// plasma membrane
218397_at FANCL Fanconi anemia, complementa9on group LDNA repair /// DNA repair /// protein monoubiqui9na9on /// response to DNA damage s9mulus /// gamete genera9on /// protein ubiqui9na9on /// regula9on of cell prolifera9onubiqui n- rotein ligas  ac9vity /// ub qui9n-protein ligase ac9vity /// ubiqui n-protein ligase ac9vity /// protein binding /// zinc ion bindin  /// ligase ac9vity /// ubiqui9n protein ligase binding /// metal ion bindingn cleus /// uclear envelope /// nucleoplasm /// cy opl sm /// Fanconi a aemia nuclear complex
204768_s_atFEN1 ﬂap structure-speciﬁc endonuclease 1S phase of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// DNA repair /// base-excision repair /// double-strand break repair /// response to DNA damage s9mulus /// memory /// UV protec9on /// telomere maintenance via semi-conserva9ve replica9on /// DNA replica9on, removal of RNA primer /// phospha9dylinositol-mediated signaling /// nucleic acid phosphodiester bond hydrolysismagnesium ion binding /// DNA binding /// damaged DNA binding /// double-stranded DNA binding /// cataly9c ac9vity /// nuclease ac9vity /// endonuclease ac9v ty /// ribonuclease H ac9vity /// exonuclease ac9vity /// protein binding /// double-stranded DNA speciﬁc exodeoxyribonucle se ac9vity /// 5'-3' exonuclease ac9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on ster bonds  5'-ﬂap endonuclease ac9vity /// 5'-ﬂap endonuclease ac9vity /// ang nese ion binding /// metal ion binding /// ﬂap e onuclea e ac9vitynucleus /// nu leoplasm / nucleolus /// mitochondrion
202451_at GTF2H1 general transcrip9on factor IIH, polypep9de 1, 62kDaregula9on of cyclin-dependent protein serine/threonine kinase ac9vity /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein phosphoryla9on /// response to DNA damage s9mulus /// gene expression /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of viral transcrip9onprotein kinas  ac9vity /// protein binding /// DNA-dependent ATPase ac9vity /// RNA polymerase II carboxy-terminal domain kinase ac9v tycore TFIIH complex / / ucleus // nucleoplasm / holo TFIIH complex
221540_x_atGTF2H2 general transcrip9on factor IIH, polypep9de 2, 44kDanucle 9de-excision repair, DNA damage removal /// G-protein coupled receptor internaliza9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// transla9on /// protein phosphoryla9on /// response to DNA damage s9mulus /// response to UV /// gene expression /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of viral transcrip9onnucleic acid binding /// sequence-speciﬁc DNA bi ding transcrip9 n factor ac9vity /// protein kinase ac9vity /// protein binding /// DNA-depe d nt ATPase ac9vity /// transla9on factor c9vity, nucleic acid binding /  zinc ion bi ding /// RNA polymeras  II carboxy-te minal domain kinase ac9vity /// metal ion binding /// p otein N-terminus bindingcore TFIIH compl x /// nucleus /// nucleo lasm /// h lo TFIIH complex
222104_x_atGTF2H3 general transcrip9on factor IIH, polypep9de 3, 34kDanucle 9de-excision repair, DNA damage removal /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// transla9on /// protein phosphoryla9on /// response to DNA damage s9mulus /// gene expression /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of viral transcrip9ondamaged DNA binding /// sequence-speciﬁc DNA binding transcrip9on factor ac9vity /// protein kinase ac9vity /// DNA-depe d nt ATPase ac9vity /// transla9on factor ac9vity, nucleic acid binding /  RNA polymerase II carboxy-terminal domai  kinase ac9vity /// metal ion binding /// protein N-terminus bindingcore TFIIH compl x /// nucleus /// nucleoplasm /// holo TFIIH complex //  holo TFIIH complex
203577_at GTF2H4 general transcrip9on factor IIH, polypep9de 4, 52kDanucle 9de-excision repair, DNA damage removal /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// transla9on /// tRNA aminoacyla9on for protein transla9on /// tRNA aminoacyla9on for protein transla9on /// valyl-tRNA aminoacyla9on /// regula9on of transla9onal ﬁdelity /// protein phosphoryla9on /// response to DNA damage s9mulus /// gene expression /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of viral transcrip9onnucleo9de b nding /// aminoacyl-tRNA edi9ng ac9vity /// sequence-speciﬁc DNA binding transcrip9on factor ac9vity /// ATP-dependent DNA helicase ac9vity /// protein kinase ac9vity /// aminoacyl-tR  ligase ac9vity /// valine-tRNA ligase ac9vit  /// protein binding / ATP binding /// DNA-dependent ATPas  ac9vity /// RNA polymerase II carb xy-terminal domain kinase ac9vity /// ligase ac9vitycore TFIIH compl x /// nucl us /// nucleoplasm /// holo TFIIH omplex /// mi och dri
213357_at GTF2H5 general transcrip9on factor IIH, polypep9de 5DNA repair /// nucle 9d -excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulusDNA bindingcore TFIIH complex /// u leus
205436_s_atH2AFX H2A histone family, member XDNA da age checkpoint /// double-strand break repair via homologous recombina9on /// DNA repair /// double-strand break repair /// double-strand break repair /// DNA recombina9on /// nucleosome assembly /// response to DNA damage s9mulus /// cell cycle /// meiosis /// spermatogenesis /// response to ionizing radia9on /// posi9ve regula9on of DNA repairDNA bindi g amaged DNA inding /// protein binding /// enzyme binding /// histone binding /// equence-speciﬁc DNA binding /// protein heterodimeriza9on ac9vitychromosome, telomeric r gion /// chroma9n /// nucleosome /  nuclear chroma9  /// condensed nucl ar chrom some /// mal  germ cell nucleus /// XY ody /// intracellular /// nucleus //  nucleoplasm /// replica9on fork /// chromosom
202983_at HLTF helicase-like transcrip9on factorATP catabolic process /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// regula9on of transcrip9on from RNA polymerase II promoter /// metabolic process /// protein ubiqui9na9on /// chroma9n modiﬁca9onucle 9de bindi g /// nucleic acid binding /  DNA bindi g /// cataly9c ac9vity /// h licase ac9vity /// protein binding /// ATP binding /// zinc ion binding /// hydrol se a 9vity /// hydrolase ac9vity, ac ng on acid anhydrides, in ph sphorus-containing anhydrides /// ligase ac9vity /// ATPase ac9vity /// metal ion bindingnucleus /// nucleoplasm /// nucleolus /// cytoplasm
204883_s_atHUS1 HUS1 checkpoint homolog (S. pombe)cell cycle checkpoint /// DNA damage checkpoint /// double-strand break repair via homologous recombina9on /// regula9on of protein phosphoryla9on /// DNA replica9on /// DNA repair /// protein phosphoryla9on /// response to DNA damage s9mulus /// mito9c cell cycle checkpoint /// nega9ve regula9on of DNA replica9on /// response to UV /// embryo development /// cellular response to ionizing radia9onprotei  bindingucleus /// nucl oplasm nucleolus /// cytoplasm /// Golgi apparat  /// checkpoint clamp complex
202726_at LIG1 ligase I, DNA, ATP-dependentS phas  of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA metabolic process /// DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// lagging strand elonga9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// response to DNA damage s9mulus /// cell cycle /// anatomical structure morphogenesis /// telomere maintenance via semi-conserva9ve replica9on /// V(D)J recombina9on /// response to hydrogen peroxide /// DNA liga9on involved in DNA repair /// cell divisionnucleo9de binding /// DNA binding /// DNA ligase ac9vity /// DNA ligase (ATP) ac9vity /// ATP binding /// ligase ac9vity /// metal ion bindingnucleus /// nu leoplasm / chromosome /// mitochondrion
204123_at LIG3 ligase III, DNA, ATP-dependentDNA replica9on /// lagging strand elonga9on /// DNA repair /// base-excision repair /// nucleo9de-excision repair /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// response to DNA damage s9mulus /// cell cycle /// reciprocal meio9c recombina9on /// spermatogenesis /// V(D)J recombina9on /// mitochondrial DNA repair /// nega9ve regula9on of DNA recombina9on /// DNA liga9on involved in DNA repair /// cell divisionucleo9de binding /// DNA binding /// DNA ligase ac9vity /// DNA lig se (ATP) ac9vity /// pr tein binding /// ATP binding /// zinc ion binding /// ligase ac9vity /// metal ion bindingconde sed nuclear chromosome /// synaptonemal complex / nucleus //  nucleoplasm /  chromosome /// mitochondrion
206235_at LIG4 ligase IV, DNA, ATP-dependentsingle strand break repair /// in utero embryonic development /// pro-B cell diﬀeren9a9on /// DNA replica9on /// DNA liga9on /// lagging strand elonga9on /// DNA repair /// nucleo9de-excision repair, DNA gap ﬁlling /// double-strand break repair /// double-strand break repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// response to DNA damage s9mulus /// cell cycle /// central nervous system development /// cell prolifera9on /// response to X-ray /// response to ionizing radia9on /// response to gamma radia9on /// viral reproduc9on /// viral reproduc9ve process /// T cell diﬀeren9a9on in thymus /// V(D)J recombina9on /// immunoglobulin V(D)J recombina9on /// T cell receptor V(D)J recombina9on /// soma9c stem cell maintenance /// nega9ve regula9on of neuron apopto9c process /// isotype switching /// posi9ve regula9on of ﬁbroblast prolifera9on /// posi9ve regula9on of neurogenesis /// DNA liga9on involved in DNA recombina9on /// DNA liga9on involved in DNA repair /// DNA liga9on involved in DNA repair /// chromosome organiza9on /// cell division /// neuron apopto9c process /// cellular response to lithium ion /// establishment of integrated proviral latencyucleo9de binding /// DNA binding /// DNA ligase ac9vity /// DNA ligase ac9vity // DNA ligase (ATP) ac9vity /// protein binding /// ATP binding /// protein C-termi s binding /// l gase ac9vity /// meta  ion bindingcondensed chromosome // nucleu  /// nucleoplasm /// nucleolus //  cytoplasm /// plasma membra e /// focal adhesion /// DNA-depend nt rotein kinase-DNA ligase 4 complex DNA-dependent protein kinas -DNA ligase 4 complex /// DNA ligase IV complex /// no homologous end joining complex
209580_s_atMBD4 methyl-CpG binding domain protein 4DNA repair /// base- xcision repair /// base-excision repair, AP site forma9on /// response to DNA damage s9mulus /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to radia9on /// G2 DNA damage checkpoint /// depyrimidina9onDNA bind g /// satellite DNA binding /// cataly9c ac9vity /// endodeoxyribonuclease ac9vity /// protein binding /// pyrimidine-speciﬁc mism tch ba e pair DNA -glycosylase ac9vity /// hydrol se ac9vitychroma9n nucleus /// ucleoplasm /// nucleolus  cytopla m
203061_s_atMDC1 mediator of DNA-damage checkpoint 1double-strand break repair via homologous recombina9on /// DNA repair /// double-strand break repair /// response to DNA damage s9mulus /// cell cycle /// intra-S DNA damage checkpointprot in binding /// protein C-terminus binding FHA domain bindingucleus /// nucleoplasm /// chr mosome /// nucleolus /// focal a hesion
204880_at MGMT O-6-methylguanine-DNA methyltransferaseDNA liga9on /// DNA repai  /// DNA methyla9on /// DNA dealkyla9on involved in DNA repair /// response to DNA damage s9mulus /// response to toxic substance /// response to organic cyclic compound /// methyla9on /// cellular response to oxida9ve stress /// response to drug /// regula9on of cysteine-type endopep9dase ac9vity involved in apopto9c process /// response to ethanol /// posi9ve regula9on of DNA repair /// response to folic acid /// nega9ve regula9on of cell death /// mammary gland epithelial cell diﬀeren9a9on /// cellular response to organic cyclic compound /// cellular response to ionizing radia9onDNA bindi g /// cataly9c ac9vity /// methylated-DNA-[protein]-cysteine S-methyltransferase ac9vity /// calcium ion binding /// methyltransferase c9vity /// DNA-methyltransferase ac9vity /// transferase ac9vity /// metal ion bindingnucleus /// nu leoplasm
219396_s_atMIR631 /// NEIL1microRNA 631 /// nei endonuclease VIII-like 1 (E. coli)DNA repair /// bas -excision r pair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// response to oxida9ve stress /// metabolic process /// RNA modiﬁca9on /// nega9ve regula9on of nuclease ac9vitynucleic cid binding /// DNA binding /// damaged DNA binding /// cataly9c c9vity /// DNA-(apurinic or apyrimidinic it ) lyase ac9vity /// protein C-terminus binding /  zinc ion binding /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on glycosyl bonds /// hydrolase ac9vity, hydrolyzing N-glycosyl compounds /// lyase ac9vity /// DNA N-glycosylase ac9vitynucleus /// chromosom  / cytoplasm /  microtubule organizing center /// cytosk leton
202520_s_atMLH1 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)pachytene /// nuclear-transcribed mRNA poly(A) tail shortening /// resolu9on of meio9c recombina9on intermediates /// response to hypoxia /// soma9c recombina9on of immunoglobulin genes involved in immune response /// ATP catabolic process /// DNA repair /// mismatch repair /// double-strand break repair via nonhomologous end joining /// response to DNA damage s9mulus /// cell cycle /// male meiosis chromosome segrega9on /// meiosis /// synapsis /// reciprocal meio9c recombina9on /// male meiosis /// spermatogenesis /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to toxic substance /// soma9c hypermuta9on of immunoglobulin genes /// soma9c recombina9on of immunoglobulin gene segments /// response to drug /// meio9c metaphase I plate congression /// meio9c chromosome segrega9on /// isotype switching /// nega9ve regula9on of mito9c recombina9on /// oogenesis /// spindle midzone assembly involved in meiosis /// cellular response to organic cyclic compoundsi gle-stranded DNA binding /// protein binding /// ATP binding /// ATPase ac9vity /// mismatched DNA binding /// guanine/thymine misp ir binding /// MutSalpha complex b ding /// structure-speciﬁc DNA bi dingcondensed chrom some /// cond sed nuclear chromosome /// synaptonemal compl x /// male erm cell nucleus //  nucleus /// chromosome /// c iasma /// m smatch repair complex /// MutLalpha complex /// MutLbeta complex
204838_s_atMLH3 mutL homolog 3 (E. coli)ATP catabolic process /// DNA repair /// mismatch repair /// mismatch repair /// response to DNA damage s9mulus /// synaptonemal complex assembly /// reciprocal meio9c recombina9on /// reciprocal meio9c recombina9on /// male meiosis /// female meiosis I /// protein localiza9onhroma9n binding /// satellite DNA binding /// single-stranded DNA binding /// protein binding /// ATP binding /// ATPase ac9vity /// centromeric DNA binding /// mis atched DNA binding /// MutSalpha complex bindingcondensed chro osome /// synapto e l omplex /// male germ cell nucleus /// nucle  chiasma /// mismatch repair compl x /// MutLbeta complex
202167_s_atMMS19 MMS19 nucleo9de excision repair homolog (S. cerevisiae)phosphorelay signal transduc9on syst m /// DNA metabolic process /// DNA repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// chromosome segrega9on /// response to hormone s9mulus /// iron-sulfur cluster assembly /// small molecule metabolic process /// posi9ve regula9on of transcrip9on, DNA-dependenttranscrip9o  c ac9vator ac9vity /// binding /// r tein binding /// receptor signaling complex scaﬀold ac9vity /// strogen receptor bindi g /// protein binding, bridgingnucleus /// nucleus /// holo TFIIH ompl x /  cytoplasm /// spindl  /// cytoskeleton /// MMXD c mplex /// CIA omplex
203565_s_atMNAT1 menage a trois homolog 1, cyclin H assembly factor (Xenopus laevis)regula9 n of cyclin-dependent protein seri e/threonine kinase ac9vity /// G1 phase of mito9c cell cycle /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// G2/M transi9on of mito9c cell cycle /// mito9c cell cycle /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// regula9on of transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase I promoter /// transcrip9on ini9a9on from RNA polymerase I promoter /// transcrip9on elonga9on from RNA polymerase I promoter /// termina9on of RNA polymerase I transcrip9on /// transcrip9on from RNA polymerase II promoter /// transcrip9on from RNA polymerase II promoter /// transcrip9on ini9a9on from RNA polymerase II promoter /// transcrip9on elonga9on from RNA polymerase II promoter /// 7-methylguanosine mRNA capping /// protein complex assembly /// protein phosphoryla9on /// apopto9c process /// cell cycle /// adult heart development /// cell prolifera9on /// gene expression /// viral reproduc9on /// ventricular system development /// viral reproduc9ve process /// nega9ve regula9on of apopto9c process /// mul9cellular organismal metabolic process /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of smooth muscle cell prolifera9on /// posi9ve regula9on of viral transcrip9on /// regula9on of cataly9c ac9vity /// response to calcium ionprotein kin e ac9vity /// protein binding /// DNA-dependent ATPase ac9vity /// zinc ion binding /// RNA polymerase II carboxy-terminal domain kinase ac9vit  /// metal ion bi ding /// protein N-terminus bindingucleus //  nucleoplasm /// holo TFIIH complex /// cytoplasm /// intra ular membrane-bounded organelle
203686_at MPG N-methylpurine-DNA glycosylaseDNA repair /// base-excision repair /// base-excision repair, AP site forma9on /// DNA dealkyla9on involved in DNA repair /// response to DNA damage s9mulus /// depurina9onDNA binding /// damaged DNA binding /// c taly9c ac9vity /// alkylbase DNA N-glyc sylase ac9vity /// protein binding /// DNA-3-methyladenine glycosylase ac9vity /// hydrolase ac9vity /// DNA-7-methylguanine glycosylase ac9vity /// DNA-7-methyladenine glycosylase ac9vity /// DNA-3-methylguanine glycosylase ac9vitynucleus /// nucleoplasm
205395_s_atMRE11A MRE11 meio9c recombina9on 11 homolog A (S. cerevisiae)regula9on of mito9c recombina9on /// cell cycle checkpoint /// double-strand break repair via homologous recombina9on /// DNA metabolic process /// DNA repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// response to DNA damage s9mulus /// telomere maintenance via telomerase /// sister chroma9d cohesion /// meiosis /// synapsis /// reciprocal meio9c recombina9on /// heart development /// cell prolifera9on /// posi9ve regula9on of protein autophosphoryla9on /// posi9ve regula9on of type I interferon produc9on /// DNA duplex unwinding /// nega9ve regula9on of DNA endoreduplica9on /// posi9ve regula9on of kinase ac9vity /// innate immune response /// chromosome organiza9on /// nucleic acid phosphodiester bond hydrolysissingle-stranded DN  speciﬁ  endod oxyribonuclease ac9vity /// DNA binding /// double-stranded DNA binding / ATP-dependent DNA helicase ac9vity /  nuclease ac9vity /// endonuclease ac9vi y /// endodeoxy ibonuclease ac9vity /// ex nuclease ac9vity /// protein binding /// protein C-ter inus binding  3'-5' exonucleas  ac9vity /// hydrolas  ac9vi y /// manganese ion bindingchr mos m , telom ric region /// nucl ar chroma9n /// co ensed nuclear chromosome /// nucleus /// nucleoplasm /// nucleolus /// cytosol /// Mr 11 omplex /// Mre11 complex /// site of double-stra d break /// perinucl ar region of cytoplas
209421_at MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)meio9c mismatch repair /// in utero embry nic development /// soma9c recombina9on of immunoglobulin genes involved in immune response /// oxida9ve phosphoryla9on /// ATP catabolic process /// DNA repair /// mismatch repair /// postreplica9on repair /// double-strand break repair /// meio9c gene conversion /// apopto9c process /// response to DNA damage s9mulus /// cell cycle arrest /// germ cell development /// spermatogenesis /// determina9on of adult lifespan /// male gonad development /// response to X-ray /// response to X-ray /// response to UV-B /// response to UV-B /// response to organic cyclic compound /// soma9c hypermuta9on of immunoglobulin genes /// soma9c recombina9on of immunoglobulin gene segments /// B cell mediated immunity /// B cell diﬀeren9a9on /// intra-S DNA damage checkpoint /// response to drug /// intrinsic apopto9c signaling pathway in response to DNA damage by p53 class mediator /// nega9ve regula9on of apopto9c process /// response to amino acid s9mulus /// nega9ve regula9on of neuron apopto9c process /// maintenance of DNA repeat elements /// nega9ve regula9on of reciprocal meio9c recombina9on /// isotype switching /// isotype switching /// nega9ve regula9on of DNA recombina9on /// nega9ve regula9on of DNA recombina9on /// posi9ve regula9on of helicase ac9vitynu leo9de binding /// magnesium ion binding /// four-way junc9on DNA bi ding /// Y-form DNA bi ding /// loop DNA binding /// double-str nd/single-strand DNA junc9on binding /// DNA binding /// damaged DNA binding d uble-stranded DNA bin ing /// single-stranded DNA binding /// protei  bindi g / ATP binding /// protein C-terminus bin ing /// DNA-dependent ATPase ac9vity /// ATPase ac9vity /// centromeric DNA binding /// enzyme binding /// protei kinase binding /// mismatched DNA bi ding /// guanine/thymine mispair binding /// guanine/thymine mispair binding /// di ucleo9de inser9on or dele9on binding /// single g anine inser9on binding /// si gle thymine ins r9on binding /// din cleo9de repeat inser9o  binding /// oxi zed purine DNA binding /// MutLalpha complex binding /// protein homodimeriza9  ac9vity //  ADP bindingnuclear chromosome /// nucleus /// MutSalpha complex /// MutSbeta complex
210947_s_atMSH3 mutS homolog 3 (E. coli)meio9c mismatch repair /// DNA repair /// mismatch repair /// response to DNA damage s9mulus /// reciprocal meio9c recombina9on /// soma9c recombina9on of immunoglobulin gene segments /// maintenance of DNA repeat elements /// nega9ve regula9on of DNA recombina9on /// posi9ve regula9on of helicase ac9vitynucleo9de binding /// Y-fo m DNA binding /// loop DNA binding /// double-strand/single-strand DNA junc on binding /// DNA binding /// damaged DNA binding /// single-stranded DNA binding /// prot in binding /// ATP binding /// DNA-dependent ATPase ac9vity /// centromeric DNA binding /// enzyme binding /// mismatched DNA binding /// guanine/thymine mispair binding /// dinucleo9de inser9on or dele9on binding /// single guanine inser9on binding /// dinucleo9de repeat inser9on binding /// oxidized purine DNA binding /// protein homodimeriza9on ac9vitynuclear chromoso e /// nucl us //  MutSbeta complex
210533_at MSH4 mutS homolog 4 (E. coli)meio9c mismatch repair /// ovarian follicle development /// mismatch repair /// meiosis /// synapsis /// reciprocal meio9c recombina9on /// spermatogenesis /// female gamete genera9on /// homologous chromosome segrega9on /// chiasma assemblynucleo9de binding /// DNA bin ing /// damaged DNA binding /// protein b nding /// ATP binding /// DNA-dependent ATPase ac9vity /// mismatched DNA bindingcondensed chromosome // cond nsed nuclear chromosome /// synaptonemal complex /// nucleus /// m smatch repair co plex
221406_s_atMSH5 /// MSH5-SAPCD1 /// SAPCD1mutS homolog 5 (E. coli) /// MSH5-SAPCD1 readthrough (NMD candidate) /// suppressor APC domain containing 1meio9c mismatch repair /// mismatc  repair /// meiosis /// reciprocal mei 9c recombina9  /// meio9c prophase II /// maintenance of ﬁdelity involved in DNA-dependent DNA replica9on /// homologous chromosome segrega9on /// chiasma assemblynucleo9de binding /// DNA binding /// damaged DNA binding /// protein bi ding ATP binding /// DNA-dependent ATPase ac9vity /// mismatched DNA bindingsynaptonemal complex /// mism ch re air co plex
211449_at MSH6 mutS homolog 6 (E. coli)meio9c mismatch repair /// meio9c mismatch repair /// ATP catabolic process /// DNA repair /// mismatch repair /// mismatch repair /// response to DNA damage s9mulus /// reciprocal meio9c recombina9on /// determina9on of adult lifespan /// intrinsic apopto9c signaling pathway in response to DNA damage /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to UV /// response to UV /// soma9c hypermuta9on of immunoglobulin genes /// soma9c hypermuta9on of immunoglobulin genes /// soma9c recombina9on of immunoglobulin gene segments /// maintenance of DNA repeat elements /// isotype switching /// isotype switching /// nega9ve regula9on of DNA recombina9on /// posi9ve regula9on of helicase ac9vity /// intrinsic apopto9c signaling pathwaynucleo9de binding /// magnesium ion binding /// four-way junc9on DNA binding DNA binding /// chro a9n binding //  damaged DNA binding /// double-stranded DNA binding /// protein binding // ATP bi ding /// DNA-dependent ATPase ac9vity /// ATPase ac9vity /// mismatch d DNA binding /// guanine/thymine mispair bi ding /// single gua ine inser9on binding // ingle thymine ins r9  binding /  oxidized purine DNA bi ding /// MutLalpha complex binding /// m thylated histone residue inding /// protein homodimer za9on ac9vity /// ADP bi dingnuclear chromosome /// nuclear chroma9n /// nu leus // chromosome /// MutSalph  complex
218463_s_atMUS81 MUS81 structure-speciﬁc endonucleaseDNA metabolic process /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// nucleic acid phosphodiester bond hydrolysisDNA binding /// cataly9c ac9vity /// nuclease ac9vity /// endonuclease ac9vity /// protein bi ding /// hydr lase ac9vity /// metal i n b nding /// 3'-ﬂap endonuclease ac9vitynucleus /// nu leolus
218903_s_atNABP2 nucleic acid binding protein 2cell cycle ch ckpoint /// double-strand break repair via homologous recombina9on /// DNA repair /// response to DNA damage s9mulus /// response to ionizing radia9onnucleic acid binding /// DNA binding /// single-stranded DNA binding //  protein bindingnucleus /// ucleolus /// SOSS c p ex
217299_s_atNBN nibrin cell cycle checkpoint /// DNA damage checkpoint /// telomere maintenance /// double-strand break repair via homologous recombina9on /// in utero embryonic development /// blastocyst growth /// DNA repair /// double-strand break repair /// double-strand break repair /// apopto9c process /// response to DNA damage s9mulus /// cell cycle /// cell cycle arrest /// mito9c cell cycle checkpoint /// mito9c G2 DNA damage checkpoint /// meiosis /// cell prolifera9on /// posi9ve regula9on of cell prolifera9on /// regula9on of DNA-dependent DNA replica9on ini9a9on /// DNA damage response, signal transduc9on by p53 class mediator /// posi9ve regula9on of protein autophosphoryla9on /// DNA duplex unwinding /// posi9ve regula9on of kinase ac9vity /// response to drug /// isotype switching /// nega9ve regula9on of neuron diﬀeren9a9on /// regula9on of ﬁbroblast prolifera9on /// neuromuscular process controlling balancedamaged DNA binding /// ATP-dependen  DNA h licase ac9vity /// pr tein binding /// transcrip9on factor binding /// protein N-terminus bindingchromosom , telomeric region /// nucle r chromosome, telomeric region /// nucleus /// nucle plasm / replica9on fork /// chromosome /// nucleolus /// PML body /// Mre11 complex //  site of double-strand b ak /// nuclear inclusion body
219502_at NEIL3 nei endonuclease VIII-like 3 (E. coli)DNA repair /// base-excision repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// metabolic processbu ble DNA binding /// nucleic aci  binding /// DNA binding /// damaged DNA binding /// double-stranded DNA binding /// single-stranded DNA binding /// cataly9c ac9vity /// DNA-(apurinic or apyrimidinic site) lyase ac9vity /// zinc ion binding /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on glycosyl bonds /// hydrolase ac9vity, hydrolyzing N-glycosyl compounds /// lyase ac9vity /// DNA N-glycosylase ac9vity /// DNA N-glycosylase ac9vity /// metal ion bindingintracellular // nucleus
219418_at NHEJ1 /// SLC23A3nonhomologous end-joining factor 1 /// solute carrier family 23 (nucleobase transporters), member 3DNA repair /// double-strand break repair /// double-strand br ak repai  via nonhomologous end joining /// DNA recombina9on /// transport /// response to DNA damage s9mulus /// central nervous system development /// response to ionizing radia9on /// B cell diﬀeren9a9on /// T cell diﬀeren9a9on /// posi9ve regula9on of ligase ac9vity /// transmembrane transportDNA binding / transporter ac9vit /// prot in bindingnucleus /// m mbrane /// i tegral to membrane /// nonho ologous end joining complex
209731_at NTHL1 nth endonuclease III-like 1 (E. coli)DNA repair /// base-excision repair /// base-excision repair, AP site forma9on /// base-excision repair, AP site forma9on /// nucleo9de-excision repair, DNA incision, 5'-to lesion /// response to DNA damage s9mulus /// metabolic process /// depyrimidina9onDNA binding /// double-stranded DNA binding /// ca aly9c ac vity /// DNA-(apurinic or apyrimidinic site) lyase ac9vity /// ndonucl ase ac9vity /// protein binding /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on glycosyl bonds /// lyase ac9vity /// DNA N-glycosylase ac9vity /// metal ion binding /// iron-sulfur cluster binding /// 4 iron, 4 sulfur cluster bindingnucleus /// nucleoplasm /// mitochondrion
204766_s_atNUDT1 nudix (nucleoside diphosphate linked moiety X)-type mo9f 1GTP catab lic process /// purine nucleo9de catabolic process /// ATP catabolic process /// dGTP catabolic process /// DNA repair /// response to oxida9ve stress /// nucleobase-containing small molecule catabolic process /// DNA protec9on /// small molecule metabolic process /// nucleobase-containing small molecule metabolic processRNA binding /// GTPase ac9vity /// 8- xo-7,8-dihydroguanosine tri h sphate pyrophosphatase ac9vity /// hyd olase ac9vity /// sn RNA binding /// 8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase ac9vity /// metal ion binding /// ATP diphos hata e ac9vity /// m7G(5')pppN diphosphatase ac9vitynucl us /// cytoplasm /// mitochondrion /// mitochond ial m rix /// cytosol
205760_s_atOGG1 8-oxoguanine DNA glycosylaseacute inﬂamm tory response /// DNA repair /// base-excision repair /// base-excision repair, AP site forma9on /// nucleo9de-excision repair /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// response to oxida9ve stress /// metabolic process /// response to radia9on /// response to estradiol s9mulus /// regula9on of protein import into nucleus, transloca9on /// response to drug /// depurina9on /// response to ethanol /// response to folic acid /// cellular response to cadmium iondamaged DNA binding /// cat ly9c ac9vity /// DNA-(apurinic or apyrimidinic site) lya e ac9vity /// endonuclease ac9vity /// rotein binding /// microtubule binding /// oxidized purine nucl obase lesion DNA N-glycosylas  ac9vity /// hydrola e ac9vity /// hydrolase ac9vity, ac9ng on glycosyl bonds /// lyase ac9vity /// DNA N-glycosylase c9vity /// 8-oxo-7,8-dihydroguanine DNA N-glycosylas  ac9vitynucleus //  nucleoplasm /// nu leoplasm /// ucleolus /// mitochondrion /// nuclear matrix /// nuclear speck
219530_at PALB2 partner and localizer of BRCA2doubl -strand break repair via homologous recombina9on /// somitogenesis /// inner cell mass cell prolifera9on /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// mesoderm development /// organ morphogenesis /// post-anal tail morphogenesis /// nega9ve regula9on of apopto9c processDN  binding /// protein bindingnucleus /// nucleoplasm
214086_s_atPARP2 poly (ADP-ribose) polymerase 2DNA repair /// base-excision repair /// protein ADP-ribosyla9onDNA binding /// NAD+ ADP-ribosyltransfera e c9vity /// protein binding /// protein binding /// transferase ac9vity /// transferase ac9vity, transferring glycosyl groupsnucleus /// nucleoplasm /// nucleolus
209940_at PARP3 poly (ADP-ribose) polymerase family, member 3DNA repair /// protein ADP-ribosyla9oncataly9c ac9vity /// NAD+ ADP-ribosyltransferase ac9vity /// transferase ac9vity /// transferase ac9vity, transferring glycosyl groupsnucleus /// cytoplasm /// ce triole /// microtubule organizing center // cytoskel ton
202239_at PARP4 poly (ADP-ribose) polymerase family, member 4DNA repair /// c llular prot in modiﬁca9on process /// protein ADP-ribosyla9on /// transport /// inﬂammatory response /// response to DNA damage s9mulus /// cell death /// response to drugDNA bind ng /// NAD+ ADP-ribosyltran ferase ac9vity /// NAD+ ADP-ribosyltransferase ac9vity /// p otein binding /// transferase ac9vity /// transferase ac9vity, transferring glycosyl groups /// enzyme bindingnucleus /// cytopla m /// pindl /// cytoskeleton /// spindle micr tubul /// ribonucleoprotein complex
201202_at PCNA prolifera9ng cell nuclear an9genDNA dam ge checkpoint /// G1/S transi9on of mito9c cell cycle /// regula9on of transcrip9on involved in G1/S phase of mito9c cell cycle /// S phase of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// regula9on of DNA replica9on /// DNA repair /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// mismatch repair /// response to DNA damage s9mulus /// heart development /// cell prolifera9on /// translesion synthesis /// posi9ve regula9on of deoxyribonuclease ac9vity /// telomere maintenance via semi-conserva9ve replica9on /// response to lipid /// response to cadmium ion /// phospha9dylinositol-mediated signalingpurin -speciﬁc misma ch base pair DNA N-glycosylase ac9vity /// DNA binding /// protein bi ding /// DNA polymeras  proc ssivity factor ac9vity /// re eptor tyrosine kinase binding /// dinucleo9de inser9on or dele9on binding /// MutLalpha complex binding /// iden9cal protein bi ingnucleus /// nucleo las  /// DNA rep ica9on factor C complex /// nucleolus /// cytoplasm /// microtubul  cytoskeleton /// che kpoint lamp omplex /// nuclear replica9on fork /// PCNA complex /// PCNA-p21 comp ex
202861_at PER1 period circadian clock 1nega9ve regula9on of transcrip9on from RNA polymerase II promoter /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// signal transduc9on /// circadian rhythm /// response to light s9mulus /// entrainment of circadian clock /// circadian regula9on of gene expression /// nega9ve regula9on of transcrip9on, DNA-dependent /// rhythmic processRNA polymera e II core promoter roximal r gion sequence-speciﬁ  DNA binding /// protein binding transcrip9on factor ac9vity /// signal ransducer ac9vity /// protein bindi g /// E-box bindingnu leus /// cytoplasm
213677_s_atPMS1 PMS1 postmeio9c segrega9on increased 1 (S. cerevisiae)ATP atabolic process /// DNA repai  /// mismatch repair /// response to DNA damage s9mulus /// reciprocal meio9c recombina9onDNA b ding /// single-stranded DNA binding /// ATP binding /// ATPase ac9vity /// mismatched DNA binding /// MutSalpha complex bindingnucleus /// mis atch repa r complex /// MutLalpha compl x
209805_at PMS2 /// PMS2CLPMS2 postmeio9c segrega9on increased 2 (S. cerevisiae) /// PMS2 C-terminal like pseudogeneATP atabolic process /// DNA repai  /// mismatch repair /// mismatch r pair /// response to DNA damage s9mulus /// reciprocal meio9c recombina9on /// soma9c hypermuta9on of immunoglobulin genes /// soma9c recombina9on of immunoglobulin gene segments /// response to drug /// nucleic acid phosphodiester bond hydrolysisDNA b ding /// single-stranded DNA binding /// nuclease ac9vity / nd uclease ac9vity /// protein binding /// ATP binding /// hydrolase ac9vity /// ATPase ac9vity /// mismatched DNA bi ding /// single base inser r dele9on binding /// MutSalpha complex bindingnucleus /// mis atch repa r complex /// MutL lpha complex
218961_s_atPNKP polynucleo9de kinase 3'-phosphatasenucleo9de-excision repair, DNA damage removal /// DNA-dependent DNA replica9on /// DNA repair /// response to DNA damage s9mulus /// response to oxida9ve stress /// metabolic process /// response to radia9on /// response to radia9on /// phosphoryla9on /// dephosphoryla9on /// DNA damage response, detec9on of DNA damage /// DNA damage response, detec9on of DNA damage /// nucleo9de phosphoryla9onnucleo9de b nding /// d mag d DNA binding /// double-strand d DNA binding /// cat ly9c ac9vity /// endonuclease ac9vity //  protein binding /// protein binding /// ATP binding /  kinase ac9vity /// tra sferase ac9vity /// hydr lase ac9vity /// purine nucl o9de binding /// nucleo9 e kinase ac9vity /// polynucleo9de 3'-phosphatase ac9vity /// ATP-depend nt polydeoxyribonucleo9de 5'-hy roxyl-kinase ac vitynucleus /// nucleolus
234907_x_atPOLB polymerase (DNA directed), beta repli a9on /// DNA-dependent DNA replica9on /// DNA repair /// base-excision repair /// base-excision repair /// base-excision repair /// base-excision repair, gap-ﬁlling /// pyrimidine dimer repair /// nucleo9de-excision repair, DNA gap ﬁlling /// response to DNA damage s9mulus /// cell death /// nega9ve regula9on of apopto9c process /// response to ethanolDNA binding /// damaged DNA binding /  cataly9c ac9vity /// DNA-direct d DNA polym rase ac9vity /  protein bindi g /// microtubul  bindi g /// t ansferase ac9vit  /// nucleo9dyltransferase ac9vity /// lyase ac9vity /// enzyme binding /// metal ion bin ingnucl us /// nucleoplasm //  cytoplasm /// microtubule /// spin le micr tubule
203422_at POLD1 polymerase (DNA directed), delta 1, cataly9c subunitS phase of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA synthesis involved in DNA repair /// DNA synthesis involved in DNA repair /// nucleobase-containing compound metabolic process /// DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair /// base-excision repair, gap-ﬁlling /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// nucleo9de-excision repair, DNA gap ﬁlling /// nucleo9de-excision repair, DNA gap ﬁlling /// regula9on of mito9c cell cycle /// response to UV /// translesion synthesis /// telomere maintenance via semi-conserva9ve replica9on /// DNA replica9on, removal of RNA primer /// small molecule metabolic process /// DNA replica9on proofreading /// nucleic acid phosphodiester bond hydrolysisnucleo9de binding /// n leic acid binding /// DNA b di g /// chroma9n binding DNA-di cted DNA polymerase ac9vity /// nuclease ac9vity /// exonuclea e ac9v ty /// protein binding /// 3'-5' exonucl ase ac9vity /// transferas  c9v ty /// nucleo9dyltransferase ac9vity /// hydrolase c9vity /// metal ion binding /// iron-sulfu  cluster binding /// 4 iron, 4 sulfur cluster bindingnucleo9de-excision repair complex /// nucl us nucl oplasm /// delta  poly eras  complex
201115_at POLD2 polymerase (DNA directed), delta 2, accessory subunitS phase of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA replica9on /// DNA-dependent DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// telomere maintenance via semi-conserva9ve replica9onDNA binding /// DNA-direct d DNA polymerase ac9v ty /// protein binding /// transferase ac9vity /// ucleo9dyltransferase ac9vitynucleus /// n leoplasm / nucleolus
216026_s_atPOLE polymerase (DNA directed), epsilon, cataly9c subunitG1/S transi9on of mito9  ce l cycle /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA synthesis involved in DNA repair /// in utero embryonic development /// nucleobase-containing compound metabolic process /// DNA replica9on /// DNA replica9on ini9a9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// base-excision repair, gap-ﬁlling /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// nucleo9de-excision repair, DNA gap ﬁlling /// response to DNA damage s9mulus /// telomere maintenance via semi-conserva9ve replica9onnucleo9de binding /// n cleic acid binding /// DNA binding /// chrom 9n bind ng /// DNA-directed DNA polymerase ac9vity /// zinc io  binding /// transferase ac9vity /// nucleo9dyltransferase ac9vity /// metal ion binding /// iron-sulfur cluster binding /// 4 iron, 4 sulfur cluster bindingnuc eus /// nucleoplasm /// epsilon DNA polym rase compl x
203366_at POLG polymerase (DNA directed), gamma metabolic process /// DNA replica9on /// DNA-dependent DNA replica9on /// mitochondrial DNA replica9on /// base-excision repair, gap-ﬁlling /// aging /// cell deathproteas  binding /// nucleic acid binding /// DNA binding /// hroma9n b nding /// DNA-directed DNA polym rase ac9vity /// exonuclease ac9vity /// protein binding /// transferase ac9vity /// nucleo9dyltransferase ac9vitymitocho drion /// mitochondrial inner membrane /// gam a DNA polymerase complex /  mitochondrial nucleoid
219380_x_atPOLH polymerase (DNA directed), eta synthesis involved in DNA repair /// DNA replica9on /// DNA repair /// regula9on of DNA repair /// pyrimidine dimer repair /// postreplica9on repair /// response to DNA damage s9mulus /// response to UV-CDNA binding /// damaged DNA binding /// DNA-directed DNA polymerase ac9vity /// protein bind ng /// transf rase ac9vity /// nucleo9dyltransferase ac9vity /// metal ion bindingucleus /// nucleoplasm //  nucleolus /// cytoplasm
219317_at POLI polymerase (DNA directed) iota repli a9on /// DNA repair /// response to DNA damage s9mulusDNA binding /// damag d DNA binding /// DNA-directed DNA polymerase ac9vity /// protein binding /// transferase ac9vity /// nucleo9dyltransferase ac9vity /// metal ion bindingintr cellular /// ucleus /// nucleoplas  /// intracellular membrane-bounded orga elle
222238_s_atPOLM polymerase (DNA directed), mu repair /// DNA recombina9on /// response to DNA damage s9mulus /// metabolic process /// soma9c hypermuta9on of immunoglobulin genes /// B cell diﬀeren9a9onDNA binding /// c taly9c ac9vity /// DNA-directed DNA polymerase ac9vity /// DNA nucleo9dylexotransferase ac9vity /// transferas  ac9vity /// nucleo9dyltransferase ac9vity /// metal ion bindingnucleus
219510_at POLQ polymerase (DNA directed), theta repli a9on /// DNA repair /// response to DNA damage s9mulusnucleo9de binding nucleic acid binding /// DNA binding /// damaged DNA binding /// DNA-directed DNA polymerase ac9vity /// helicase ac9vity /// ATP binding /// ATP-dependent helicase ac9vity /// transferase ac9vity /// nucleo9dyltransferase ac9vity /// hydrolase ac9vity /// single-stranded DNA-dependent ATPase ac9vitynucleoplasm
208694_at PRKDC protein kinase, DNA-ac9vated, cataly9c polypep9det lomere maintenance /// somitogenesis /// B cell lineage commitment /// pro-B cell diﬀeren9a9on /// T cell lineage commitment /// DNA repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// cellular protein modiﬁca9on process /// apopto9c process /// response to DNA damage s9mulus /// brain development /// heart development /// response to gamma radia9on /// phosphoryla9on /// pep9dyl-serine phosphoryla9on /// lymphocyte diﬀeren9a9on /// protein destabiliza9on /// posi9ve regula9on of type I interferon produc9on /// cellular response to insulin s9mulus /// T cell diﬀeren9a9on in thymus /// immunoglobulin V(D)J recombina9on /// T cell receptor V(D)J recombina9on /// germ cell programmed cell death /// posi9ve regula9on of apopto9c process /// innate immune response /// posi9ve regula9on of transcrip9on from RNA polymerase II promoternucleo9d binding /// DNA binding /// protein kinase ac9vity // protein serine/threonine kinase ac9vity /// DNA-d pendent protein kinase ac9vity /// inding /// protein binding /// ATP binding /// transcrip9on factor bindi g //  kinase ac9vity /// transferase ac9vity /// transfer se ac9vity, transferring phosphorus-containing groups /// phosphotransferase c9vity, alcohol group as accept r /// enzym  bindingnucleus /// ucleoplasm // tr nscrip9on factor com lex /// nucleolus /// cytosol /// DNA-dependent protein kinase-DNA ligase 4 complex /// nonhomol gous end joining compl x
203103_s_atPRPF19 pre-mRNA processing factor 19protein polyubiqui9na9on /// spliceosomal complex assembly /// mRNA splicing, via spliceosome /// mRNA splicing, via spliceosome /// inner cell mass cell prolifera9on /// DNA repair /// mRNA processing /// response to DNA damage s9mulus /// RNA splicing /// lipid biosynthe9c process /// protein ubiqui9na9on /// nega9ve regula9on of neuron diﬀeren9a9on /// posi9ve regula9on of mRNA splicing, via spliceosome /// posi9ve regula9on of astrocyte diﬀeren9a9onDNA binding /// ubiqui9n-protein ligase c9vity /// protein binding /// ubiqui9n-ubiqui9n ligase ac9vity /// iden9cal protein bi dingubiqui9n ligase complex /// Prp19 com lex /// nuc eus /// nucleoplas  /// sp ceosomal complex /// cytoplasm /// lipid par9cle /// spindle /// cytoskeleton /// nuclear speck /// cataly9c tep 2 spliceosome
204053_x_atPTEN phosphatase and tensin homologregula9on of cyclin-dependent protein serine/threonine kinase ac9vity /// angiogenesis /// nega9ve regula9on of protein phosphoryla9on /// regula9on of B cell apopto9c process /// protein dephosphoryla9on /// protein dephosphoryla9on /// lipid metabolic process /// phospholipid metabolic process /// phospha9dylinositol biosynthe9c process /// apopto9c process /// induc9on of apoptosis /// ac9va9on of mito9c anaphase-promo9ng complex ac9vity /// epidermal growth factor receptor signaling pathway /// neuron-neuron synap9c transmission /// nervous system development /// synapse assembly /// central nervous system development /// heart development /// learning or memory /// locomotory behavior /// cell prolifera9on /// posi9ve regula9on of cell prolifera9on /// nega9ve regula9on of cell prolifera9on /// nega9ve regula9on of cell prolifera9on /// ﬁbroblast growth factor receptor signaling pathway /// regula9on of neuron projec9on development /// nega9ve regula9on of phospha9dylinositol 3-kinase cascade /// dephosphoryla9on /// cell migra9on /// dentate gyrus development /// central nervous system neuron axonogenesis /// nega9ve regula9on of cell migra9on /// nega9ve regula9on of myelina9on /// regula9on of protein stability /// nega9ve regula9on of cyclin-dependent protein serine/threonine kinase ac9vity involved in G1/S transi9on of mito9c cell cycle /// central nervous system myelin maintenance /// regula9on of cellular component size /// regula9on of myeloid cell apopto9c process /// mul9cellular organismal response to stress /// social behavior /// pep9dyl-tyrosine dephosphoryla9on /// Fc-epsilon receptor signaling pathway /// maternal behavior /// nega9ve regula9on of apopto9c process /// protein kinase B signaling cascade /// endothelial cell migra9on /// inositol phosphate metabolic process /// small molecule metabolic process /// innate immune response /// locomotor rhythm /// nega9ve regula9on of cell size /// nega9ve regula9on of organ growth /// inositol phosphate dephosphoryla9on /// phospha9dylinositol dephosphoryla9on /// phospha9dylinositol dephosphoryla9on /// neurotrophin TRK receptor signaling pathway /// phospha9dylinositol-mediated signaling /// cardiac muscle 9ssue development /// forebrain morphogenesis /// brain morphogenesis /// nega9ve regula9on of epithelial cell prolifera9on /// nega9ve regula9on of axonogenesis /// protein stabiliza9on /// T cell receptor signaling pathway /// posi9ve regula9on of sequence-speciﬁc DNA binding transcrip9on factor ac9vity /// regula9on of cell cycle /// nega9ve regula9on of focal adhesion assembly /// nega9ve regula9on of protein kinase B signaling cascade /// rhythmic synap9c transmission /// canonical Wnt receptor signaling pathway /// synapse matura9on /// prepulse inhibi9on /// male ma9ng behavior /// long-term synap9c poten9a9on /// prostate gland growth /// dendri9c spine morphogenesis /// nega9ve regula9on of dendri9c spine morphogenesis /// nega9ve regula9on of ribosome biogenesis /// nega9ve regula9on of cell aging /// nega9ve regula9on of excitatory postsynap9c membrane poten9al /// presynap9c membrane assembly /// postsynap9c density assembly /// posi9ve regula9on of protein ubiqui9na9on involved in ubiqui9n-dependent protein catabolic process /// nega9ve regula9on of G1/S transi9on of mito9c cell cycle /// posi9ve regula9on of excitatory postsynap9c membrane poten9al /// nega9ve regula9on of synap9c vesicle clusteringmagnesium ion binding /// phospha9dylinositol-3-phosphatase ac9vity /// phosphoprotein phosphatase ac9vity /// protein serine/threonine phosphatase ac9vity /// protein tyrosine phosphatase ac9vity /// prot in binding /// protein tyrosine/serine/threonine phosphatase ac9vity /// lipid binding /// anaphase-pr mo9ng complex binding /// ph spha9dylinositol-3,4,5-trisphos hate 3-phosphatase ac9vity /// phospha9dylinositol-3,4,5-trisphosphat  3-phosphatase ac9vity /// hydrolase ac9vity /// phosphatase ac9vity /// enzyme binding /// prot in kina e binding /// PDZ domain binding /// inositol-1,3,4,5-t trakisphosphat  3-phosphatase ac9vity /// inositol-1,3,4,5-tetrakisphosphate 3-phosphatase ac9vity / phospha9dylinositol-3,4-bisphosphate 3-phosphatase ac9vity /// phospha9dyli ositol-3,4-b sphosphate 3-phosphatase ac9vityucleus /// cytopla m /// cytoplasm /// ytosol / plasma membra e /// int rnal side lasma membrane /// PML body /// myelin she th adaxonal region // cell proj c9on /// neuron projec9o /// Schmidt-Lante man ncisure
204460_s_atRAD1 RAD1 homolog (S. pombe)cell cycle ch ckpoint /// DNA damage checkpoint /// DNA replica9on /// DNA repair /// response to DNA damage s9mulus /// meio9c prophase I /// cellular response to ionizing radia9on /// nucleic acid phosphodiester bond hydrolysisdamaged DNA binding /// nuclease ac9vity /// xonuclease ac9vity /// protein binding /// 3'-5' exonuclease ac9vity /// exodeoxyribonuclease III ac9vity /// hydrolase c9vitynucleus //  nucl us /// nucleoplasm /// nucleolus /// intracellular membrane-bounded organelle
207405_s_atRAD17 RAD17 homolog (S. pombe)cell cycle checkpoint /// DNA replica9on checkpoint /// DNA damage checkpoint /// DNA replica9on /// DNA repair /// response to DNA damage s9mulus /// cell cycle /// mito9c cell cycle checkpoint /// nega9ve regula9on of DNA replica9on /// regula9on of phosphoryla9onnucleo9de binding /// protein binding //  ATP binding /// nucleoside-triphosphatase ac9vitychromosome, telomer c region /// nucleus /// nucle plasm /// nucleolus
200608_s_atRAD21 RAD21 homolog (S. pombe)M phase of mito9c cell cycle /// mito9c prometaphase /// mito9c cell cycle /// cytokinesis /// DNA repair /// double-strand break repair /// DNA recombina9on /// regula9on of transcrip9on from RNA polymerase II promoter /// apopto9c process /// response to DNA damage s9mulus /// cell cycle /// chromosome segrega9on /// mitosis /// metaphase/anaphase transi9on of mito9c cell cycle /// reciprocal meio9c recombina9on /// cell division /// protein localiza9on to chroma9nprotein bindinguclear chr moso e /// chromosome, entromeric region /// nucleus /// nucleoplasm /// chromosome /// nucleolus /// cytosol /// cohesin complex /// nuclear meio9c cohesin co plex
201039_s_atRAD23A RAD23 homolog A (S. cerevisiae)DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// virus-host interac9on /// regula9on of proteasomal ubiqui9n-dependent protein catabolic process /// proteasomal ubiqui9n-dependent protein catabolic process /// posi9ve regula9on of viral genome replica9ondam g d DNA binding /// s ngle-stranded DNA binding /// protein binding /// polyubiqui n bindinproteasom  complex /// nucleus
201222_s_atRAD23B RAD23 homolog B (S. cerevisiae)nucleo9de-exc on repair, DNA damage recogni9on /// nucleo9de-excision repair, DNA damage recogni9on /// nucleo9de-excision repair, DNA damage removal /// DNA repair /// nucleo9de-excision repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// spermatogenesis /// regula9on of proteasomal ubiqui9n-dependent protein catabolic process /// proteasomal ubiqui9n-dependent protein catabolic processdam ged DNA binding /// single-stranded DNA binding /// protein b nding /// polyubiqui9n bi dingproteasome complex /// nucleus /// ucl opla m /// nucleolus / cytoplasm /// XPC complex
209349_at RAD50 RAD50 homolog (S. cerevisiae)regula9on of mito9c recombina9on /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA repair /// DNA repair /// double-strand break repair /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// telomere maintenance via telomerase /// cell cycle /// meiosis /// reciprocal meio9c recombina9on /// posi9ve regula9on of protein autophosphoryla9on /// DNA duplex unwinding /// posi9ve regula9on of kinase ac9vity /// nucleic acid phosphodiester bond hydrolysissingle-stranded DNA speciﬁc endod oxyribo uclease ac9vity /// nucleo9de binding /// DNA binding /// ATP-dependent DNA helicase ac9vity //  nucleas  ac9vity /// protein binding /// ATP binding /// zinc ion binding /// 3'-5' exonucl ase ac9vity /// hydrolase ac9vity protein binding, bridging /// metal ion bindingchromos me, telo eric reg on /// nucl ar chromosome, t lom ric e ion /// nucleus //  nucleoplasm // chromosome /// Mre11 compl x /// site of double-strand break // pronucl us
205023_at RAD51 RAD51 homolog (S. cerevisiae)d uble-st and break repair via homologous recombina9on /// double-strand break repair via homologous recombina9on /// DNA recombinase assembly /// DNA metabolic process /// DNA unwinding involved in replica9on /// DNA repair /// double-strand break repair /// DNA recombina9on /// mito9c recombina9on /// response to DNA damage s9mulus /// response to DNA damage s9mulus /// meiosis /// reciprocal meio9c recombina9on /// SOS response /// regula9on of double-strand break repair via homologous recombina9on /// posi9ve regula9on of DNA liga9on /// protein homooligomeriza9on /// cellular response to ionizing radia9on /// cellular response to camptothecinnucl o9d  binding /// DNA binding /// damaged DNA inding /// double-stranded DNA binding /// single-stranded DNA binding /// protein binding /// ATP binding /// protein C-terminus bi ding /// DNA-dependent ATPase c9vity /// nucleosi e-triphos hatase ac9vity /// iden9cal protein binding /// single-stranded DNA-dependent ATPase ac9vitynuclear chromosom  /// co dens  chromosome / cond nsed nuclear chromosome /// l teral element /// ucleus // nucleus / nucleoplasm /// cyto lasm /// mitocho drion /// mitochondrial ma rix /// PML body / perinuclea  regi n of cytoplasm
206066_s_atRAD51C RAD51 homolog C (S. cerevisiae)DNA metabolic process /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// sister chroma9d cohesion /// female meiosis sister chroma9d cohesion /// reciprocal meio9c recombina9on /// male meiosis I /// spermatogenesis /// blood coagula9onnucle 9de binding /// DNA binding /// protein bi ding /// ATP binding /// DNA-dependent ATPase ac9vity /// cros ver junc9on endodeoxyribonuclease a 9vity /// nucleoside-triphosphatase ac9vitynucleus /// nucleoplasm // cytoplasm /// mit chondrion  perinuclear r gion of cytoplasm
37793_r_at RAD51D RAD51 homolog D (S. cerevisiae)DNA metabolic process /// DNA replica9on /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// reciprocal meio9c recombina9onnucle 9de binding /// DNA bi ding /// DNA helicase ac9vity /// protein binding /// ATP bin ing /// DNA-dependent ATP se ac9vity /// nucleoside-triphosphatase ac9vitynucleus
205647_at RAD52 RAD52 homolog (S. cerevisiae)d uble-st and break repair via homologous recombina9on /// DNA recombinase assembly /// DNA repair /// double-strand break repair /// DNA recombina9on /// mito9c recombina9on /// response to DNA damage s9mulus /// reciprocal meio9c recombina9onDNA binding /// protein binding /// iden9cal protein bindingnucleus /// nucleoplasm
219494_at RAD54B RAD54 homolog B (S. cerevisiae)d uble-strand break repair via homologous recombina9on /// DNA repair /// mito9c recombina9on /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// reciprocal meio9c recombina9on /// DNA duplex unwindingnucleo9d  binding /// nucleic acid bind g /// DNA binding /// DNA heli ase ac9vity /// RNA heli ase ac9vity /// helicase ac9vity /// protein bi ding /// ATP binding /// DNA t anslocase ac9vity /// hydrolase ac9vitynucleus
204558_at RAD54L RAD54-like (S. cerevisiae)double- trand break repair via homologous recombina9on /// DNA strand renatura9on /// DNA repair /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// meiosis /// response to ionizing radia9on /// response to drug /// chromosome organiza9onnucleo9d  binding /// nucleic acid bind g /// DNA binding /// helicase ac9vity /// p otein bin ing /// ATP binding /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on cid anhydrides /// annealing h licase ac9v tynucleus
204828_at RAD9A RAD9 homolog A (S. pombe)cell cycle checkpoint /// cell cycle checkpoint /// DNA replica9on checkpoint /// DNA damage checkpoint /// DNA replica9on /// DNA repair /// response to DNA damage s9mulus /// posi9ve regula9on of apopto9c process /// cellular response to ionizing radia9on /// nucleic acid phosphodiester bond hydrolysisnuclease ac9vity /// exonuclease ac9vity /// protein binding /// 3'-5' exonucle s ac9vity /// exodeoxyribonuclease III ac9vity //  hydrolase ac9vity /// SH3 domain binding /// enzyme binding /// protein kinase binding /// histone deacetylase bindingnucleus /// oplasm /// nucle lus /// cyto lasm /// checkpoint cl mp compl
203344_s_atRBBP8 re9noblastoma binding protein 8cell cycle checkpoint /// G1/S transi9on of mito9c cell cycle /// nega9ve regula9on of transcrip9on from RNA polymerase II promoter /// double-strand break repair via homologous recombina9on /// blastocyst hatching /// DNA repair /// regula9on of transcrip9on from RNA polymerase II promoter /// response to DNA damage s9mulus /// cell cycle /// mitosis /// meiosis /// DNA double-strand break processing involved in repair via single-strand annealing /// G2 DNA damage checkpoint /// cell divisionsingle-s randed DNA speciﬁc endodeoxyribonuclease ac ity /// RNA p lymerase II repressing transcrip9on factor binding / RNA polymeras  II t ansc ip9on corepres or ac9vity /// DNA inding /// damaged DNA binding /  nucle se ac9vity /// end uclease ac9vit  /// protein binding  hydr lase ac9vitynucleus /// transcrip9onal repressor complex
205091_x_atRECQL RecQ protein-like (DNA helicase Q1-like)DNA strand renatura9on /// DNA replica9on /// DNA repair /// DNA recombina9on /// DNA duplex unwinding /// DNA duplex unwindingnu leo9de binding /// nucleic acid binding /// DNA binding /// DNA helicase ac9vity /// ATP-dependent DNA helicase ac9vity /// helicase ac9vity /// protein binding /// ATP binding /// ATP-dependent helicase ac9vity /// hydrolase ac9vity /// ATP-dependent 3'-5' DNA helicase ac9vitynucleus /// nucle lus // mic otubule cytosk leton
213520_at RECQL4 RecQ protein-like 4DNA strand renatura9on /// DNA replica9on /// DNA repair /// DNA recombina9on /// mul9cellular organismal development /// DNA duplex unwindingnucleo9de binding /// bubble DNA binding /// nucleic acid binding /// helicase a 9vity /// ATP binding /// ATP-dependent helicase ac9vity /// zinc ion binding /// hydrolase ac9vity /// ATP-dependent 3'-5' DNA helicase ac9vitynucleus /// cytoplasm
221686_s_atRECQL5 RecQ protein-like 5DNA metabolic process /// DNA replica9on /// DNA replica9on /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// cell cycle /// mitosis /// DNA duplex unwinding /// DNA duplex unwinding /// nega9ve regula9on of transcrip9on elonga9on from RNA polymerase II promoter /// cell division /// chromosome separa9onnucle 9de binding /// RNA polymerase II core binding /// nucleic acid binding /// DNA binding /// DNA helicase c9vity /// helicase ac9vity /// ATP binding /// TP-dependent helicase ac9vity /// hydrolase ac9vitynucleus /// nucleoplasm /// nucl olus cytoplasm /  cytoplasm / DNA-direct d RNA polymerase II, holoenzyme / nu lear me bra e
218428_s_atREV1 REV1, polymerase (DNA directed)DNA replica9on /// DNA repair /// response to DNA damage s9mulus /// response to UV /// error-prone translesion synthesismagn sium ion b nding /// DNA binding /// damaged DNA binding /// DNA-directed DNA polymerase ac9vity /// protein binding /// transferase ac9vity /// nucleo9dyltransferase ac9vity /// deoxycy9dyl transferase ac9vity /// metal ion bindingnucleus // nucleoplasm
208070_s_atREV3L REV3-like, polymerase (DNA directed), zeta, cataly9c subunitnucl obase-containing compound metabolic process /// DNA replica9on /// DNA-dependent DNA replica9on /// DNA repair /// DNA repair /// nucleo9de-excision repair, DNA gap ﬁlling /// response to DNA damage s9mulus /// translesion synthesisnucleo9d binding /// nucleic a id binding // DNA binding /// DNA-dir cted DNA polymerase ac9vity /// protein binding /// 3'-5' exonuclease ac9vity /// transferase ac9vity /// nucleo9dyltransferase ac9vity /// metal ion binding /// iron-sulfur cluster binding /// 4 iron, 4 sulfur cluster bindingnucle s /// nu leoplasm /// chromosome /// zeta  polym rase complex
208021_s_atRFC1 replica9on factor C (ac9vator 1) 1, 145kDaS phase of mi 9c cell cycle /// mito9c cell cycle /// telomere maintenance via recombina9on /// telomere maintenance /// DNA replica9on /// DNA-dependent DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// telomere maintenance via telomerase /// telomere maintenance via semi-conserva9ve replica9on /// posi9ve regula9on of cataly9c ac9vitynucleo9de binding /// DNA binding /// DNA clamp load r c9vity /// protei  binding /// ATP binding /// enzyme ac9vator ac vity /// nucleoside-triphosphatase ac9vitynucleus /// nu leoplasm / DNA replic 9on f tor C complex
214700_x_atRIF1 RAP1 interac9ng factor homolog (yeast)telomere maintenance /// response to DNA damage s9mulus /// cell cycle /// stem cell maintenancebindi  /// prot in bindingch om some, telomeric region /// female pronucleus /// male pro ucleus /// nucleus /// chromosome /// cytoplasm /// spindle /// cytoskeleton
212696_s_atRNF4 ring ﬁnger protein 4transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// protein ubiqui9na9on /// androgen receptor signaling pathway /// proteasomal ubiqui9n-dependent protein catabolic process /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// response to arsenic-containing substance /// protein autoubiqui9na9on /// protein K63-linked ubiqui9na9on /// protein K48-linked ubiqui9na9on /// protein K11-linked ubiqui9na9on /// protein K6-linked ubiqui9na9on /// regula9on of spindle assembly /// regula9on of kinetochore assemblyDNA binding /// sequence-speciﬁc DNA binding transcrip9o  factor ac9vi y /// transcrip  coac9vator ac9vity /// ubiqui9n-protein ligase ac9vity /// prote n binding /// ranscr p9on factor binding / zinc ion binding /// ligase ac9vity /// estrogen receptor binding /// nucleos me bind ng /// SUMO polymer binding /// progesterone recep r bind ng /// metal ion binding / androgen receptor bindi gucleus // n cle plasm /// cytoplasm /// microtubule cytosk leton /// PML body
203160_s_atRNF8 ring ﬁnger protein 8, E3 ubiqui9n protein ligaseDNA repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// ubiqui9n-dependent protein catabolic process /// response to DNA damage s9mulus /// cell cycle /// mitosis /// sperma9d development /// response to ionizing radia9on /// protein ubiqui9na9on /// chroma9n modiﬁca9on /// histone H2A ubiqui9na9on /// histone H2B ubiqui9na9on /// interstrand cross-link repair /// histone exchange /// isotype switching /// posi9ve regula9on of DNA repair /// nega9ve regula9on of transla9onal elonga9on /// cell division /// protein autoubiqui9na9on /// protein K63-linked ubiqui9na9on /// histone H2A K63-linked ubiqui9na9on /// histone H2A K63-linked ubiqui9na9on /// protein K48-linked ubiqui9na9onchroma9n binding /// ubiqui9n-protein ligase ac9vity /// protein bi ding /// zinc io  bindi  /// ligase ac9vity /// acid-amino acid ligase ac9vity /// ubiqui9n protein ligase binding /// histone binding /// protein homodimeriza9 n ac9vity /// metal ion bi dub qui9n ligase complex /// ch omosome, telomeric regio  /  nucleus /// chromosome /// midbody /// site of double-strand break
201529_s_atRPA1 replica9on protein A1, 70kDacell cycle checkpoint /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// mito9c cell cycle /// nucleo9de-excision repair, DNA damage removal /// telomere maintenance via recombina9on /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA recombinase assembly /// in utero embryonic development /// DNA replica9on /// DNA-dependent DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// meiosis /// posi9ve regula9on of cell prolifera9on /// hemopoiesis /// telomere maintenance via semi-conserva9ve replica9on /// homeostasis of number of cells within a 9ssue /// chromosome organiza9onnucleic acid binding /// DNA binding /// chroma9n binding /// single-stranded DNA binding /// protein binding /// metal ion bindingcondensed chromosome / cond nsed uclear chromosome /// lateral element // male germ cell nucl us /// nucleus /// nucleoplasm /// DNA replica9on factor A compl x /// nucleolus // cytoplas  /// ac9n cytoskeleton /// PML body
201756_at RPA2 replica9on protein A2, 32kDacell cycle checkpoint /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// mito9c cell cycle /// nucleo9de-excision repair, DNA damage removal /// telomere maintenance via recombina9on /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA recombinase assembly /// DNA replica9on /// DNA-dependent DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// regula9on of double-strand break repair via homologous recombina9on /// telomere maintenance via semi-conserva9ve replica9onnucleic acid binding /// DNA binding /// single-stranded DNA binding /// prot in binding /// protein phosphatase bind ng /// rotein N-ter inus bindingnucleus /// nucleoplasm / DNA replica9on factor A complex /// nucleolus /// PML body
209507_at RPA3 replica9on protein A3, 14kDacell cycle checkpoint /// G1/S transi9on of mito9c cell cycle /// S phase of mito9c cell cycle /// mito9c cell cycle /// nucleo9de-excision repair, DNA damage removal /// telomere maintenance via recombina9on /// telomere maintenance /// double-strand break repair via homologous recombina9on /// DNA recombinase assembly /// DNA replica9on /// DNA strand elonga9on involved in DNA replica9on /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// nucleo9de-excision repair, DNA gap ﬁlling /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// telomere maintenance via semi-conserva9ve replica9onsingle-s randed DNA bindi g /// protein bindingnucleus /// nucleoplasm /// DNA replica9on factor A complex /// cytoplasm
221143_at RPA4 replica9on protein A4, 30kDaDNA damage checkpoint /// G1/S transi9on of mito9c cell cycle /// mito9c cell cycle /// DNA replica9on ini9a9on /// DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// nuclear cell cycle DNA replica9onnucl ic ac d binding /// single-stranded DNA bindingnucleus /// nuc opl s  /// DNA rep ica9on factor A complex
202276_at SHFM1 split hand/foot malforma9on (ectrodactyly) type 1double-strand break ep ir via homologous recombina9on /// proteolysispr tein bin ing /// pe 9dase ac9vityp oteas e complex /// integrator compl x
218685_s_atSMUG1 single-strand-selec9ve monofunc9onal uracil-DNA glycosylase 1DNA repair /// base-excision repair /// base-excision repair /// base-excision repair, AP site forma9on /// response to DNA damage s9mulus /// metabolic process /// depyrimidina9onDNA binding /// uracil DNA N-glyco ylase ac9vity /// protein bi ding /// hydrolase ac vity / hydrolase ac9vity, ac9ng on glycosyl bonds /// single-strand s lec9ve ur cil DNA N-glycosylase ac9vity /// DNA N-glycosylase ac9vitynucleus /// nucle plasm /// nucleolus
222259_s_atSPO11 SPO11 meio9c protein covalently bound to DSBzygotene /// ovarian follicle development /// DNA metabolic process /// meiosis /// synapsis /// reciprocal meio9c recombina9on /// male meiosis I /// spermatogenesis /// sperma9d development /// female gamete genera9on /// protein localiza9on to chromosomeDNA bi ding /// cata y9c ac9vity /// TP binding /// hydrolase ac9vityhromos me, telomeric region /// nucleus /// chromo ome
203743_s_atTDG thymine-DNA glycosylasenega9ve regula9on of transcrip9on from RNA polymerase II promoter /// DNA repair /// base-excision repair /// base-excision repair /// base-excision repair, AP site forma9on /// mismatch repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// metabolic process /// embryo development /// chroma9n modiﬁca9on /// nega9ve regula9on of protein binding /// nega9ve regula9on of chroma9n binding /// regula9on of gene expression, epigene9c /// depyrimidina9on /// DNA demethyla9onRNA polymera e II tra scrip9on cofactor ac9vity /// damaged DNA binding // double-stranded DNA binding /// protein kinase C binding /// rotein binding /// pyrimidine-speciﬁc m smatch base pair DNA N-glycosylase ac9vity /// hydrol se ac9vity /// hy rolase ac9vity, ac9ng on glycosyl bonds /// hydrolase ac9vity, hydrolyzing N-glycosyl compounds DNA N-glycosylase ac9vity /// mismatched DNA binding /// SUMO binding /// protein homodimeriza9on ac9vity /// structure-sp ciﬁc DNA bindingnu leus /// nucleoplasm /// PML body
219715_s_atTDP1 tyrosyl-DNA phosphodiesterase 1single strand b eak repair /// single strand break repair /// DNA repair /// double-strand break repair /// response to DNA damage s9mulus /// cell death /// nucleic acid phosphodiester bond hydrolysisdoubl -str nded DNA bindi g /// single-st anded DNA binding /// nucle se ac9vity /// exonuclease ac9vity /// protein binding /  phosphoric diester hydrolase ac9vity /// hydrolase ac9vity /// 3'-tyrosyl-DNA phosphodiesterase ac9vitynucleus /// cytoplasm
202266_at TDP2 tyrosyl-DNA phosphodiesterase 2DNA repair /// double-strand break repair /// double-strand break repair /// response to DNA damage s9mulus /// cell surface receptor signaling pathway /// nucleic acid phosphodiester bond hydrolysismagn sium io  binding /// magnesium ion bi ing /// single-stranded DNA binding /// transcrip9on cor pressor ac9vity /// nuclease ac9vity /  protein bin ing /// y rolase ac9vity /// manganese ion binding /// tyrosyl-RNA phosphodiesterase ac9vity /// metal ion binding /// 5'-tyrosyl-DNA phosphodiesterase ac9vity /// 5'-tyrosyl-DNA phosphodiesterase ac9vitynucleus /// nucleolus /// cytopl sm /// PML body
204946_s_atTOP3A topoisomerase (DNA) III alphaDNA topological change /// meiosisnuc eo9de binding /// nucleic acid binding /// DNA binding /// DNA topoisomerase ac9vity /// DNA topoisomerase type I ac9vity /// protein binding /// ATP binding /// zinc ion binding /// isomerase ac9vity /// metal ion bindingnucleus /// chromosome /// PML body
213660_s_atTOP3B topoisomerase (DNA) III betaDNA topological change /// chromosome segrega9onnuc eo9de binding /// DNA binding /// DNA topoisomerase ac9vity /// DNA topoisomerase type I ac9vity /// ATP binding /// isomerase ac9vitycondensed chromosome // nucleus /// ch omosome
202633_at TOPBP1 topoisomerase (DNA) II binding protein 1DNA metabolic process /// DNA repair /// response to DNA damage s9mulus /// response to ionizing radia9onDNA binding /// prot in binding /// protein C-terminus binding //  isomerase ac9vity /// iden9cal protein bindingcondens d nuclear chromos me /// spindle pole /// mal  germ cell nucleus /// ucleus /// chromosome /// cytoplasm /// microtubule organizing center /// cytoskeleton /// PML body
211300_s_atTP53 tumor protein p53protein import into nucleus, transloca9on /// cell cycle checkpoint /// nega9ve regula9on of transcrip9on from RNA polymerase II promoter /// nega9ve regula9on of transcrip9on from RNA polymerase II promoter /// nega9ve regula9on of transcrip9on from RNA polymerase II promoter /// DNA strand renatura9on /// in utero embryonic development /// somitogenesis /// release of cytochrome c from mitochondria /// T cell prolifera9on involved in immune response /// B cell lineage commitment /// T cell lineage commitment /// response to ischemia /// base-excision repair /// nucleo9de-excision repair /// double-strand break repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// protein complex assembly /// apopto9c process /// induc9on of apoptosis /// response to DNA damage s9mulus /// DNA damage response, signal transduc9on by p53 class mediator resul9ng in cell cycle arrest /// DNA damage response, signal transduc9on by p53 class mediator resul9ng in transcrip9on of p21 class mediator /// response to oxida9ve stress /// ER overload response /// cell cycle /// cell cycle arrest /// cell cycle arrest /// transforming growth factor beta receptor signaling pathway /// Ras protein signal transduc9on /// mul9cellular organismal development /// gastrula9on /// nega9ve regula9on of neuroblast prolifera9on /// central nervous system development /// cell aging /// blood coagula9on /// protein localiza9on /// nega9ve regula9on of DNA replica9on /// cell prolifera9on /// nega9ve regula9on of cell prolifera9on /// determina9on of adult lifespan /// rRNA transcrip9on /// response to UV /// response to salt stress /// embryo development ending in birth or egg hatching /// response to X-ray /// response to gamma radia9on /// posi9ve regula9on of cardiac muscle cell apopto9c process /// virus-host interac9on /// cell diﬀeren9a9on /// nega9ve regula9on of cell growth /// DNA damage response, signal transduc9on by p53 class mediator /// DNA damage response, signal transduc9on by p53 class mediator /// nega9ve regula9on of transforming growth factor beta receptor signaling pathway /// posi9ve regula9on of histone deacetyla9on /// chroma9n assembly /// mito9c G1 DNA damage checkpoint /// posi9ve regula9on of protein oligomeriza9on /// T cell diﬀeren9a9on in thymus /// regula9on of 9ssue remodeling /// cellular protein localiza9on /// cellular response to UV /// mul9cellular organism growth /// cellular response to drug /// regula9on of cell prolifera9on /// cellular response to glucose starva9on /// response to drug /// intrinsic apopto9c signaling pathway in response to DNA damage by p53 class mediator /// regula9on of apopto9c process /// posi9ve regula9on of apopto9c process /// nega9ve regula9on of apopto9c process /// nega9ve regula9on of apopto9c process /// regula9on of neuron apopto9c process /// posi9ve regula9on of neuron apopto9c process /// nega9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// response to an9bio9c /// regula9on of mitochondrial membrane permeability /// nega9ve regula9on of ﬁbroblast prolifera9on /// posi9ve regula9on of pep9dyl-tyrosine phosphoryla9on /// nega9ve regula9on of helicase ac9vity /// protein tetrameriza9on /// chromosome organiza9on /// neuron apopto9c process /// regula9on of cell cycle /// posi9ve regula9on of thymocyte apopto9c process /// posi9ve regula9on of cell cycle arrest /// cellular response to hypoxia /// cellular response to ionizing radia9on /// mito9c cell cycle arrest /// intrinsic apopto9c signaling pathway by p53 class mediator /// posi9ve regula9on of release of cytochrome c from mitochondria /// posi9ve regula9on of cell aging /// replica9ve senescence /// oxida9ve stress-induced premature senescence /// intrinsic apopto9c signaling pathway /// oligodendrocyte apopto9c process /// nega9ve regula9on of macromitophagy /// nega9ve regula9on of reac9ve oxygen species metabolic process /// posi9ve regula9on of reac9ve oxygen species metabolic process /// posi9ve regula9on of intrinsic apopto9c signaling pathwayRNA polymera e II core promoter proximal region sequence-speciﬁc DNA binding transcrip9on factor ac9vit  involved in posi9ve regula9on of transcrip9on /// RNA polymerase II transcrip9on factor binding /// RNA polymerase II transcrip9on egulatory region sequence-speciﬁc DNA bindi g transcrip factor ac9vity involved in posi9ve regula9on of transcrip9on /// pr tease binding /// p53 binding /// DNA binding /// chroma9n bin ing /// damaged DNA binding /// sequence-speciﬁc DNA binding transcrip9on fac or ac9vity /// c pper ion binding /// protein binding /// ATP binding /// transcrip9on factor binding /// zinc ion binding /// enzyme binding /// protein kin se binding /// receptor tyrosin  kinase binding /// ubiqui9n protein ligase binding /// hi tone dea etylase regulator ac9vity /// histone acetyltransferase binding /// iden9cal protein binding /// transcrip9on regulatory regi n DNA bindi g /// metal ion binding /// protein heterodimeriza9o  ac9vity /// protein N-terminus binding /// ch perone binding /// protein ph sphata e 2A binding /// MDM2/MDM4 fami y protein bindingchroma9n /// nucl ar chro 9n /// nucleus /// nucl oplasm /// nucleoplasm /// replica9on fork /// transc i 9 n factor TFIID c mplex /// nucleolus /// cytoplasm /// mito hondrion /// mitochondrial matrix /// endopl smic re9culu  /// c t sol /// cytosol /// nuclear matrix /// nuclear body /// PML body /// protein complex
203050_at TP53BP1 tumor protein p53 binding protein 1double-stra d b eak repair via homologous recombina9on /// DNA repair /// double-strand break repair /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of sequence-speciﬁc DNA binding transcrip9on factor ac9vityRNA polymerase II ac9va9ng transcrip9on factor binding /// RNA p lymerase II transcrip9on cofactor ac9vity /// p53 binding //  DNA binding /// damaged DNA bin ing /// protein binding /// methylated histone residue binding /// telomeric DNA bindingchromosome, centromeric regi   kinetochore / c nd nsed chromosome kinetochore /// chromosom , telomeric reg on /// nucleus /// nucleoplasm /  replica9on f rk /  chromosome /// cytoplasm
34689_at TREX1 three prime repair exonuclease 1DNA metabolic process /// DNA replica9on /// DNA repair /// mismatch repair /// DNA recombina9on /// response to DNA damage s9mulus /// cell death /// regula9on of type I interferon produc9on /// posi9ve regula9on of type I interferon produc9on /// cellular response to interferon-beta /// innate immune response /// nucleic acid phosphodiester bond hydrolysisnucleic acid binding /// double-stranded DNA binding /// single-stranded DNA bind g /// nuclease ac9vity /// exonucl ase ac9vity /// 3'-5'-exodeoxyribonuclease ac9vity /// 3'-5' exonuclease ac9vity /// 3'-5' exonuclease ac9vity /// exodeoxyribonuclease III ac9vi y /// hyd lase ac9vity /// MutLalpha complex binding /// MutSalpha compl x inding /// adenyl deoxyribonucleo9de binding /// protein homodimeriza9on ac9vity /// protein homodimeriza9on ac9vity /// metal ion binding /// metal ion bindingintracellular /// nucleus /// nuclear envelope /// cytoplasm /// ndoplasmic re9 ulum membrane
211788_s_atTREX2 three prime repair exonuclease 2DNA metabolic process /// DNA repair /// response to DNA damage s9mulus /// nucleic acid phosphodiester bond hydrolysismagn sium ion binding /// nucleic acid binding /// nuclease ac9vity /// exonuclease ac9vity /// 3'-5'-exode x r bonuclease ac9vity /// exodeoxyribonuclease III ac9vity /// hydrolase ac9vity /// protein homodimeriza9on ac9vity /// metal ion bindingintracellular  nucleus
201899_s_atUBE2A ubiqui9n-conjuga9ng enzyme E2Aprotei  polyubiqui9na9on /// in utero embryonic development /// an9gen processing and presenta9on of pep9de an9gen via MHC class I /// DNA repair /// postreplica9on repair /// ubiqui9n-dependent protein catabolic process /// response to DNA damage s9mulus /// posi9ve regula9on of cell prolifera9on /// response to UV /// protein ubiqui9na9on /// chroma9n modiﬁca9on /// histone H2A ubiqui9na9on /// protein autoubiqui9na9on /// maternal process involved in female pregnancy /// protein K48-linked ubiqui9na9on /// protein K11-linked ubiqui9na9onnucl o de bi ding /// ubiqui9n-protein ligase ac9vity /// protein binding /// ATP binding /// ligase ac9vity /// acid-amino cid ligase ac9vity /  ubiqui9n protein lig se bindingchroma9n /// nuclea  chroma9n /// XY body /// cytosol /// HULC complex
202333_s_atUBE2B ubiqui9n-conjuga9ng enzyme E2Bprotei  polyubiqui9na9on /// response to hypoxia /// in utero embryonic development /// DNA repair /// postreplica9on repair /// postreplica9on repair /// maintenance of chroma9n silencing /// ubiqui9n-dependent protein catabolic process /// ubiqui9n-dependent protein catabolic process /// protein monoubiqui9na9on /// response to DNA damage s9mulus /// spermatogenesis /// sperm axoneme assembly /// response to UV /// posi9ve regula9on of reciprocal meio9c recombina9on /// protein ubiqui9na9on /// regula9on of histone modiﬁca9on /// cellular response to insulin s9mulus /// nega9ve regula9on of histone phosphoryla9on /// histone H2A ubiqui9na9on /// response to drug /// nega9ve regula9on of apopto9c process /// proteasomal ubiqui9n-dependent protein catabolic process /// nega9ve regula9on of cAMP-mediated signaling /// protein stabiliza9on /// chiasma assembly /// protein autoubiqui9na9on /// canonical Wnt receptor signaling pathway /// histone lysine demethyla9on /// synaptonemal complex organiza9on /// protein K63-linked ubiqui9na9on /// protein K48-linked ubiqui9na9on /// protein K11-linked ubiqui9na9onnucl o de bi ding /// ubiqui9n-pr tein ligase ac9vity /// ubiqui9n-prot i  ligase ac9vity /// protein binding /// ATP binding /// ligase ac9vity acid-amino acid ligase c9vity /// ubiqui9n protein ligase bindingchroma9n /// nuclea  chroma9n /// XY bod /// n cl us /// replica9on fork /  cyt plasm /// plasma membrane / memb ane /// HULC complex
201523_x_atUBE2N ubiqui9n-conjuga9ng enzyme E2Ndouble-strand break repair via homologous recombina9on /// DNA double-strand break processing /// toll-like receptor signaling pathway /// MyD88-dependent toll-like receptor signaling pathway /// DNA repair /// regula9on of DNA repair /// postreplica9on repair /// cellular protein modiﬁca9on process /// proteolysis /// ubiqui9n-dependent protein catabolic process /// response to DNA damage s9mulus /// Toll signaling pathway /// protein ubiqui9na9on /// protein ubiqui9na9on /// histone ubiqui9na9on /// cytokine-mediated signaling pathway /// posi9ve regula9on of histone modiﬁca9on /// regula9on of histone ubiqui9na9on /// toll-like receptor 1 signaling pathway /// toll-like receptor 2 signaling pathway /// toll-like receptor 4 signaling pathway /// toll-like receptor 5 signaling pathway /// toll-like receptor 9 signaling pathway /// toll-like receptor 10 signaling pathway /// nucleo9de-binding domain, leucine rich repeat containing receptor signaling pathway /// Fc-epsilon receptor signaling pathway /// toll-like receptor TLR1:TLR2 signaling pathway /// toll-like receptor TLR6:TLR2 signaling pathway /// posi9ve regula9on of I-kappaB kinase/NF-kappaB cascade /// posi9ve regula9on of I-kappaB kinase/NF-kappaB cascade /// innate immune response /// posi9ve regula9on of DNA repair /// T cell receptor signaling pathway /// T cell receptor signaling pathway /// posi9ve regula9on of NF-kappaB transcrip9on factor ac9vity /// posi9ve regula9on of ubiqui9n-protein ligase ac9vity /// nucleo9de-binding oligomeriza9on domain containing signaling pathway /// protein K63-linked ubiqui9na9onnucl o9d  binding /// ubiqui9n-pr tein ligase ac9vity /// protein binding /// ATP binding // ligas ac9vity /// acid-amino acid ligase ac9vity /// ubiqui9n bindingubiqui9n ligase com lex /// nucl us // cytoplasm /// cytoplasm /// cytosol  UBC13-MMS2 complex /// UBC13-UEV1A omplex
209096_at UBE2V2 ubiqui9n-conjuga9ng enzyme E2 variant 2protei  polyubiqui9na9on /// DNA double-strand break processing /// regula9on of DNA repair /// cell prolifera9on /// posi9ve regula9on of neuron projec9on development /// protein ubiqui9na9on /// posi9ve regula9on of proteasomal ubiqui9n-dependent protein catabolic process /// error-free postreplica9on DNA repair /// nega9ve regula9on of neuron apopto9c process /// posi9ve regula9on of DNA repair /// posi9ve regula9on of synapse assemblyprotein bindi g / acid-amino acid ligas  ac9vityucleus /// cytoplasm /// UBC13-MMS2 compl x
202330_s_atUNG uracil-DNA glycosylaseDNA repair /// base-excision repair /// response to DNA damage s9mulus /// metabolic process /// soma9c hypermuta9on of immunoglobulin genes /// soma9c recombina9on of immunoglobulin gene segments /// virus-host interac9onuracil DNA N-glycosylase ac9vity /// hydrolase ac9vity /// hydrolase ac9vity, ac9ng on glycosyl bonds /// hydrolase ac9vity, hydrolyzing N-glyc syl compoundsnucleus /// mitoch drion
205667_at WRN Werner syndrome, RecQ helicase-liketelomer  maintenance /// DNA synthesis involved in DNA repair /// replica9ve cell aging /// nucleobase-containing compound metabolic process /// ATP catabolic process /// DNA metabolic process /// DNA replica9on /// DNA repair /// base-excision repair /// double-strand break repair /// DNA recombina9on /// response to DNA damage s9mulus /// response to oxida9ve stress /// aging /// cell aging /// metabolic process /// cellular response to starva9on /// response to UV-C /// mul9cellular organismal aging /// replica9on fork processing /// replica9on fork processing /// nucleolus to nucleoplasm transport /// DNA duplex unwinding /// DNA duplex unwinding /// regula9on of growth rate /// regula9on of apopto9c process /// cellular metabolic process /// posi9ve regula9on of hydrolase ac9vity /// cellular response to gamma radia9on /// nucleic acid phosphodiester bond hydrolysisnucleo9d binding /// magnesium ion binding /// Y-form DNA binding /// bubble DNA inding /// nucleic acid binding /// DNA binding /// DNA helicase ac9vity / DNA h licase ac9vity /// cataly9c ac9vity /  ATP-dependent DNA helicase ac9v ty / helicase ac9vity /// nuclease ac9vity /// exonuclease ac9vity /// protein binding /// ATP binding /// ATP-dependent h licase ac9vity /// 3'-5' exonucl ase ac9vity /// four-way junc9on helicase ac9vity /// hydr la  ac9vity ATPase ac9vity /// mang nese ion binding /// p otein complex binding /// pr tein homodimeriza9on ac9vity /// 3'-5' DNA helicase ac9vity /// ATP-depe ent 3'-5' DNA helicase ac9vity metal ion binding /// G-quad uplex DNA bindingtracellular /// nucleus /// ucleoplasm / nucleolus /// centrosome /// MutLalpha complex
218110_at XAB2 XPA binding protein 2mRNA splicing, via spliceosome /// blastocyst development /// DNA repair /// transcrip9on-coupled nucleo9de-excision repair /// transcrip9on-coupled nucleo9de-excision repair /// nucleo9de-excision repair /// transcrip9on, DNA-dependent /// RNA processing /// mRNA processing /// response to DNA damage s9mulus /// RNA splicingprotein bindingi trac llular /// nucleus /// nucleoplasm /// s liceosom l complex /// cataly9c step 2 spli eosome
205672_at XPA xeroderma pigmentosum, complementa9on group Anucl o9de-ex ision repair, DNA damage removal /// DNA repair /// nucleo9de-excision repair /// response to DNA damage s9mulus /// response to oxida9ve stress /// intrinsic apopto9c signaling pathway in response to DNA damage /// response to UV /// response to toxic substance /// mul9cellular organism growthnucleo9de b nding /// DNA binding /// damaged DNA binding /// protein binding /// protei  domain speciﬁc binding /// prot in homodimeriza9on ac9vity /// metal ion bindingucleus /// nucleoplasm
203655_at XRCC1 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 1single stra d break repair /// response to hypoxia /// DNA repair /// base-excision repair /// response to DNA damage s9mulus /// response to organic substance /// hippocampus development /// response to drugdam g d DNA binding /// protein b ndingnucleu  //  nucleoplasm
207598_x_atXRCC2 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 2doub -strand br ak repair vi  homologous recombina9on /// in utero embryonic development /// DNA metabolic process /// DNA repair /// DNA recombina9on /// response to DNA damage s9mulus /// meiosis /// response to X-ray /// response to gamma radia9on /// nega9ve regula9on of neuron apopto9c process /// posi9ve regula9on of neurogenesisDNA binding /// protein binding /// ATP bindi g /// DNA-dependent ATPase ac9vitynucleus
216299_s_atXRCC3 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 3DNA metabolic process /// DNA repair /// DNA recombina9on /// transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// response to organic substancenucle 9de binding /// DNA binding /// DNA-directed RNA polymerase ac9vity /// protein binding /// ATP binding /// DNA-dependent ATPase ac9vitynucleus /// cytoplasm /  mitochondrion /// pe nucle r region of cytoplasm
210812_at XRCC4 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 4in utero embryonic development /// pro-B cell diﬀeren9a9on /// DNA liga9on /// DNA repair /// double-strand break repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// response to DNA damage s9mulus /// central nervous system development /// response to X-ray /// response to ionizing radia9on /// response to gamma radia9on /// viral reproduc9on /// viral reproduc9ve process /// T cell diﬀeren9a9on in thymus /// V(D)J recombina9on /// immunoglobulin V(D)J recombina9on /// nega9ve regula9on of neuron apopto9c process /// isotype switching /// posi9ve regula9on of ﬁbroblast prolifera9on /// posi9ve regula9on of neurogenesis /// DNA liga9on involved in DNA repair /// posi9ve regula9on of ligase ac9vity /// cellular response to lithium ion /// establishment of integrated proviral latencyDNA binding /// pro ein binding /// prot in C-terminus binding /// ligase ac9vitycond s d chr mosome /// ucleus  nucleus /// ucleopl sm /// cytosol /// DNA- ep ndent p otein kinase-DNA ligase 4 complex /// DNA ligase IV complex /// nonhomologous end joining complex
208643_s_atXRCC5 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 5 (double-strand-break rejoining)telom re maintenan e /// DNA repair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// cell prolifera9on /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of type I interferon produc9on /// nega9ve regula9on of apopto9c process /// innate immune response /// nega9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of neurogenesis /// hematopoie9c stem cell diﬀeren9a9on /// establishment of integrated proviral latencynucleo9d binding /// DNA binding /// damage  DNA binding /// double-stranded DNA binding /// double-stranded telomeric DNA binding /// ATP-depende t DNA helicas  ac9vity //  helicase ac9vity /// protein binding /// ATP binding /// protein C-terminus bi ding /// hydrolas  ac9vity /// hydr la  ac9vity, ac9n  on acid anhydrides /// ubiqui9n protein ligase binding // telomeric DNA binding /  transcrip9on regulat ry regio  DNA bi ding /// 5'-deoxyribose-5-phosphate lyase ac vitynuclear telom re cap compl x /// nucl ar chromosome, elome ic region /// ucleus // nucleopl sm /// chrom some /// ucleolus /// cytoplasm /// cytosol /// DNA-dependent protein kinase-DNA ligase 4 c mplex /// Ku70:Ku80 complex /// nonhomolog us end joining complex
200792_at XRCC6 X-ray repair complemen9ng defec9ve repair in Chinese hamster cells 6telom re maintenan e /// DNA liga9o  /// DNA r pair /// double-strand break repair /// double-strand break repair via nonhomologous end joining /// double-strand break repair via nonhomologous end joining /// DNA recombina9on /// transcrip9on, DNA-dependent /// regula9on of transcrip9on, DNA-dependent /// response to DNA damage s9mulus /// metabolic process /// response to ionizing radia9on /// viral reproduc9on /// viral reproduc9ve process /// posi9ve regula9on of type I interferon produc9on /// V(D)J recombina9on /// innate immune response /// nega9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on, DNA-dependent /// posi9ve regula9on of transcrip9on from RNA polymerase II promoter /// posi9ve regula9on of neurogenesis /// establishment of integrated proviral latencynucleo9d binding /// nucl ic acid binding  DNA binding /// d maged DNA binding /// ouble-stranded DNA binding /// double-stranded telomeric DNA binding /// cataly9c ac9vity /// ATP-depe dent  helicase ac vity /// heli ase ac9vity /// protein binding /// ATP binding /// protein C-termi us binding /// hydrolase ac9vity /// lyase ac9vity /// telomeri  DNA binding /// ranscr p9on regulatory region DNA binding // 5'-deoxyribose-5-pho phate lyase ac9vitynuclear telom re cap com l x /// nucleus /// nucl opl sm //  transcrip9on factor complex /// chromos me /// cytoplasm /  cytosol /// D A-d pe dent protein kinase-DNA ligase 4 complex /// m mbra e /// Ku70:Ku80 complex //  nonhomologous end joi ing complex


